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FORSCHUNGSZUSAMMENFASSUNG 
Die Verwendung von optisch schaltbaren Molekülen in denen strukturelle Änderungen durch Beleuchtung 
hervorgerufen werden können, sogenannte Photoschalter, wurde in den letzten Jahren erfolgreich auf eine 
Vielzahl von Anwendungsgebieten ausgeweitet. Dazu gehören unter anderem die Photopharmakologie 
und Optogenetik, so wie die strukturbiologische Untersuchung von Proteinfaltungsprozessen. Während 
die ersten beiden Gebiete die strukturelle Änderung des Rezeptors nutzen um die Funktionen von 
biologischen Molekülen und Systemen zu steuern, wird diese bei der Untersuchung von Faltungsprozessen 
zur Bildung und Auflösung von Strukturelementen, wie zum Beispiel a-helikalen oder b-Faltblatt 
Sekundärstrukturen, verwendet. Zudem zeigt die Verleihung des Nobelpreises in Chemie 2016 an die drei 
Forscher Bernard Feringa, Jean-Pierre Sauvage und James Fraser Stoddart, dass die Entwicklung von 
molekularen Maschinen und steuerbaren Molekülen in den letzten 30 Jahren weit vorangeschritten ist und 
auch in den nächsten Jahren spannende Neuerungen zu erwarten sind. 
In dieser Arbeit wurden neue Systeme für die optisch-chemische Kontrolle von Rezeptoren und für die 
Peptidfaltung entwickelt. Voranstehend ist eine Zusammenfassung in Englisch und Deutsch zu finden, 
gefolgt von einer detaillierten Beschreibung der an den Projekten beteiligten Personen. Der allgemeinen 
Einleitung folgt TEIL I, welcher nach einer Einführung in die Welt der photoschaltbaren Moleküle die 
Entwicklung und Synthese von Azobenzol-basierten Photoschaltern beschreibt. Darunter befinden sich 
zum einen Photoschalter, welche als Festphasenbausteine in der Peptidsynthese zur Herstellung von 
optisch-responsiven Peptiden verwendet wurden, zum anderen photoschaltbare Crosslinker, welche über 
reaktive Gruppen in Peptide eingeführt werden. 
In TEIL II werden zunächst allgemeine Aspekte der Pharmakologie, Photopharmakologie und Optogenetik 
besprochen, gefolgt von drei in dieser Arbeit aufgeführten (photo)pharmakologischen Projekten, welche 
die in TEIL I besprochenen Photoschalter zur Anwendung bringen. Dabei beschreibt KAPITEL 2 die 
Herstellung und Evaluation des Hormones TOP271, welches eine photoschaltbare Variante des Atrial 
Natriuretischen Peptides (ANP) ist. ANP ist ein potenter Vasodilator und hat eine Vielzahl von Funktionen, 
wie zum Beispiel die Blutdrucksenkung und die Regulation des Blut- und Wasserhaushaltes. Neue 
Erkenntnisse lassen zudem eine wesentlich vernetztere Rolle von ANP im Körper vermuten, allerdings wird 
hier der Effekt von ANP teils kontrovers diskutiert, da gegenläufige Ergebnisse zu unterschiedlichen 
Aussagen führen. Mit TOP271 konnte erfolgreich die Aktivität des Atrial Natriuretischen Peptid Rezeptors 
(NPR-A) mit Licht reguliert und somit direkt die Synthese von cyclischem Guanosinmonophosphat (cGMP) 
gesteuert werden. In weiterführenden Experimenten konnte in explantierten Aorten der Tonus der glatten 
Muskulatur mittels Licht reversibel beinflusst werden, was eine Anwendung für kardiovaskuläre 
Untersuchungen ermöglicht. Zudem wurde in Langerhans-Inseln aus der Bauchspeicheldrüse, welche den 
NPR-A Rezeptor endogen exprimieren, eine reversible, licht-regulierte Unterdrückung der zellulären Ca2+-
Ströme mit TOP271 gezeigt. Um genaueren Einblick in die differenzielle NPR-A Rezeptor Aktivierung zu 
bekommen wurden Molekulardynamik-Simulationen durchgeführt, welche die unterschiedlichen 
Strukturen der beiden Isomere von TOP271 im Vergleich zu ANP zeigen. Die Simulationen des Apo- und 
F O R S C H U N G S Z U S A M M E N F A S S U N G    P A G E  | V 
hormongebundenen Rezeptors lieferten dabei neue Erkenntisse für den Mechanismus der Aktivierung von 
rezeptorgebundenen Enzymen.  
KAPITEL 3 widmet sich der Herstellung und Evaluation des photoschaltbaren Hormones LirAzo, welches auf 
dem Medikament Liraglutide (Victozaâ) zur Behandlung von Typ 2 Diabetes (T2D) basiert. T2D ist die 
häufigste Form von Diabetes, in der eine wachsende zelluläre Insulinresistenz durch eine erhöhte 
Insulinsekretion der b-Zellen der Bauchspeicheldrüse ausgeglichen werden muss. In fortgeschrittenem 
Stadium kann der Insulinbedarf nicht mehr gedeckt werden, was zu einer kontinuierlichen Abnahme der 
b-Zellmasse und ultimativ zum Verlust der endogenen Insulinproduktion führt. Liraglutide selbst ist ein 
langwirkendes Inkretin-Mimetikum, das dem endogenen Hormon Glucagon-like peptide 1 (GLP-1) 
nachempfunden ist. GLP-1 wird nach der Nahrungsaufnahme im Darm ausgeschüttet und erhöht in erster 
Linie die Insulinsekretion in b-Zellen der Bauchspeicheldrüse. Weitere Funktionen sind die Unterdrückung 
der Glukagonsekretion (dem Gegenspieler von Insulin), die Verzögerung der Magenentleerung und die 
Unterdrückung von Appetit. Die Halbwertszeit von GLP-1 im Blut beträgt nur 1-2 Minuten, wodurch eine 
beständige Sekretion stattfinden muss. Langwirkende Inkretin-Mimetika wie Liraglutide nutzen die 
Eigenschaften von GLP-1, um die verminderte Insulinsekretion in T2D Patienten, bei gleichzeitiger 
Bekämpfung von Ursachen wie Übergewicht, zu behandeln. Allerdings sind erst wenige Studien über die 
Langzeitwirkung dieser Medikamente bekannt, wobei jedoch erste Hinweise auf erhöhte Risiken für 
Bauchspeicheldrüsen- und Schilddrüsenkrebs vorliegen. Das photoschaltbare Inkretin-Mimetikum LirAzo 
ermöglicht es die Rezeptoraktivierung des GLP-1 Rezeptors und die folgenden intrazellulären 
Signaltransduktionskaskaden optisch zu steuern und zu untersuchen. Für G-Protein-gekoppelte Rezeptoren 
(GPCRs), zu denen auch der GLP-1 Rezeptor gehört, wurde bereits gezeigt, dass die unterschiedliche 
Rezeptoraktivierung zu verschiedenen intrazellulären Signalen führt. Die beiden Isomere von LirAzo 
bewirken dabei eine unterschiedliche Signalwirkung des GLP-1 Rezeptors über cyclisches 
Adenosinmonophosphat (cAMP) oder Ca2+, was zum einem zu einer erhöhten Insulinausschüttung und 
zum anderen zu stimulierter Zellproliferation führt. Mit LirAzo konnte somit die Bedeutung des cAMP-
Signalweges für die Insulinsekretion verstärkt und ein weiteres Puzzleteil für die komplexe Aktivierung von 
GPCRs geliefert werden. 
In KAPITEL 4 wird ein weiteres modifziertes Inkretin-Mimetikum, ExONatide, besprochen, welches auf dem 
T2D Medikament Exenatide (Byettaâ) basiert. ExONatide besitzt eine Benzylguaningruppe, die durch einen 
flexiblen Linker und eine Disulfidbrücke an den Liganden gebunden ist. Die Benzylguaningruppe 
ermöglicht die kovalente Anbindung von ExONatide an ein reaktives Cystein eines SNAP-Tags. Um 
tieferen Einblick in die Rezeptor-Desensibilisierung nach Aktivierung und anschließender endosomaler 
Sortierung und Degradation zu bekommen, wurde ExONatide an den GLP-1 Rezeptor mit SNAP-Tag 
(SNAP-GLP-1R) gebunden. Durch das kovalent gebundene ExONatide wird der Rezeptor konstitutiv 
aktiviert und die Internalisierung sowie das Recycling des Rezeptor-Liganden-Komplexes konnte 
beobachtet werden. Dabei wurde gezeigt, dass kein Recycling des SNAP-GLP-1 Rezeptors mit gebundenen 
ExONatide stattfindet. Erst nach der reduktiven Abspaltung des Liganden findet eine Rückkehr des 
Rezeptors an die Zellmembran statt. Vor allem in Anbetracht der Frage, ob die beobachteten erhöhten 
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cAMP-Level nach GLP-1 Rezeptoraktivierung auf sehr schnelle Recycling-Prozesse oder auf endosomale 
cAMP-Produktion zurückzuführen sind, beweist ExONatide eindeutig, dass eine fortwährende Bindung 
des Liganden an den Rezeptor zu einem verzögerten Recycling führt.  
Der dritte und letzte Teil dieser Arbeit widmet sich der Verwendung von photoschaltbaren Peptiden für 
die Untersuchung von Proteinfaltungsprozessen. Aufgrund der Komplexität dieser Vorgänge existieren bis 
heute nur wenige einheitliche Modelle, und diese ändern sich zudem stetig. Dank zunehmender 
Rechenleistung können heute die Strukturen und Faltungsvorgänge komplizierter Biomoleküle simuliert 
und detaillierte theoretische Modelle erstellt werden, welche jedoch der experimentellen Bestätigung 
bedürfen. In Anbetracht von neurodegenerativen Krankheiten wie Alzheimer oder Creutz-Feldt-Jakob, die 
mit einer erhöhten Fehlfaltung und Aggregation von Proteinen verbunden werden, ist das Verständnis der 
Proteinlebenszyklen – von der Proteinbiosynthese, über die Faltung und Qualtitätskontrolle bis hin zur 
Degradation – von eminenter Wichtigkeit. Wie in der allgemeinen Einleitung zu TEIL III beschrieben, gibt 
es verschiedene Ansätze zur Untersuchung von Faltungsprozessen, wobei sich diese Arbeit auf kleine 
Modellsysteme von b-Hairpinpeptiden konzentriert. Bedingt durch die Vermutung, dass dieses 
Strukturmotiv in Proteinen als Kristallisationskeime für die Proteinfaltung dient, wurden in den letzten 
Jahrzehnten viele solcher Modellsysteme entwickelt. Dabei wurden Azobenzolphotoschalter, welche mit 
hoher zeitlicher und räumlicher Genauigkeit strukturelle Änderungen hervorrufen, verwendet, um die 
Faltungs- und Entfaltungsprozesse der b-Hairpinpeptide zu steuern. In KAPITEL 5 wird ein neues 
photoschaltbares b-Hairpinpeptid aufgezeigt, das auf dem Miniprotein Chignolin basiert. Anhand dieses 
AzoChignolin-Peptids und verwandter Mutanten können hydrophile und hydrophobe, stabilisierende 
Wechselwirkungen im b-Hairpin bei der Faltung und Entfaltung untersucht, und Rückschlüsse auf den 
jeweiligen Anteil bei Faltungsprozessen gezogen werden. 
Zusammenfassend demonstriert diese Arbeit die Verwendung molekularer Schalter in verschiedenen 
Forschungsbereichen, von der praktischen Anwendung als „Biologische Forschungswerkzeuge“ in der 
Diabetesforschung, bis hin zu Modellsystemen für Proteinfaltungsstudien. Die photopharmakologischen 
Verbindungen wurden dabei in in vitro- und ex vivo-Studien biologisch evaluiert, wobei in vivo-Studien 
bereits in Planung sind. Die Peptidfaltung wurde mittels verschiedener spektroskopischer Methoden 
untersucht, allen voran der Ultrakurzzeit-Spektroskopie. In naher Zukunft sind weitere Untersuchungen 
und Modifkationen der neuentwickelten Systeme geplant.  
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ABSTRACT 
The development of photochromic peptides and ligands for ever more targets has delivered a growing 
library of various photopharmaceuticals and research tools, and has helped to promote the viability of 
these molecular machines not only in health and disease, but in many aspects of life. The optical control 
of proteins, the ubiquitous actors and regulators of cellular processes, life and death, is a key step in 
understanding and regulating biological processes. For this reason, the growing exploitation of optical 
research tools should enable it researchers to address almost any biological question in the future.  
This work presents different photochromic compounds and tethered ligands, which were implied in the 
(optical) control of different biological targets, or as model systems for structural studies. Except for the 
different photoswitches discussed in PART I, the projects either have been already published or have been 
submitted to peer-reviewed journals, wherefore they appear as embedded articles or manuscripts. The 
conceptual idea and rational design, as well as the synthesis and testing of the different compounds are 
described in these files. To the addressed targets for optical control belong the Atrial Natriuretic Peptide 
Receptor (NPR-A) and the Glucagon-like Peptide 1 Receptor (GLP-1R). Furthermore, a novel 
photoswitchable b-hairpin peptide was developed that represents a model system for studying the folding 
processes in this protein structural element.  
In each case, the photocontrol of the targeted processes was demonstrated in the corresponding system. 
For instance, optical regulation over NPR-A activity was demonstrated in Islets of Langerhans and ex vivo 
in explanted mouse aorta. The photocontrol of GLP-1R activity with a photochromic incretin-mimetic was 
also shown in Islets of Langerhans. Furthermore, compound-biased receptor signaling could be 
demonstrated, which leads to a differential stimulation of insulin secretion and cell proliferation. Utilizing 
a tethered ligand, the GLP-1R could be constitutively activated, facilitating the study of receptor 
internalization and trafficking. In case of the b-hairpin model system, the switching of the chromophore 
directs the folding and unfolding of the hairpin structure, allowing the monitoring of folding processes with 
spectroscopic methods. These optical research tools deliver a blueprint for the next generation of such 
systems, and will hopefully contribute to the progression of knowledge and understanding in these and 
related fields of research. 
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ABSTRACT (DEUTSCH) 
Der stetige Fortschritt auf dem Gebiet optisch-schaltbarer Moleküle hat zu der Entwicklung einer Vielzahl 
von Photopharmazeutika und Forschungswerkzeuge geführt, welche dabei helfen den Nutzen dieser 
Systeme in der Forschung, zur Bekämpfung von Krankenheiten und in vielen weiteren Aspekten des 
Lebens, zu zeigen. Dabei ist die optische Kontrolle von Proteinen, den allgegenwärtigen Akteuren und 
Regulierern zellulärer Prozesse, der Schlüssel zu einem besseren Verständnis und Kontrolle biologischer 
Funktionen. Aus diesem Grund sollten Forscher in Zukunft in der Lage sein, jedwede biologische 
Fragestellung mittels optischer Forschungswerkzeuge zu adressieren. 
Diese Arbeit stellt verschiedene photoschaltbare Verbindungen und angebundene Liganden vor, die 
entweder für die (optische) Kontrolle von verschiedenen biologischen Targets, oder aber als Modellsystem 
für Proteinfaltungsstudien verwendet wurden. Bis auf die Photoschalter, welche in TEIL I dieser Arbeit 
aufgeführt sind, wurden die Projekte bereits in angesehenen wissenschaftlichen Zeitungen publiziert oder 
zur Veröffentlichung eingereicht. Die Artikel und Manuskripte sind dementsprechend als Ganzes in diese 
Arbeit eingefügt, und geben Einblick in die Entwicklung der konzeptionellen Idee, über die Planung und 
Synthese der Verbindung bis hin zu der Untersuchung an den biologischen Targets. Zu diesen gehören 
unter anderem der Atrial Natriuretische Peptidrezeptor (NPR-A) und der Glucagon-like Peptid 1 Rezeptor 
(GLP-1R). Desweiteren wurde auch ein neues photoschaltbares b-Hairpinpeptid Modellsystem entwickelt, 
welches die Untersuchung von Faltungsprozessen in diesem Strukturelement ermöglicht. 
Die optische Kontrolle der anvisierten Prozesse wurde in den entsprechenden Projekten in physiologisch 
relevanten System demonstriert. So wurde die lichtgesteuerte Regulierung des NPR-A Rezeptors in 
Langerhans’schen Inseln der Bauchspeicheldrüse und in explantierten Mausaorten gezeigt. Die optische 
Kontrolle des GLP-1 Rezeptors konnte ebenfalls in den Inselzellen demonstriert werden, wobei die 
Verzerrung des Rezeptor-Signals zu einer unterschiedlichen Stimulierung von Insulinsekretion und 
Zellproliferation führte. Durch Verwendung eines angebundenen Liganden konnte zudem der GLP-1 
Rezeptor konstitutiv aktiviert werden, wodurch die Internalisierung und das Rezeptorrecycling unter diesen 
Bedingungen beobachtet werden konnte. Im Falle des b-Hairpinpeptid Modellsystems steuerte der 
Photoschalter die Faltung und Entfaltung der Hairpin-Struktur, was durch spektroskopische Methoden wie 
der Ultrakurzzeitspektroskopie beobachtet werden konnte. Diese optischen Forschungswerkzeuge stellen 
Blaupausen für die nächste Generation solcher Systeme dar, und sollen bei dem Verständnis und der 
Weiterentwicklung dieses Forschungsgebietes helfen. 
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GENERAL INTRODUCTION 
The fundamental challenge in solving a problem is to understand the underlying coherences and form a 
solution based upon this knowledge. This not only translates to many aspects in life but also to science 
and particularly to the interdisciplinary fields of biochemistry and chemical biology. Scientists working in 
this area of research combine biological approaches with chemical design and synthesis of small 
molecules, to tackle pressing global challenges such as future nutrition, environmental sustainability and 
pathologies. In the case of the latter these are represented by different diseases, such as metabolic (i.e. type 
2 diabetes (T2D)), cardiovascular (i.e. atrial fibrilliation and heart failure) and neurodegenerative (i.e. 
Alzheimer’s and Creutz-Feldt-Jakob’s) disorders, which affect a growing share of the global population and 
have far-reaching social and economic effects.  
The first step towards every sucessful investigation of biological behavior, function and response is the 
dissection of complex biological signaling processes. A major approach is to gain control over biological 
systems through manipulation of biomolecules and their responses. Through introduction of responsive 
units, the action and function of the target molecules can be remotely altered and the role it plays in a 
biological ensemble can be detected. Light, with its high spatial and temperol precision, is used by a variety 
of organisms as regulatory signal in photoresponsive proteins, i.e. flavoproteins1 and rhodopsins2. 
Genetically modified versions of these proteins have been successfully implied in optogenetics to control 
defined events at distinct times in intact biological systems3. Furthermore, small native biomolecules such 
as endogeneous hormones and drugs have been equipped with photoresponsive units and been applied 
to a large variety of targets, including G-protein coupled receptors (GPCRs), ion channels and enzymes4–6. 
This relatively new and vivid field was dubbed photopharmacology, as it implies the use of synthetic 
photoswitches or photopharmaceuticals to control biological function and together with optogenetics it 
has become a major frontier in scientific research. 
Pharmacology has come a long way from magical and natural remedies of ancient medicine over 
iatrochemistry to modern pharmacology7. Crucial for therapeutic efficacy of modern pharmaceuticals is 
the correct diagnosis and an appropriate choice of the drug8. Success of the therapy depends on the correct 
induction of appropriate drug concentrations in the target organ or tissue, whereby the therapeutic window 
(the gap between effective and toxic levels) is mostly narrow. Distinct diffusion rates and rapid drug 
elimination lead to decreased efficacy after high starting concentrations and make it challenging to hit and 
maintain the designated drug concentration. Moreover, after administration a drug may diffuse to the whole 
organism via the bloodstream and lead to off-target effects. Another major issue is drug resistance, 
especially in the light of elevating numbers of antibiotic resistant bacteria. Photopharmacology is a 
promising attempt to overcome these issues by increasing the selectivity of drugs through reversible 
switching between an active or inactive state and thus enabling targeting of drug action only to the tissue 
of interest. Using light as input signal is not only reasonable because of its high spatiotemporal precision, 
but also due to its non-invasivness and non-toxicity. Intense focus on the optimization of photoswitches in 
the recent years has yielded a remarkable library of compounds with far red-shifted absorption 
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characteristics9–12. Shifting the switching wavelengths of the photoswitch to red/IR light is a necessity to 
achieve deep tissue penetration for non-invasive photopharmacology, without the need to ingest or 
implement a light source into the patient. Introducing the recent ground-breaking and basic research in 
this field13–17 to clinical studies will be the next big leap forward and possibly help to establish 
photopharmacology as a new method for clinical treatment. 
 
Figure 1:  Giovanni Stradano – Il laboratorio dell’alchemista. The workshop of an alchemist, sixteenth century 
(Firenze, Palazzo Vecchio)18.  
Besides optogenetics and photopharmacology pioneering work using photochromic compounds in 
biomolecules was the incorporation of azobenzenes into the side chain of polypeptides to photomodulate 
conformational states of poly-a-amino acids19. Since then, various chromopeptides have been introduced 
as model systems for experimental protein folding studies20–26. Although these model peptides comprise 
buildings blocks which are not constituents of any natural biomolecule, these studies have helped to bridge 
the gap between experimental and theoretical results. The verification or falsification of theoretical 
predictions based on experimental data is vital to develop precise theoretical descriptions20. The 
complexity and evolution of processes involved in protein folding and signaling are one of the great 
mysteries in biology and have fascinated generations of researchers. Protein misfolding and aggregation is 
correlated with many diseases, such as the neurodegenerative and age-related Alzheimer’s and Creutz-
Feldt-Jakob’s disease27, and our ageing population urges the need for a deaper understanding of these 
maladies. 
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This work comprises new studies in the mentioned fields and is divided into three parts. PART I outlines the 
design and synthesis of known and new photoswitches, which were used in the projects described in PART 
II and PART III. PART II thereby pictures the projects conducted in the field of pharmacology and 
photopharmacology, while latter focuses on structural biology and peptide folding. 
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PART I 
PHOTOSWITCHES: 
DESIGN AND SYNTHESIS 
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PART I – PHOTOSWITCHES: DESIGN AND SYNTHESIS 
1 AZOBENZENES AS MOLECULAR SWITCHES 
1.1 PRINCIPLES OF OPTICAL CONTROL 
Sun light is the ubiquitous donor of energy for many living organisms and it triggers several processes in 
plants (photosynthesis, phototaxis), phototrophic prokaryotes (light-energy conversion through ion pumps) 
and animals (vision, circadian timing)12. Some of these responses, like phototactical movement or visional 
responses involve the absorption of light and conversion into an electrical signal (phototransduction). In 
the visual cycle of mammals, visible light energy induces the conformational isomerization of the 
chromophore 11-cis-retinal (cis-1.1), which is bound to the GPCR opsin and forms the photosensory 
rhodopsin receptor complex in the rod and cone cells of the eye. The photoisomerization of receptor bound 
cis-1.1 to rigid all-trans-retinal (trans-1.1) (Figure 1.1) leads to dissociation of trans-1.1 from the receptor 
and activates G-protein and subsequent neuronal signaling and ultimately vision28,29. Special emphasis lies 
on the regulation of these processes by light in the visible region of the solar spectrum, which is harmless 
compared to UV light. Latter is typically phototoxic to cells, absorbed nonselectively by any chromophores 
and exhibits weak tissue penetration30. 
 
Figure 1.1:  Examples for molecular switches. Shown are the photoisomerizations of cis/trans-1.1, cis/trans-stilbene 
1.2, open- and closed-DAE 1.3 and cis/trans-HTI 1.4 (ref. 31). 
Since many decades’ researchers have been inspired and guided by natures design principles and have 
developed many synthetic photosensitive systems, ranging from photovoltaic cells32 and photochemical 
synthesis33,34 to optogenetics with protein-engineered rhodopsins3,35–37 and photopharmacology4,16,38. These 
systems rely on photochromic molecules based on biological chromophores or industrial dyes and 
comprise molecular switches such as stilbenes39,40, diarylethenes (DAEs)41–43, hemithioindigos (HTIs)31,44–46 
and azobenzenes47–52, with several more not mentioned here (Figure 1.1). Although most of these 
O
O
11-cis-retinal
(cis-1.1)
all-trans-retinal
(trans-1.1)
cis-stilbene 
(cis-1.2)
trans-stilbene 
(trans-1.2)
SS
R2
R3R1 R4SS
R2
R3R1 R4
hν
hν1
hν2
closed-diarylethene
(closed-1.3)
open-diarylethene
(open-1.3)
S
O
S
O
trans-hemithioindigo
(trans-1.4)
cis-hemithioindigo
(cis-1.4)
λ > 400 nm
λ = 500 nm
or Δ
hν
Δ
P A R T  I  –  C H A P T E R  1 :  A Z O B E N Z E N E    P A G E  | 9 
chromophores have been sucessfully used for biological and nonbiological applications, azobenzenes, 
despite being one of the oldest photoswitch class, still offer the largest range of activation wavelengths and 
photoactivated states, and their versatile derivatization possibilites enables tuning of their spectral 
properties depending on the application. For this reason, azobenzene or azobenzene based photoswitches 
were exclusively used throughout this work and the following chapters will focus on the photochemical 
and photophysical properties of known and new azobenzene derivatives. 
1.1.1 AZOBENZENE 
Azobenzene (1.5), the core structure of several reliable and cheap dyes, consists of two phenyl groups 
which are linked through a diazene bridge and photoisomerization with UV light (l = 350-380 nm) or blue 
light (l = 430-480 nm) leads to trans ⇾ cis or cis ⇾ trans isomerization, respectively (Figure 1.2). The 
isomerization events occur very fast on the picosecond timescale, with high quantum yields and minimal 
degradation/photo bleaching even after many cycles. This prevents the formation of triplett states and 
formation of cell damaging reactive oxygen species (ROS) by singlet oxygen avoided, which enables 
biocompability4. 
While cis-1.5 formation can also be induced by mechanical stress53 or electrostatic stimulation54,55, trans-
1.5 forms spontaneously in the dark due to its higher thermodynamic stability. The thermal relaxation 
thereby is significantly slower than the photoisomerization, thus seperating both process in time47. In 
unsubstituted azobenzene the thermal relaxation yields up to >99.99% of the trans-isomer, but light-
induced isomerization produces a photostationary state (PSS) with maximal ~80% of the cis or ~95% of 
the trans-form56. The formation of this PSS is due to the distinct, but overlapping absorption spectra of 
cis/trans-1.5. The trans-isomer exhibits a strong p-p* transition at 316 nm (e = 22000 L·M-1·cm-1) and a 
weak, symmetry-forbidden n-p* band near 440 nm (e = 440 L·M-1·cm-1). The cis-isomer has a stronger, 
formally not forbidden n-p* transition near 440 nm (e = 1250 L·M-1·cm-1) and shorter wavelength bands at 
280 and 250 nm. Despite the rather low extinction coefficient, irradation of the n-p* band leads to complete 
cis ⇾ trans-isomerization57. 
 
Figure 1.2:  Azobenzene (1.5) isomerization. Basic parameters of the cis ⇾ trans and trans ⇾ cis photoisomerization 
of 1.5 (ref. 4).  
Both phenyl rings in trans-1.5 are slightly twisted 17° around the N=N-bond and form a planar structure 
with a dipole moment near zero. In the cis-isomer, both phenyl rings are twisted ~55° out of the N=N-
bond plane and exhibit a dipole moment of µ = 3 D. Besides these changes, there is a distance alteration 
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of ~3.5 Å between the two para-positioned 4- and 4’-carbon atoms of the two phenyl rings in both 
isomers58,59. Although changes in dipole moment and compactness of the azobenzene structure upon 
isomerization are remarkable, it is this end-to-end distance shift which is the dominant feature for the 
utilization of these photoswitches in biological applications. 
The most important properties of azobenzene photoswitches for controlling biological processes are (i) the 
photoisomerization wavelengths must be compatible with cells and tissues (> 400 nm), (ii) the 
isomerization should be effective with a sufficient rate and capability of undergoing many switching cycles, 
(iii) depending on the application the conformational shift or end-to-end distance change upon 
isomerization has to be large enough to affect the activity or the function of the target biomolecule, (iv) 
while simultaneously being small enough to mimic the template compound or be noninvasively 
incorporated into the the target molecule. Furthermore, (v) the photoswitch should be stable in the cellular 
environment and unsusceptible towards modification or degradation, for example through reduction by 
glutathione. These properties can be tweaked by introducing different substituents to the azobenzene core 
and the next chapter will provide a brief overview of the most recent advances. 
1.1.2 TUNING THE SPECTRAL PROPERTIES OF AZOBENZENE 
The most demanding aspect of biological photoswitches is achieving switching wavelengths in the non-
toxic and tissue penetrating far red/IR region, while maintaining fast and robust switching, high 
isomerization rates and distinctively stable isomers. The red-shifting of the isomerization wavelengths is 
amenable by three general approaches; the first and most prominent method is to alter the intrinsic 
molecular design of the photoswitch to lower the HOMO-LUMO gap for direct photoexcitation. The 
second strategy relies on indirect photoexcitation through energy transfer of sensitizers, e.g. triplett 
photosensitizers, or multiphoton antennae, which absorb long-wavelength energy of one or multiple 
quanta and transfer it to the photoswitch. The last method utilizes electrochemical or long-wavelength 
induced oxidation/reduction through electron transfer to/from a sensitizer to drive the isomerization12. 
Engineering of the HOMO-LUMO gap affects the energy needed for the p-p* transition, i.e. the energy 
needed for trans ⇾ cis isomerization, and lowering of this excitation energy can be classically achieved by 
extending the p-electron system with aromatic residues or through introduction of electron-donating (EDG) 
or electron-withdrawing (EWG) groups in ortho/para-position to the azo-bridge (Scheme 1.1). Although an 
extended p-system may result in a great red-shift of the p-p* transition, this does not necessarily influence 
the absorbtion wavelengths of the n-p* transition. Thus, the two bands can overlap leading to a shifted, 
“early” PSS and reduced isomerization rates with lower selectivity. In addition, tweaking of the 
photochromic molecule’s electronic system may also result in shorter or longer half-lives of the thermal 
relaxation rate due to a diminished N=N-double bond character or stabilized dipoles in the transition 
states, respectively51,60. 
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Scheme 1.1:  Tuning of the azobenzene (1.5) electronic system. Overview of the three approaches for HOMO-LUMO 
gap engineering for the red-shifting of photoconversion wavelengths in the direct photoexcitation of 1.5. 
1.1.3 MODIFYING AZOBENZENE WITH SUBSTITUENTS 
There are diverse methods to synthesize azobenzenes, ranging from classical azo-coupling over Mill’s 
reaction to hydrazine cross-coupling and oxidation4,61. This offers various approaches for azobenzene 
derivatization and many substituted azobenzene photoswitches have been synthesized and published so 
far. The introduction of para-amino groups as EDGs or the incorporation of five-membered aromatic 
heterocycles not only leads to a red-shift of the absorption bands, but also increases the solubility in 
physiologically relevant aqueous media (Figure 1.3). Thereby, the solvent has a large influence on the 
photophysical properties and the photoswitches should be adjusted accordingly. For example, the 
electron-donating amino groups in ortho-position in compounds 1.10 – 1.13 facilitate a further red-shift of 
the absorption bands, but at the expense of bistability56,62,63. 
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Figure 1.3:  Modified azobenzene derivatives and their photophysical properties. Optimal photoswitching 
wavelengths for the trans ® cis isomerization and thermal relaxation half-lives of bis(para-iodoacetamido)-azobenzene 
(1.6) crosslinker for incorporation via cysteine side chains64,65, DENAQ 1.7 for the restoration of visual responses66 
and the photochromic sulfonylurea JB558 1.8 (ref. 67) under physiological conditions, i.e. phosphate buffered saline 
(PBS) or HEPES-Krebs-Ringer buffer (HKS). Absorption maxima and thermal relaxation half-lives for bis(para-
chloroacetamido)-azobenzene (1.9) ortho-substituted with piperidin (1.10), diethylamine (1.11) and pyrrolidine (1.12) 
in PBS, and piperazine (1.13) in *70% MeCN / 30% PBS solution56,62. Long-lived half-life of the cis-isomer in Fuchter’s 
arylazopyrazole 1.14 (ref. 68).  
The introduction of a pair of ortho-methoxy groups leads to a red-shifted p-p* transition, while the 
occupation of all four ortho-positions with methoxy substituents causes a red-shift of the p-p* and n-p* 
bands, yielding the chromophore 1.15 with photoswitching wavelengths exclusively in the visible 
spectrum and a long-lived cis-state under physiological conditions (t1/2 = 12 hrs at 40 °C in PBS)
48. 
Nevertheless, a drawback is the impaired stability towards intracellular glutathione reduction, rendering 
these compounds unsuitable for biological applications. Alternatively, electron-poor azobenzenes with 
electron-withdrawing ortho-halogeno substituents are resistant to glutathione reduction, have clearly 
separated cis- and trans-n-p* bands in the visible spectrum and longer thermal half-lives (Figure 1.4)12,49,69. 
Para-positioned electron-donating substituents in these compounds narrow the gap between the two n-p*-
bands, while electron-withdrawing substituents, e.g. ester groups as in compound 1.18, increase this gap 
up to 50 nm and lead to compounds with high photoconversion and remarkable thermal half-lives of the 
cis-isomer69.  
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Figure 1.4:  Shifting of maximale absorption in azobenzenes with ortho-substituents. Amino azobenzenes with 
electron-donating methoxy groups (1.15) or fluoro (1.16) and chloro (1.17) substituents in ortho-position show red-
shifted transition bands, high photoconversion rates and bistability56,69,70. Electron-withdrawing ester groups in tetra-
fluoro compound 1.18 exhibit long thermal half-lives69. 
1.1.4 MODIFYING THE AZOBENZENE CORE 
Introducing substituents can be easily used to alter the electronic and therefore photophysical properties 
of azobenzene, but it is also possible to modify the azobenzene core structure. As seen for the compounds 
1.8 and 1.14 in the preceeding chapter, the integration of aromatic heterocycles greatly influences 
photoswitching wavelengths and thermal half-lives. Another series involves bridged azobenzene 
chromophores that are based on diazocin (1.19). Although this structure has already been discovered over 
one century ago71, it was only recently that it was evaluated, modified and employed as a 
photoswitch68,72,73. These cyclic azobenzenes show large separations of the cis/trans-isomer n-p* bands 
due to geometrical constraints and can be switched, in contrast to unsubstituted azobenzene, in both 
directions by irradiation of these bands (blue or green light). One of the most interesting features of these 
chromophores is the inversion of the thermal stability of both isomers, meaning the cis-isomer is thermally 
more stable than the trans-form. Amino substituents in ortho- or para-position to the N=N-bridge influence 
the red-shift and separation of the cis-/trans-n-p* bands, thermal half-lives and photoconversion rates 
(Scheme 1.2). While the latter is >90% for unsubstituted diazocin 1.19, bis(para-acetamido) compound 
1.20 only shows 70% and bis(ortho-acetamido) compound 1.21 53% photoconversion rates73–75. 
 
Scheme 1.2:  Bridged azobenzene compounds. Photoswitching wavelengths of the n-p* transition bands of diazocin 
1.19 and related compounds 1.20 and 1.21 (ref. 73, 75). 
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1.1.5 METHODS OF AZOBENZENE IMPLEMENTATION AND PHOTOCONTROL 
The optical control over the structure and function of peptides with azobenzenes can be achieved by 
several ways, including i) introduction of a chromophore into the peptide backbone by extension or 
substitution of parts of the amino acid sequence, and ii) through attachement via reactive side chains or 
side chain modifications. Photoswitches implied in the first method include molecules with amino and 
carboxy functional groups and azobenzene-modified natural amino acids. 
The term amino acid photoswitch already reveals the nature of attachment for these chromophores: they 
contain an amino and carboxyl functional group for incorporation into the backbone/sequence of peptides 
and proteins. This can be done synthetically through solid-phase peptide synthesis56, or in cellulo through 
expanding the genetic code with modified transfer RNA (tRNA)/aminoacyl-tRNA pairs76–78. Thereby the 
former approach allows site-specific substitution of amino acids in the primary sequence without severly 
affecting the overall function and potency towards the target. Moreover, if the photoswitch is to be 
integrated into de novo peptides, e.g. small photoswitchable model systems for structural biology, the 
primary sequence can be designed based on the application. To access these optical responsive amino 
acids the azobenzene unit can be i) functionalized with the amino and carboxyl functional groups, ii) 
attached directly or through a linker to an amino acid functional group (i.e. e-amino group of lysine), or iii) 
introduced via the aromatic side chain of phenylalanine and tyrosine. 
 
Figure 1.5:  Peptide backbone photoswitches AMPP and APB. Structures and photoswitching wavelengths of AMPP 
1.22 (ref. 25) and 1.23 (ref. 79) with adjacent amino acids (C=O, NH and dashed lines). Overlay of peptide backbone 
over chromophore structure 1.22 and 1.23 shows that both compounds span four amino acids: Thereby latter structure 
is twisted and more rigid than the former one. 
Examples of this the first approach are provided by the chromophores 3-[3-(aminomethyl)phenylazo]-
phenylacetic acid (AMPP, 1.22)20,25,80 and 4-[4-(amino)phenylazo]benzoic acid (APB, 1.23)79,81, which are 
both inserted into the peptide backbone (Figure 1.5). Photoswitching wavelengths are similar for both 
compounds, with a slight red-shift for the cis ⇾ trans isomerization in APB 1.23. Furthermore, both 
azobenzenes exhibit high photoconversion rates (>90% and 75% for 1.22 and 1.23, respectively) and good 
bistability. The meta-amino/carboxyl groups in AMPP 1.22 are connected via two methylene groups, which 
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act as flexible spacers and facilitate the adoption of native peptide structures. In contrast, APB 1.23 
comprises a more rigid and twisted structure, where the N- and C-terminal amide bonds are directly 
attached to the azobenzene core. This leads to an overall increase of the photoinduced conformational 
shift between the cis/trans-isomers of APB-peptides. Although this might seem advantageous, it can also 
suppress the formation of native conformations in small linear peptides. Thus, this photoswitch was mainly 
used in cyclic peptides79,81.The substitution of amino acids in the peptide backbone with photoswitches 
represents a rather invasive approach for receiving photochromic peptides and often leads to a reduced 
potency towards the biological target, e.g. in case of peptidic drugs. This can be circumvented by 
incorporating the photoswitch as an amino acid side chain modification. In the photoswitchable amino 
acid (S)-3-(4-(phenyldiazenyl)phenyl)propanoic acid (AzoPhe, 1.24) the azobenzene structure is connected 
via a side chain para-extension of the aromatic ring in phenylalanine or tyrosine (Figure 1.6). While this 
photoswitch can be incorporated into peptides by a single amino acid exchange, the structural changes 
provoked by cis-/trans-isomerization are less pronounced than in backbone-functionalized 
photoswitchable peptides. This is obviously due to sterical rearrangement of the azobenzene in the side 
chain, rather than large structural shifts of the peptide secondary structure. Nevertheless, AzoPhe 1.24 and 
related photoswitches were successfully integrated and used to optically control protein function82,83.  
 
Figure 1.6:  Side chain amino acid and crosslinker photoswitches AzoPhe 1.24 and p-BDCA 1.25. Structures and 
photoswitching wavelengths of 1.24 (ref. 82, 83) and 1.25 (ref. 64, 73).  
Another approach utilizes photoswitchable crosslinkers which are fused onto the peptide through reactive 
groups, i.e. reactive cysteine residues. A recent example is the photoswitchable crosslinker (Z)-N,N'-
(11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)bis(2-chloroacetamide) (p-BDCA, 1.25), which 
possess two chloroacetamido groups in para-position to the azo bridge and can be reacted with two thiol 
groups of distal cysteines (Figure 1.5). The photoswitch thus acts as a conformational bridge that enables 
the optical control of the distance between both cysteine residues. Since a-helical structures need defined 
distances between involved residues, the distance change upon isomerization in crosslinked peptides was 
used to optically control the helix content64,73. 
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is still subject to design and synthetic optimizations. From the second group of photoswitches the successful 
synthesis of the known photoswitch crosslinker N,N'-(11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-
diyl)bis(2-chloroacetamide) (p-BDCA, 1.25)73, as well as the synthesis of  the bis(chloroacetamido) analog 
of crosslinker 1.21, N,N'-(11,12-dihydrodi-benzo[c,g][1,2]diazocine-3,8-diyl)bis(2-chloroacetamide) (m-
BDCA, 1.29), is shown. Furthermore, the synthesis of the novel photoswitch crosslinker based on 
azobenzothiazole, N,N'-(diazene-1,2-diylbis(benzo[d]thiazole-2,6-diyl))bis(2-chloroacet-amide) (DABT, 
1.30), is presented and the photochromic properties are discussed. 
1.2.1 SYNTHESIS OF FMOC-AMPP 1.26 
 
Scheme 1.3:  Synthesis of Fmoc-AMPP 1.26. Reagents and conditions: a) Fmoc-OSu, DMF/MeCN (1:5), rt, 4 hrs (46%); 
b) NH4Cl, zinc, 2-methoxyethanol, 0 °C ⇾ rt, 30 min; FeCl3·6 H2O, EtOH/H2O (5:1), 0 °C ⇾ rt, 90 min (67%) and c) 
AcOH, rt, 24 hrs, (29%). 
The synthesis of Fmoc-AMPP 1.26 was adapted from Dong et al.80, who themselves optimized the original 
strategy from Aemissegger et al.25. It is a fast three step synthesis, which involves the classical Mill’s 
reaction61 between an amino and nitroso compound to generate the asymmetrically substituted 
azobenzene 1.26 (Scheme 1.3). In a first step the benzylic amino group in 3-(aminomethyl)anilin (1.31) 
was Fmoc-protected with N-(9-fluorenylmethoxycarbonyloxy)-succinimide (Fmoc-OSu) to yield 
compound 1.32. In the next step, 2-(3-nitrophenyl)acetic acid (1.33) was first reduced with zinc to 
hydroxylamine and subsequently oxidized with FeCl3 to form nitroso compound 1.34. Both compounds 
1.32 and 1.34 were then reacted with each other to form the desired Fmoc-AMPP 1.26. Spectral and 
photophysical data of this chromophore incorporated into peptides can be found in the publications of 
Aemissegger, Dong and Podewin et al.21,25,80. 
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1.2.2 SYNTHESIS OF FMOC-AZOPHE 1.27 
 
Scheme 1.4:  Synthesis of Fmoc-AzoPhe 1.27. Reagents and conditions: a) PhNO, AcOH, 25 hrs, rt (98%); b) TFA, 
CH2Cl2, 18 hrs, rt and c) Fmoc-Cl, dioxane, 0 °C/1 hr ⇾ rt/72 hrs (88%). 
The chromophore 1.27 was synthesized following the protocol of Bose et al.78, in which commercial 
available L-N-tert-butoxycarbonyl-para-phenylalanine (1.35) was reacted with nitrosobenzene to form N-
(tert-butoxycarbonyl)-L-phenylalanine-4’-azobenzene (1.36) (Scheme 1.4). Deprotection of the Boc-
protecting group and subsequent Fmoc-protection yielded the photoswitch amino acid Fmoc-AzoPhe 1.27 
with good yields. Spectral and photophysical data to this chromophore can be found in the publication of 
Bose et al.78. 
1.2.3 SYNTHETIC ROUTE TOWARDS FMOC-AMBD 1.28 
 
Scheme 1.5:  Synthetic route towards Fmoc-AMBD 1.28. Reagents and conditions: a) NBS, BPO, CCl4, 10 min, rt 
(92%); b) SOCl2, 110 °C, 3 hrs; c) t-BuOH, CH2Cl2, 0 °C/2 hrs ⇾ rt/18 hrs (78%); d) PPh3, PhMe, 120 °C, 18 hrs (52%); 
e) 3-Cyanobenzaldehyd, KHMDS, abs. THF, 0 °C/2 hrs ⇾ rt/20 hrs (76%); f) H2, Pd/C, THF/MeOH, 72 hrs (98%); g) 
succinic anhydride, AcOH, DMAP, 130 °C, 18 hrs (81%) and h) KNO3, H2SO4, 60 °C, 6 hrs (68%). Further reaction 
steps: i) azo coupling; j) succinimide deprotection and k) Fmoc-protection. 
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The planned synthesis of the bridged azobenzene photoswitch Fmoc-AMBD 1.28 comprised at first the 
construction of the ethylene bridge through a Wittig olefination, followed by reductive azo bridge formation 
and final Fmoc-protection (Scheme 1.5). Initially (steps a-d), para-tolylacetic acid (1.37) was brominated 
and then reacted with thionyl chloride to generate a reactive acyl chloride. Subsequent formation of the 
tert-butyl ester with tert-butanol and reaction with triphenylphosphine yielded the Wittig phosphonium salt 
1.38 with an overall yield of 37%.  
Compound 1.38 was then reacted with 3-cyanobenzaldehyde to form stilbene 1.39. In the Wittig reaction 
(step e), the first step was the formation of a phosphonium ylide through treatment of the phosphonium salt 
1.38 with a strong base, in this case potassium bis(trimethylsilyl)amide (KHMDS). Nucleophilic attack of 
the carbanion to 3-cyanobenzaldehyde then leads to formation of an intermediate betaine from which 
elimination delivers the desired cis/trans-stilbene 1.39. Although the cis/trans-ratio is not of particular 
interest for the succeeding reactions, due to the loss of stereo information upon reduction of the stilbene 
double bond at a later stage, it should be noted that the obtained cis/trans-ratio was 1:1.7 (determined 
through 1H-NMR). Furthermore, several strong non-nucleophilic bases such as sodium hydride, n-
butyllithium and lithium bis(trimethylsilyl)amide (LiHMDS) have been tested, but only the use of KHMDS 
delivered acceptable yields of 1.39. 
The palladium on carbon (Pd/C) catalyzed hydrogenation of stilbene 1.39 in tetrahydrofuran and methanol 
simultaneously reduced the ethenyl bridge to ethylene and the cyano group to benzylamine. In the 
following step, the amino group was then protected as a succinimide to form compound 1.40. The 
consequent double nitration of both phenyl rings in meta-position to the ethylene bridge was adapted from 
Sell et al.75 and delivered the precursor azo coupling compound 1.41.  
Intramolecular azo bridge formation can be achieved through reductive coupling of two nitro groups and 
the most frequently used protocol uses zinc as reducing agent in barium or sodium hydroxide84,85, with 
subsequent oxidation of the formed hydrazine intermediate. These procedures however suffer from low 
and irreproducible yields ranging from 2-19%. For this reason, Sell et al.75 recently used glucose in 
ethanolic solution as reducing agent and achieved constant yields of >20%. Hence, for the azo bridge 
formation in compound 1.41 glucose under the same conditions was tried, but the bridged azobenzene 
product 1.42 could not be obtained. Switching to the established zinc/barium or sodium hydroxide 
procedure also failed to deliver the desired compound 1.42.  
A further attempt to construct the azo bridge was to change from a reductive to an oxidative coupling 
process, in which two intramolecular amino groups are coupled with oxidative reagents such as meta-
chloroperoxybenzoic acid (m-CPBA), potassium peroxymonosulfate (Oxoneâ), Cu(I)Br with catalytical 
amounts of pyridine86 or with tert-butyl hypoiodite (t-BuOI)87,88 (Scheme 1.6). Therefore, dinitro compound 
1.41 was hydrogenated with hydrogen and Pd/C to diamino compound 1.43. Although the oxidative 
reagents were tested under different reaction conditions, all of them failed to afford product 1.44. To rule 
out any interference of the free carboxylic acid in 1.44, it was planned to transfer it into a methyl ester 
group. However, product 1.45 could not be obtained using thionyl chloride in methanol and at this point 
this synthesis route towards Fmoc-AMBD 1.28 was neglected.  
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Scheme 1.6:  Oxidative coupling approach for Fmoc-AMBD 1.28. Reagents and conditions: a) H2, Pd/C, THF/MeOH, 
48 hrs (94%) and b) SOCl2, MeOH, 0 °C ⇾ 75 °C, 12 hrs. Oxidative coupling with meta-CPBA, Oxone, Cu(I)Br/cat. 
Py and tert-BuOI failed to afford compound 1.44 or 1.46. 
1.2.4 SYNTHESIS OF P-BDCA 1.25 
 
Scheme 1.7:  Synthesis of p-BDCA 1.25. Reagents and conditions: a) Pd2Dba3, Xanthphos, tert-butyl carbamate, 
dioxane, 0 °C ® rt, 90 min (80%); b) CH2Cl2, TFA, anisol (6:1:1), rt, 5 hrs (70%) and c) chloroacetic anhydride, 
pyridine, diethyl ether, 1 hr, rt (55%). 
Photoswitch crosslinker p-BDCA 1.25 was synthesized based on bisbromo diazocin 1.47, which was 
kindly provided by D. H. Woodmansee and D. Trauner. The first step was a Buchwald-Hartwig amination 
with tris(dibenzylideneacetone)dipalladium(0) (Pd2dba3) and 4,5-bis(diphenylphosphino)-9,9-
dimethylxanthene (Xantphos) in absolute dioxane to generate a Boc-protected bisamide, which was 
consequently deprotected with trifluoroacetic acid  to forge bisamino diazocin 1.48 (Scheme 1.7). The last 
step was the reaction of 1.48 with chloroacetic anhydride to form p-BDCA 1.25. Detailed spectral and 
photophysical data to this chromophore can be found in the publication of Samanta et al.73.  
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1.2.5 SYNTHESIS OF M-BDCA 1.29 
 
Scheme 1.8:  Synthesis of m-BDCA 1.29. Reagents and conditions: a) KNO3, H2SO4, 60 °C, 6 hrs, (88%); b) zinc, 
Ba(OH)2, EtOH/H2O (5:1), rt, 3 hrs (40%) and c) chloroacetic anhydride, pyridine, diethyl ether, rt, 1 hr (42%).  
The first two steps of the m-BDCA 1.29 synthesis followed the protocol of Sell et al.75 (Scheme 1.8). 
Commercially available 4,4'-(ethane-1,2-diyl)dianiline (1.49) was meta-nitrogenated with potassium 
nitrate in sulfuric acid. This was followed by a reductive azo coupling with zinc and barium hydroxide in 
ethanolic solution to yield bisamino diazocin 1.50 with satisfactory yield (40%). The last step involved the 
reaction of 1.50 with chloroacetic anhydride to form m-BCDA 1.29.  
The UV/Vis spectra of cis-/trans-bis(meta-chloroacetamido) diazocin 1.29 revealed as expected similar 
photochromic properties to the bis(meta-acetamido) diazocin 1.21 (Figure 1.8)75. The UV spectrum of cis-
1.29 exhibits a shoulder at 320 nm for the p-p* transition and a maximum at 400 nm for the n-p* transition. 
Irradiation at 405 nm leads to isomerization and generation of 51% of the trans isomer, as determined by 
1H-NMR. The rather low conversion rate compared to unsubstitued diazocin 1.19 (>90%) probably 
originates from the overlapping p-p* and n-p* transitions. The UV spectrum of trans-1.29 shows a slightly 
shifted shoulder for the p-p* transition at 330 nm and a large shift to 490 nm for the n-p* transition. The 
distinctive separation of the latter to any other bands leads to complete back conversion to the cis-isomer 
upon irradiation with 530 nm light. 
Repeated photoswitching of 1.29 with 405 and 530 nm light demonstrates the speed and reliability of 
isomerization and negligible photobleaching after several cycles (Figure 1.8). The observed t-values of 
tcis⇾trans = 98.9 ± 3.9 sec and ttrans⇾cis = 60.4 ± 4.0 sec show a roughly 1.5x faster back conversion to the cis-
isomer. This corresponds to the isolated n-p* transition of the trans-isomer, which enables a fast and 
complete trans ⇾ cis isomerization. Detection of the thermal back-relaxation rate of 1.29 after generation 
of the trans-isomer in the PSS shows a rate of kobs = 2.72 ´ 10-4 au490nm/min (in DMSO at 25 °C). This is a 
slightly lower rate compared to kobs = 3.58  ´ 10-4 au330nm/min of unsubstituted azobenzene (in benzene at 
0 °C)89 and is similar to the thermal half-live of t1/2 = 46 hrs for bis(meta-acetamido) diazocin 1.21 (in 
MeCN at 27 °C)75.  
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Figure 1.8:  Photophysical properties and photoswitching kinetics of m-BDCA 1.29. Left: UV/Vis spectra of cis-1.29 
and trans-1.29 in the PSS at 530 and 405 nm, respectively (in DMSO at 25 °C). Right: switching kinetics of 1.29 for 
the cis ⇾ trans and trans ⇾ cis isomerization at 405 or 530 nm, respectively. Measured as absorbance change of the 
trans-1.29 n-p*
 
transition at 490 nm (in DMSO at 25 °C).  
1.2.6 SYNTHESIS OF DABT 1.30 
 
Scheme 1.9:  Synthesis of DABT 1.30. Reagents and conditions: a) NaOCl solution (13%), 60 °C, 1 hr, (90%); b) NaS, 
THF, 80 °C, 3 hrs (86%) and c) 3-chloropropionyl chloride, DMAP, DMF, 0 °C ⇾ rt, 2 hrs (64%). 
Azobenzothiazoles were first synthesized in the mid of the last century90, but their use as dyes is impeded 
due to the low photostability and high oxidation potential of these compounds91,92. Nevertheless, since 
their photophysical properties have not been properly assessed, especially with respect to their 
photoswitching capabilities, the azobenzothiazole crosslinker DABT 1.30 was synthesized and 
characterized. The synthesis of DABT 1.30 followed a fast three step route starting with commercially 
available 2-amino-6-nitrobenzothiazole (1.51), which was homo azocoupled under oxidative conditions 
with NaOCl to form 1,2-bis(6-nitrobenzothiazol-2-yl)diazene (1.52). Upon reduction with sodium sulfide 
and subsequent reaction with 3-chloropropionyl chloride the desired bis(chloroacetamido) 
azobenzothiazole 1.30 could be generated. 
The UV spectra of cis-/trans-DABT 1.30 show both a very strong, red-shifted absorption band at  
lmax = 536 nm, with a small shoulder between 630 – 710 nm (Figure 1.9). Illumination of trans-1.30 with 
green light (530 nm) leads to a minimal reduction of the absorption band at 536 nm, indicating the 
formation of the cis-isomer. The difference in the absorption spectra of both isomers is marginal, and no 
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shifting of bands could be observed. The switching kinetics were assessed through measurement of 
absorbtion change upon illumination of the transition band at 530 nm (Figure 1.9). The isomerization rate 
is very fast, with the thermal cis ⇾ trans back-relaxation in the dark occurring as rapid as the corresponding 
light-induced cis-formation (ttrans⇾cis = 274.5 ± 33.7 msec and tcis⇾trans = 289.8 ± 40.0 msec). Moreover, the 
switching was robust and no photobleaching or degradation were detected. The fast kinetics are in line 
with other red-shifted compounds, which also show fast photoconversion and thermal back-relaxation 
rates10,11. The molar extinction coefficient was determined as e530 nm = 28400 L·mol-1·cm-1 (in DMSO at 25 
°C) and is therewith comparable to azobenzene and other dyes93,94. The fluorescence quantum yield was 
determined to f = 0.5% (vs. perylen-S13 standard in DMSO at 25 °C), thus 1.30 exhibits no fluorescence. 
 
Figure 1.9:  Photophysical properties and photoswitching kinetics of DABT 1.30. Left: UV/Vis spectra of cis/trans-
1.30 (in DMSO at 25 °C). Right: switching kinetics of 1.30 for the trans ⇾ cis and cis ⇾ trans thermal back-relaxation 
at 530 nm or in the dark, respectively. Measured as absorbance change at 530 nm (in DMSO at 25 °C).  
Of the six photoswitches discussed in this chapter, AMPP 1.22, AzoPhe 1.24, p-BDCA 1.25 and m-BDCA 
1.29 have successfully been incorporated into target peptides, however peptides containing the 
photoswitchable crosslinkers 1.25 and 1.29 lack preliminary results and are not discussed in detail. Thus, 
all the photoswitchable peptides presented in the following chapters utilized chromophores 1.26 and 1.27. 
An overview of the photoswitches and the modified peptides is given in Figure 1.10. 
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1.3 EXPERIMENTAL 
1.3.1 SYNTHESIS 
1.3.1.1 N-(9-FLUORENYLMETHOXYCARBONYLOXY)-SUCCINIMIDE (1.32) 
 
To a solution of 14.1 g (44.0 mmol, 1 eq.) Fmoc-OSu in 100 mL MeCN was added slowly a solution of 
4.42 mL (44.0 mmol, 1 eq.) 3-(aminobenzyl)amine 1.31 in 6.1 mL (44.0 mmol, 1 eq.) triethylamine and 
55 mL of a MeCN/DMF (10:1) mixture. The resulting solution was stirred for 4 hrs at room temperature 
and subsequently quenched with 50 mL water. The obtained precipitate was filtered off, washed with 50 
mL of a tert-butyl methyl ether/trifluoroethanol (1:1) mixture and dried in vacuo. The product 1.32 was 
obtained as colorless solid (7.85 g, 22.9 mmol, 52%) and used in the next reaction without further 
purification.  
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.77 (d, J = 7.2 Hz, 2H), 7.60 (d, JH1,H2 = 7.4 Hz, 2H), 7.40 (t, J = 
7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 7.12 (t, J = 7.6 Hz, 1H), 6.65 (d, J = 7.6 Hz, 1H), 6.62-6.58 (m, 3H), 
5.03 (bs, 1H), 4.45 (d, J = 6.9 Hz, 2H), 4.30 (d, J = 5.8 Hz, 2H), 4.24 (t, J = 7.0 Hz, 1H).  
13C-NMR (75 MHz, CDCl3): δ [ppm] = 156.4, 146.6, 143.9, 141.3, 139.6, 129.7, 128.7, 127.6, 127.0, 
125.0, 120.1, 114.2, 114.0, 66.7, 47.3, 45.0. 
HRMS (+EI): calc. for C22H20O2N2
 [M]+: 344.1525; found: 344.1596.  
1.3.1.2 (9H-FLUOREN-9-YL)METHYL (3-AMINOBENZYL)CARBAMATE (1.34) 
 
A solution of 2.50 g (13.2 mmol, 1.0 eq.) 2-(3-nitrophenyl)acetic acid (1.33) in 100 mL 2-methoxyethanol 
under an argon atmosphere was stirred for 10 min at room temperature before addition of a solution of 
1.09 g (20.3 mmol, 1.5 eq.) NH4Cl in 25 mL water. The solution was cooled to 0 °C and 2.10 g (32.3 
mmol, 2.5 eq.) zinc was added portionwise within 30 min. After 1 hour, the zinc was filtered off and the 
filtrate was added within 15 min to a 0 °C cooled solution of 11.2 g (41.4 mmol, 3.0 eq.) FeCl3·6 H2O in 
120 mL of a EtOH/H2O (2:1) mixture. After stirring for 1.5 hrs, the solution was diluted with 200 mL water 
and extracted with 5 x 100 mL diethyl ether. The combined organic fractions were dried with magnesium 
sulfate and the solvent was evaporated. The crude product was purified via column chromatography on 
silica (eluent EtOAc/cHex/AcOH 10:1:0.5). The product was obtained as green-turquoise oil with 95% 
(2.18 g, 13.2 mmol) yield. 
NH2
NHFmoc
Chemical Formula: C22H20N2O2
Exact Mass: 344.1525
Molecular Weight: 344.4140
NO
COOH
Chemical Formula: C8H7NO3
Exact Mass: 165.04
Molecular Weight: 165.15
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1H-NMR (400 MHz, CDCl3): δ [ppm] = 8.16 (d, JH4,H5 = 7.5 Hz, 1H), 7.88 (d, JH5,H6 = 7.3 Hz, 1H), 7.76 (s, 
1H), 7.63 (t, JH4,H5,H6 = 7.5 Hz, 1H), 3.82 (s, 2H). 
13C-NMR (100 MHz, CDCl3): δ [ppm] = 176.6, 165.5, 136.2, 136.0, 129.6, 121.4, 120.5, 40.3. 
MS (+EI) m/z: calc. for C8H7O3N
 [M]+: 165.04; found: 165.09. 
1.3.1.3 3-[3-(AMINOMETHYL)PHENYLAZO]PHENYLACETIC ACID (1.26) 
 
To a solution of 0.27 g (1.65 mmol, 1.0 eq.) 2-(3-nitrosophenyl)acetic acid (1.34) in 8.0 mL glacial acetic 
acid were added portionwise 0.57 g (1.65 mmol, 1 eq.) (9H-fluoren-9-yl)methyl (3-
aminobenzyl)carbamate (1.32). The solution was stirred over night at room temperature, then solvent was 
evaporated and the crude product was purified via flash chromatography on silica (EtOAc/cHex/AcOH 
1:1:0.01). The product was obtained as orange solid (3.83 g, 7.80 mmol, 59%).  
1H-NMR (600 MHz, CDCl3): δ [ppm] = 7.85-7.81 (m, 4H), 7.75 (d, J = 7.4 Hz, 2H), 7.60 (d, J = 7.1 Hz, 
2H), 7.48 (t, J = 8.3 Hz, 2H), 7.42-7.36 (m, 4H), 7.30 (t, J = 7.6 Hz, 2H) 5.22 (bs, 1H), 4.51-4.47 (m, 4H), 
4.24 (t, JH9,CH2 = 6.9 Hz, 1H), 3.75 (s, 2H).  
13C-NMR (150 MHz, CDCl3): δ [ppm] = 175.8, 156.5, 152.8, 152.7, 143.9, 141.3, 139.6, 134.7, 134.5, 
132.0, 130.1, 129.5, 129.4, 127.7, 127.1, 125.0, 123.6, 122.4, 122.3, 121.4, 120.0, 66.8, 47.3, 44.8, 
40.7.  
HRMS (+EI) m/z: calc. for C22H20O2N2
 [M]+: 491.1845; found: 491.1845.  
1.3.1.4 N-(TERT-BUTOXYCARBONYL)-L -PHENYLALANINE-4’-AZOBENZENE (1.36) 
 
To a solution of 0.50 g (1.78 mmol, 1.0 eq.) N-tert-butoxycarbonyl-para-L-phenylalanine (1.35) in 50 mL 
glacial acetic acid was added 0.29 g (2.69 mmol, 1.5 eq.) nitrosobenzene. The solution was stirred for 24 
hrs at room temperature, before 150 mL saturated sodium carbonate solution was added. The aqueous 
phase was extracted with 4 x 50 mL ethyl acetate. The combined organic layers were dried with magnesium 
sulfate and after removal of the solvent the crude product was purified via flash chromatography on silica 
gel (eluent EtOAc/cHex/AcOH 5:1:0.05). The product was obtained as orange solid with 98% (6.55 g, 
1.77 mmol) yield.  
N N COOHFmocHN Chemical Formula: C30H25N3O4Exact Mass: 491.18
Molecular Weight: 491.55
BocHN COOH
N N
Chemical Formula: C20H23N3O4
Exact Mass: 369.17
Molecular Weight: 369.42
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1H-NMR (400 MHz, MeOD-d4): δ [ppm] = 7.89 (dt, 2H, H9, H9’), 7.85 (d, J = 8.1 Hz, 2H, H6, H6’), 
7.58-7.46 (m, 3H, H10, H10’, H11), 7.43 (d, J = 8.1 Hz, 2H, H5, H5’), 4.42 (dd, J = 9.3, 5.0 Hz, 1H, H2), 
3.27 (dd, J = 13.8, 5.1 Hz, 1H, H3), 3.01 (dd, J = 13.8, 9.2 Hz, 1H, H3’) and 1.38 (s, 9H, (CH3)3).
  
13C-NMR (100 MHz, MeOD-d4): δ [ppm] = 175.2 (COOH), 157.8 (NH-COOtBu), 154.0 (C8), 152.8 (C7), 
142.5 (C4), 132.2 (C11), 131.3 (C5, C5’), 130.2 (C10, C10’), 123.8 (C6,C6’), 123.7 (C9,C9’), 80.6 (O-
C(CH3)3), 56.1 (C2), 38.6 (C3) and 28.7 ((CH3)3).  
HRMS (+ESI) m/z: calc. for C20H24O4N3
 [M+H]+: 370.1761; found: 370.1769.  
1.3.1.5  (S,E)-2-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-3-(4-(PHENYLDIAZENYL)PHENYL)-
PROPANOIC ACID, FMOC-AZOPHE (1.27) 
 
To a solution of 0.64 g (1.72 mmol, 1.0 eq.) N-(tert-butoxycarbonyl)-L-phenylalanine-4’-azobenzene (1.36) 
in 40 mL absolute dichloromethane was added 30 mL trifluoroacetic acid and the solution was stirred over 
night at room temperature. The solvent was evaporated and the remaining trifluoroacetic acid was co-
evaporated five times with 20 mL toluene each. The product was obtained as orange solid with quant. 
(0.46 g, 1.71 mmol) yield and was directly employed in the next step. A solution of 0.46 g (1.71 mmol, 
1.0 eq.) H2N-AzoPhe-OH in 25 mL dioxane was cooled to 0 °C and 65 mL of a 10% sodium carbonate 
solution and 0.57 g (1.70 mmol, 1.0 eq.) Fmoc-Cl in 30 mL dioxane was added. The mixture was stirred 
for 1 hour at 0 °C and subsequently stirred 72 hrs at room temperature. The reaction was triturated with 
120 mL water and the aqueous phase was extracted with 3 x 100 mL dichloromethane. The aqueous phase 
was acidified with 1 M HCl to pH = 2 and extracted with 3 x 50 mL dichloromethane. The combined 
organic layers were dried with magnesium sulfate and the solvent was removed under reduced pressure. 
The crude product was purified via flash chromatography on silica (eluent cHex/EtOAc/AcOH 5:1:0.05). 
The product was retained as a slight-orange solid with 88% (0.73 g, 1.50 mmol) yield.  
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.91-7.77 (m, 6H, H-ar.), 7.67-7.23 (m, 11H, H-ar.), 4.32-
4.08 (m, 4H, H2, H13, H13’, H14), 3.20 (dd, J = 13.7, 4.1 Hz, 1H, H3) and 2.98 (dd, J = 13.7, 11.0 Hz, 
1H, H3’).  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 173.1 (COOH), 155.9 (NH-COO), 152.0 (C7), 143.8, 143.7, 
142.0, 140.7, 131.4, 130.2, 129.5, 127.6, 127.0, 125.2, 122.4, 120.1, 65.6 (C14), 55.2 (C2), 46.6 (C13) 
and 36.3 (C3).  
HRMS (+ESI) m/z: calc. for C30H26O4N3
 [M+H]+: 492.1918; found: 492.1916.  
FmocHN COOH
N N
Chemical Formula: C30H25N3O4
Exact Mass: 491.18
Molecular Weight: 491.55
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1.3.1.6 2-(4-(BROMOMETHYL)PHENYL)ACETIC ACID (1.53) 
 
A solution of 25.6 g (171 mmol, 1.0 eq.) para-tolylacetic acid (1.37) in 300 mL carbon tetrachloride was 
heated to 60 °C. A mixture of 30.3 g (171 mmol, 1.0 eq.) N-bromosuccinimide and 2.50 g (10.3 mmol, 
0.1 eq.) dibenzoylperoxide was added quickly to the reaction solution, which was then heated to 95 °C. 
After a short period, a white precipitate formed and the reaction was complete. After cooling 100 mL of 
water were added and the precipitate was filtered and washed with 700 mL warm water. The colorless 
solid product was dried and used in the next reaction without further purification (32.5 g, 141 mmol, 82%). 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 10.8 (bs, 1H, COOH), 7.38 (d, J = 8.3 Hz, 2H, H2, H6), 7.22 
(d, J = 8.3 Hz, 2H, H3, H5), 4.47 (s, 2H, CH2Br) and 3.55 (s, 2H, CH2COOH).
  
HRMS (+ESI) m/z: calc. for C9H9BrO2
 [M]+: 227.9786; found: 227.9764.  
Rf (cHex/EtOAc 2:1) = 0.18. 
1.3.1.7 TERT-BUTYL 2-(4-(BROMOMETHYL)PHENYL)ACETATE (1.54) 
 
A solution of 3.00 g (13.0 mmol, 1.0 eq.) 2-(4-(bromomethyl)phenyl)acetic acid (1.53) in 60 mL 
thionylchloride was refluxed for 3 hrs at 110 °C. After cooling the excess thionylchloride was removed 
under reduced pressure and the residue dissolved in 5 mL dichloromethane. This solution was then slowly 
added to a 0 °C cooled solution of 50 mL tert-butanol and 10 mL dichloromethane. The reaction was kept 
2 hrs at 0 °C and then allowed to warm to room temperature. After being stirred over night, the solvent 
was removed under reduced pressure and the residue was dissolved in 50 mL dichloromethane. The 
organic layer was washed with 1 x 50 mL water, 1 x 50 mL sodium bicarbonate, again with 1 x 50 mL 
water and then dried with magnesium sulfate. The solvent was removed and the product was received as 
yellow oil (2.90 g, 10.2 mmol, 78%). 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.30 (m, 4H, H-ar.), 4.49 (s, 2H, CH2Br), 3.53 (s, 2H, 
CH2COOH) and 1.44 (s, 9H, CH3).
  
HRMS (+EI) m/z: calc. for C13H19O2
79Br1
 [M]+: 286.0391; found: 286.0414. calc. for C13H17O2
+ [M-Br]+: 
205.1229; found: 205.1186.  
Rf (cHex/EtOAc 2:1) = 0.64. 
Chemical Formula: C9H9BrO2
Exact Mass: 227.98
Molecular Weight: 229.07
COOH
Br
Chemical Formula: C13H17BrO2
Exact Mass: 284.04
Molecular Weight: 285.18
COOt-Bu
Br
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1.3.1.8 TERT-BUTYL 2-(4-((BROMOTRIPHENYLPHOSPHANEYL)METHYL)PHENYL)-ACETATE (1.38) 
 
A solution of 2.80 g (9.83 mmol, 1.0 eq.) tert-butyl 2-(4-(bromomethyl)phenyl)acetate (1.54) and 2.58 g 
(9.83 mmol, 1.0 eq.) triphenylphosphine in 100 mL toluene was heated to 120 °C and stirred over night. 
After cooling, the formed precipitate was filtered and washed with 2 x 100 mL chilled diethyl ether. The 
colorless solid product (3.18 g, 5.12 mmol, 52%) was dried and used in the next reaction without further 
purification. 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.93-7.89 (m, 3H, H-p-PPh3), 7.76-7.65 (m, 12H, H-o/m-
PPh3), 7.10 (d, J = 7.8 Hz, 2H, H2, H6), 6.94 (dd, J = 8.1, 2.6 Hz, 2H, H3, H5), 5.23 (d, J = 15.6 Hz, 2H, 
CH2P), 3.50 (s, 2H, CH2COOH) and 1.36 (s, 9H, CH3).
  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 170.1 (COOt-Bu), 135.1 (C1-q), 135.0 (C-p-PPh3), 134.0 (C-
m-PPh3), 133.9 (C-m-PPh3), 130.7 (C3, C5), 130.1 (C-o-PPh3), 130.0 (C-o-PPh3), 129.6 (C2, C6), 126.2 
(C4), 118.2 (C-q-PPh3), 117.4 (C-q-PPh3), 80.2 (C-q-t-Bu), 41.1 (CH2COOt-Bu), 28.1 (CH2PPh3) and 27.6 
(CH3).  
IR: ν [ppm] = 2876 (w), 2781 (w), 1715 (m), 1516 (w), 1436 (m), 1372 (w), 1288 (m), 1154 (s), 1111 (s), 
996 (w), 944 (w), 881 (w), 837 (m), 748 (s), 718 (s), 685 (s). 
MS (+EI) m/z (rel. intensity): calc. for C31H32O2P
 [M]+: 467.21; found: 467.16. 
Elemental analysis [%]: calc. (C31H32BrO2P): C 68.01, H 5.89, Br 14.60; found: C 67.84, H 5.84, Br 13.73. 
Melting point: 219 – 221 °C. 
1.3.1.9 TERT-BUTYL 2-(4-(4-CYANOSTYRYL)PHENYL)ACETATE (1.39) 
 
A suspension of 7.50 g (13.7 mmol, 1.0 eq.) tert-butyl 2-(4-((bromotriphenyl-λ5-
phosphaneyl)methyl)phenyl)acetate (1.38) in 40 mL of absolute tetrahydrofuran under argon atmosphere 
was stirred for 10 min at room temperature and then cooled to 0 °C. A 0.5 M solution of potassium 
bis(trimethylsilyl)amide (KHMDS) (2.73 g, 13.7 mmol, 1.0 eq.) in 27.4 mL abs. tetrahydrofuran and a 
solution of 1.80 g (13.7 mmol, 1.0 eq.) 4-cyanobenzaldehyde in 10 mL abs. tetrahydrofuran, both kept 
under argon atmosphere, were prepared in dried flasks. At first, the KHMDS solution was added to the 
cooled solution of 1.38 over a period of 15 min. The immediate formation of the ylide was indicated by a 
dark red color of the solution. After stirring for an additional 15 min, the 4-cyanobenzaldehyde solution 
PPh3  Br
COOt-Bu
Chemical Formula: C31H32BrO2P
Exact Mass: 546.13
Molecular Weight: 547.47
COOt-Bu
NC
Chemical Formula: C21H21NO2
Exact Mass: 319.16
Molecular Weight: 319.40
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was added swiftly. The solution was then stirred for 2 hrs at 0 °C, subsequently warmed to room 
temperature and stirred over night. The reaction was aborted through addition of 100 mL of 1 M ammonium 
chloride solution and the organic solvent was removed under reduced pressure. The aqueous layer was 
extracted with 3 x 100 mL ethyl acetate and the united organic layers were dried with magnesium sulfate 
and the solvent removed under reduced pressure. The crude product was purified via flash chromatography 
on silica (eluent cHex/EtOAc 4:1) to give the slight yellow solid product (3.34 g, 10.5 mmol, 76%) as 
cis/trans (1:1.7) isomer mixture.  
NMR atom numbering: 
 
1H-NMR (400 MHz, CDCl3): cis-1.39 δ [ppm] = 7.48 (d, J = 8.6 Hz, 2H, H11, H13), 7.32 (d, J = 8.3 Hz, 
2H, H10, H14), 7.30 (d, J = 8.4 Hz, 2H, H4, H6), 7.15 (d, J = 8.2 Hz, 2H, H1, H3), 6.54 (d, J = 12.3 Hz, 
1H, H7), 6.27 (d, J = 12.3 Hz, 1H, H8), 3.50 (s, 2H, CH2) and 1.44 (s, 9H, CH3). trans-1.39 δ [ppm] = 
7.61 (d, J = 8.6 Hz, 2H, H11, H13), 7.56 (d, J = 8.3 Hz, 2H, H10, H14), 7.48 (d, J = 8.4 Hz, 2H, H4, H6), 
7.29 (d, J = 8.2 Hz, 2H, H1, H3), 7.19 (d, J = 16.3 Hz, 1H, H7), 7.06 (d, J = 16.3 Hz, 1H, H8), 3.54 (s, 2H, 
CH2) and 1.45 (s, 9H, CH3). 
13C-NMR (100 MHz, CDCl3): cis-1.39 δ [ppm] = 170.7 (COOt-Bu), 142.2 (C9), 134.8 (C5), 134.5 (C2), 
133.1 (C7), 132.2 (C11, C13), 129.6 (C4, C6), 129.5 (C1, C3), 128.9 (C10, C14), 128.3 (C8), 119.0 (C16), 
110.5 (C12), 81.0 (C20), 42.4 (C15) and 28.1 (CH3). trans-1.39 δ [ppm] = 170.7 (COOt-Bu), 141.9 (C9), 
135.2 (C2), 135.0 (C5), 132.5 (C11, C13), 132.1 (C7), 129.8 (C1, C3), 127.1 (C4, C6), 126.9 (C10, C14), 
126.6 (C8), 119.1 (C16), 110.6 (C12), 81.1 (C20), 42.5 (C15) and 28.1 (CH3). 
IR: ν [ppm] = 3050 (w), 1728 (w), 1590 (w), 1483 (w), 1437 (m), 1189 (m), 1116 (s), 997 (w), 753 (w), 694 
(vs). 
HRMS (+EI) m/z: calc. for C21H21NO2
 [M]+: 319.1572; found: 319.1564. Calc. for C17H13NO2
+ [M-t-Bu+H]+: 
263.0946; found: 263.1012.  
Elemental analysis [%]: calc. (C21H21NO2): C 78.97, H 6.63, N 4.39; found: C 78.78, H 6.76, N 4.34. 
Rf (cHex/EtOAc 3:1) = trans 0.64; cis 0.58. 
Melting point: 150 – 152 °C. 
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15 COOt-Bu
17
NC
16
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1.3.1.10 TERT-BUTYL 2-(4-(4-(AMINOMETHYL)PHENETHYL)PHENYL)ACETATE (1.55) 
 
In a large flask a solution of 9.20 g (28.8 mmol, 1.0 eq.) tert-butyl 2-(4-(4-cyanostyryl)phenyl)acetate (1.39) 
in mixture of 200 mL methanol/tetrahydrofuran (1:1) was prepared. To this solution 800 mg palladium on 
charcoal was added and the reaction flask was evacuated and purged three times with hydrogen through 
a mounted hydrogen ballon. The solution was stirred 36 hrs at room temperature and subsequently filtered 
through Hyflo® celite. The celite was rinsed with 100 mL methanol and the resulting filtrate was removed 
under reduced pressure. The product was obtained as colorless crystalline solid with almost quantitive 
yield (9.14 g, 28.1 mmol, 98%) and was used directly in the next reaction without further purification. 
NMR atom numbering: 
 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.21 (m, 2H, H-ar.), 7.16 (m, 4H, H-ar.), 3.66 (s, 2H, H2), 
3.49 (s, 2H, H17), 2.83 (s, 4H, H9, H10) and 1.39 (s, 9H, CH3).
  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 172.6 (COOt-Bu), 141.6 (C6-q), 133.9 (C3-q), 130.7 (C11-q), 
132.2 (C14-q), 129.0 (C4, C8), 128.3 (C5, C7), 128.0 (C12, C16), 126.9 (C13, C15), 45.4 (C2), 41.3 (C17), 
36.8 (C9), 36.7 (C10) and 27.7 (CH3).  
IR: ν [ppm] = 2981 (w), 2916 (w), 2226 (m), 1731 (s), 1606 (w), 1517 (w), 1455 (w), 1412 (w), 1368 (m), 
1340 (m), 1226 (m), 1150 (s), 1021 (w), 938 (w), 872 (m), 828 (m), 744 (m), 721 (w), 691 (w). 
HRMS (+ESI) m/z: calc. for C21H28O2N
 [M+H]+: 326.2115; found: 326.2167. 
Elemental analysis [%]: calc. (C21H27NO2): C 77.50, H 8.36, N 4.30; found: C 77.24, H 8.37, N 4.26. 
Rf (cHex/EtOAc 1:1) = 0.01. 
Melting point: 101 – 102 °C. 
1.3.1.11 2-(4-(4-((2,5-DIOXOPYRROLIDIN-1-YL)METHYL)PHENETHYL)PHENYL)ACETIC ACID (1.40) 
 
To a solution of 2.60 g (8.00 mmol, 1.0 eq.) tert-butyl 2-(4-(4-(aminomethyl)phenethyl)phenyl)acetate 
(1.55) and 1.62 g (16.0 mmol, 2.0 eq.) succinic anhydride in 25 mL acetic acid was added a catalytic 
COOt-Bu
Chemical Formula: C21H27NO2
Exact Mass: 325.20
Molecular Weight: 325.45H2N
1
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COOt-Bu
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H2N
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COOH
Chemical Formula: C21H21NO4
Exact Mass: 351.1471
Molecular Weight: 351.4020
N
O
O
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amount of 4-(dimethylamino)pyridine. The solution was heated to 130 °C and stirred for 42 hrs. After 
cooling, the solvent was removed under reduced pressure and the residue was dissolved in 100 mL 
dichloromethane. The organic layer was washed with 1 x 100 mL sodium bicarbonate solution and 1 x 
100 mL brine and then dried with magnesium sulfate. The product was yielded as colorless solid (2.27 g, 
6.46 mmol, 81%) and was used in the next reaction without the need for further purification.  
 
NMR atom numbering: 
 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 7.31 (d, J = 8.0 Hz, 2H, H4, H8), 7.20 (d, J = 8.2 Hz, 2H, H13, 
H15), 7.15 (d, J = 8.2 Hz, 2H, H12, H16), 7.13 (d, J = 8.2 Hz, 2H, H5, H7), 4.63 (s, 2H, H2), 3.62 (s, 2H, 
H17), 2.87 (s, 4H, H9, H10) and 2.70 (s, 4H, H20, H20’).  
13C-NMR (100 MHz, CDCl3): δ [ppm] = 177.0 (C19, C19’), 177.0 (C18), 141.7 (C6-q), 140.9 (C11-q), 
133.6 (C3-q), 131.1 (C14-q), 129.0 (C4, C8), 129.5 (C13, C15), 129.2 (C4, C8), 128.8 (C12, C16), 128.7 
(C5, C7), 42.3 (C2), 40.6 (C17), 37.5 (C9, C10) and 28.4 (C20, C20’).  
IR: ν [ppm] = 2921 (m), 1702 (s), 1606 (m), 1513 (m), 1414 (s), 1337 (m), 1245 (s), 1170 (s), 891 (m), 815 
(m), 668 (m). 
HRMS (+EI) m/z: calc. for C21H21NO4
 [M]+: 351.1471; found: 351.1154. 
Elemental analysis [%]: calc. (C21H21NO4): C 71.78, H 6.02, N 3.99; found: C 71.32, H 6.11, N 3.96. 
Rf (cHex/EtOAc 3:1) = 0.1. 
Melting point: 85 – 91 °C. 
1.3.1.12 2-(4-(4-((2,5-DIOXOPYRROLIDIN-1-YL)METHYL)-2-NITROPHENETHYL)-3-NITROPHENYL)ACETIC ACID 
(1.41) 
 
To 20 mL of sulfuric acid was added 1.56 g (3.83 mmol, 1.0 eq.) 2-(4-(4-((2,5-dioxopyrrolidin-1-
yl)methyl)phenethyl)phenyl)acetic acid (1.40) and the solution was stirred until the solid was dissolved (1 
hr). To the solution was added portionwise 0.79 g (7.85 mmol, 2.1 eq.) potassium nitrate and then it was 
heated to 60 °C and stirred for 6 hrs. After cooling, the solution was poured into 100 mL of ice water and 
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the precipitate was filtered, washed with 1 x 100 mL water and dried. The product was yielded as pale 
brown solid (1.15 g, 2.60 mmol, 68%) and used in the next reaction without further purification.  
NMR atom numbering: 
 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 7.83 (m, 2H, H4, H15), 7.50 (m, 4H, H6-8, H11-13), 4.60 (s, 
2H, H2), 3.70 (s, 2H, H17), 3.08 (s, 4H, H9, H10) and 2.67 (s, 4H, H20, H20’). 
IR: ν [ppm] = 1702 (m), 1543 (s), 1401 (w), 1349 (m), 1170 (m), 912 (w), 820 (w), 722 (w), 667 (w). 
HRMS (+ESI) m/z: calc. for C21H19N3O8
 [M+H]+: 442.1245; found: 442.1245. 
Melting point: 99 – 104 °C. 
1.3.1.13 2-(3-AMINO-4-(2-AMINO-4-((2,5-DIOXOPYRROLIDIN-1-YL)METHYL)PHEN-ETHYL)PHENYL)ACETIC 
ACID (1.43) 
 
In a large flask a solution of 1.00 g (2.88 mmol, 1.0 eq.) 2-(4-(4-((2,5-dioxopyrrolidin-1-yl)methyl)-2-
nitrophenethyl)-3-nitrophenyl)acetic acid (1.41) in a mixture of 50 mL methanol/tetrahydrofuran (1:1) was 
prepared. To this solution 200 mg palladium on charcoal was added and the reaction flask was evacuated 
and purged three times with hydrogen through a mounted hydrogen ballon. The solution was stirred 24 
hrs at room temperature and subsequently filtered through Hyflo® celite. The celite was rinsed with 50 mL 
methanol and the resulting filtrate was removed under reduced pressure. The product was obtained as 
colorless crystalline solid with almost quantitive yield (1.03 g, 2.71 mmol, 94%) and was used directly in 
the next reaction without further purification. 
NMR atom numbering: 
 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.32 (d, J = 7.9 Hz, 1H, H12), 7.26 (d, J = 7.9 Hz, 1H, H7), 
7.13 (d, J = 1.8 Hz, 1H, H15), 7.08 (dd, J = 7.9, 1.7 Hz, 1H, H13), 7.03 (d, J = 1.8 Hz, 1H, H4), 6.97 (dd, 
J = 7.9, 1.8 Hz, 1H, H8), 4.49 (s, 2H, H2), 3.56 (s, 2H, H17), 2.80 (s, 4H, H9, H10) and 2.69 (s, 4H, H20, 
H20’).  
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13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 177.9 (C19, C19’), 172.9 (C18), 136.5 (C5-q), 135.3 (C3-q), 
134.5 (C14-q), 133.8 (C16-q) 131.4 (C11-q), 130.6 (C6-q), 127.2 (C13), 123.6 (C8), 122.7 (C15), 119.7 
(C4), 41.3 (C2), 40.6 (C17), 30.0 (C9), 29.7 (C10) and 28.6 (C20, C20’).  
HRMS (+ESI) m/z: calc. for C21H23N3O4
 [M+H]+: 382.1761; found: 382.1783. 
1.3.1.14 (Z)-DI-TERT-BUTYL (11,12-DIHYDRODIBENZO[C,G][1,2]DIAZOCINE-2,9-DIYL)DICARBAMATE (1.56) 
 
Xanthphos (6.6 mg, 11.5 µmol, 10 mol%) and Pd2dba2 (5.25 mg, 5.73 µmol, 5 mol%) were transferred into 
a purged 10 mL Schlenk tube under argon atmosphere. The tube walls were washed down with 1.5 mL 
absolute dioxane, sealed, and both compounds could complex over 30 min at room temperature. Tert-
butyl carbamate (85 mg, 0.75 mmol, 5.0 eq.), bisbromo diazocin 1.47 (42 mg, 14.7 mmol, 1.0 eq.), and 
cesium carbonate (286 mg, 0.882 mmol, 6.0 eq.) were added and an additional 1.5 mL of absolute dioxane 
was used to wash down the sides of the tube. The reaction vile was kept under argon pressure and heated 
to 100 °C for 15 min. After that the reaction vessel was sealed and kept at 100 °C for further 90 min. The 
reaction was cooled to room temperature and after addition of 15 mL water and 15 mL ethyl acetate the 
phases where thoroughly mixed, separated, and the aqueous layer was again extracted with 2 x 15 mL 
portions of ethyl acetate. The combined organic layers were washed with 2 x 15 mL portions of sodium 
bicarbonate, 3 x 15 mL portions of brine, dried with magnesium sulfate, filtered and concentrated in vacuo. 
The resulting crude product was purified on silica (eluent 0 ⇾ 50% EtOAc/DCM) to yield 51.2 mg (11.7 
mmol, 80%) of the pure product as a yellow green solid. 
1H-NMR (600 MHz, CDCl3): δ [ppm] = 7.14 (s, 2H, H1, H10), 7.04 (dd, J = 8.5, 2.3 Hz, 2H, H3, H8), 
6.78 (d, J = 8.5 Hz, 2H, H4, H7), 2.04 (s, 4H, H13, H13’) and 1.48 (s, 18H, CH3).
  
13C-NMR (150 MHz, CDCl3): δ [ppm] = 122.4 (C4, C7), 114.3 (C1, C10), 112.4 (C3, C8) and 28.2 (C13, 
C13’).  
HRMS (+EI) m/z: calc. for C24H31N4O4
+ [M+H]+: 439.2340; found: 439.2344. Calc. for C24H33N5O4
+ 
[M+NH4]
+: 456.2605; found: 456.2610.  
1.3.1.15  (Z)-11,12-DIHYDRODIBENZO[C,G][1,2]DIAZOCINE-2,9-DIAMINE (1.48) 
 
To a solution of 40.0 mg (0.92 mmol, 1.0 eq.) (Z)-di-tert-butyl (11,12-dihydrodibenzo[c,g][1,2]-diazocine-
2,9-diyl)-dicarbamate (1.56) in 10 mL dichloromethane was added 0.5 mL anisole. After addition of 0.5 
mL of trifluoroacetic acid the solution was stirred for 5 hrs at room temperature. The reaction was quenched 
by addition to an ice-cold sodium bicarbonate solution, the organic layer was separated and the aqueous 
phase was extracted with 2 x 10 mL dichloromethane. The united organic layers were dried with 
NN
NHBocBocHN Chemical Formula: C24H30N4O4
Exact Mass: 438.23
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magnesium sulfate and the solvent was removed under reduced pressure. The crude product was purified 
via flash chromatography on silica (eluent DCM/MeOH 1:0  ⇾ 1:0.1) to give 15.4 mg (0.64 mmol, 70%) 
of the solid red product.  
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 6.54 (d, J = 8.3 Hz, 2H, H4, H7), 6.34 (dd, J = 8.4, 2.3 Hz, 
2H, H3, H8), 5.07 (bs, 4H, NH2) and 6.22 (d, J = 2.4 Hz, 2H, H1, H10).  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 156.3 (C5-q, C6-q), 144.1 (C3-q, C8-q), 130.3 (C1, C10), 
118.3 (C11-q, C12-q), 113.9 (C2, C9), 105.1 (C4, C7) and 32.0 (C13).  
HRMS (+EI) m/z: calc. for C14H15N4
+ [M] +: 239.1291; found: 239.1291.  
1.3.1.16  (Z)-N,N'-(11,12-DIHYDRODIBENZO[C,G][1,2]DIAZOCINE-2,9-DIYL)BIS(2-CHLOROACETAMIDE) 
(1.25) 
 
A solution of 30.1 mg (126 µmol, 1.0 eq.) (Z)-11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diamine (1.48) 
in 1.8 mL pyridine and 2.0 mL abs. tetrahydrofuran was kept under argon and was cooled to 0 °C. To this 
cold solution was added dropwise a solution of 85.8 mg (505  µmol, 4.0 eq.) chloroacetic anhydride in 
2.0 mL abs. tetrahydrofuran. The solution was warmed to room temperature and stirred for 1 hr. The 
solvents were removed under reduced pressure and the remaining oily residue was diluted with 10 mL 
ethyl acetate. The organic phase was washed with 2 x 10 mL water, dried with magnesium sulfate and 
evaporated. The crude product was purified through semi-preparative RP-HPLC with a water/acetonitrile 
gradient of 90:10 ⇾ 0:80 in 40 min and lyophilized to yield the product as fine yellow powder (27.1 mg, 
69.3 umol, 55%). 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 10.3 (s, 2H, NH), 7.35 (m, 4H, H1, H3, H8, H10), 6.34 (d, 
J = 9.0 Hz, 2H, H4, H7), 4.18 (s, 4H, CH2Cl) and 2.77 (m, 4H, H13, H13’).  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 120.3 (C3, C8), 120.0 (C4, C7), 118.1 (C1, C10), 43.8 (CH2Cl), 
31.5 (C13) and 31.4 (C13’).  
HRMS (+EI) m/z: calc. for C18H17Cl2N4O2
+ [M+H]1+: 391.0723; found: 391.0724. 
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1.3.1.17 4,4'-(ETHANE-1,2-DIYL)BIS(3-NITROANILINE) (1.57) 
 
5.00 g (24.0 mmol, 1.0 eq.) 4,4'-(ethane-1,2-diyl)dianiline (1.49) was dissolved in 40 mL sulfuric acid and 
heated to 60 °C. 5.26 g (52.0 mmol, 2.2 eq.) freshly grounded potassium nitrate was dissolved in 45 mL 
sulfuric acid and then slowly added to the first solution. The reaction was then kept at 60 °C for 6 hrs. The 
solution was poured into 200 mL of ice water and made basic with aqueous ammonia solution (32%). The 
formed precipate was filtered off, washed with 500 mL water and dried to afford the product as red orange 
solid (7.20 g, 23.6 mmol, 99%). 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.06 (d, J = 2.4 Hz, 2H, H2), 6.99 (d, J = 8.3 Hz, 1H, H5), 
6.78 (dd, J = 8.3, 2.4 Hz, 2H, H5), 5.58 (s, 4H, H-NH2) and 2.86 (s, 4H, H7).
  
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 149.9 (C3), 148.6 (C1), 136.7 (C3), 132.9 (C5), 121.8 
(C4),119.2 (C6), 108.4 (C2) and 33.2 (C7).  
HRMS (+EI) m/z: calc. for C14H14N4O4
+ [M]+: 302.1015; found: 302.1015. Calc. for C14H10N2O2
+ [M-NO2]
+: 
256.1086; found: 256.1067. 
1.3.1.18  (Z)-11,12-DIHYDRODIBENZO[C,G][1,2]DIAZOCINE-3,8-DIAMINE (1.50) 
 
A solution of 1.00 g (3.31 mmol, 1.0 eq.) 4,4'-(ethane-1,2-diyl)bis(3-nitroaniline) (1.57) in 200 mL of 
ethanol was heated to 40 °C. Then a solution of 4.20 g (13.3 mmol, 4.0 eq.) Ba(OH)2 · 6 H2O in 40 mL 
water was added, followed by the portionswise addition 3.40 g (52.0 mmol, 15.6 eq.) zinc. The solution 
was kept 3 hrs under reflux (80 °C) and after cooling was filtered through celite to remove the zinc. After 
removal of the solvent under reduced pressure, the crude product was purified via flash chromatography 
on silica (eluent cHex/EtOAc 1:2) to give 0.33 g (1.40 mmol, 40%) of the solid yellow orange product.  
1H-NMR (400 MHz, CDCl3): cis-1.50 δ [ppm] = 6.73 (d, J = 8.1 Hz, 2H, H1, H10), 6.34 (dd, J = 8.1, 2.4 
Hz, 1H, H2, H9), 6.40 (d, J = 2.4 Hz, 2H, H4, H7) and 2.70 (m, 4H, H13, H13’). trans-1.50 δ [ppm] = 
6.76 (d, J = 8.2 Hz, 2H, H1, H10), 6.48 (dd, J = 8.1, 2.4 Hz, 1H, H2, H9), 6.34 (dd, J = 8.3, 2.4 Hz, 1H, 
H4), 6.34 (dd, J = 8.3, 2.4 Hz, 1H, H7) and 2.90 (m, 4H, H13, H13’). 
13C-NMR (100 MHz, CDCl3): cis-1.50 δ [ppm] = 156.3 (C5-q, C6-q), 144.1 (C3-q, C8-q), 130.3 (C1, C10), 
118.3 (C11-q, C12-q), 113.9 (C2, C9), 105.1 (C4, C7) and 31.0 (C13). trans-1.50 δ [ppm] = 146.5 (C5-q, 
C6-q), 145.3 (C3-q, C8-q), 131.4 (C1, C10), 121.5 (C11-q, C12-q), 116.9 (C2, C9), 114.1 (C7), 108.0 (C4) 
and 31.0 (C13). 
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HRMS (+EI) m/z (rel. intensity): calc. for C14H13N2
3+ [M-2NH2+3H]
3+: 209.1062; found: 209.1078. Calc. for 
C14H14N4
+ [M] +: 238.1218; found: 238.1213.  
1.3.1.19  (Z)-N,N'-(11,12-DIHYDRODIBENZO[C,G][1,2]DIAZOCINE-3,8-DIYL)BIS(2-CHLOROACETAMIDE) 
(1.29) 
 
A solution of 37.3 mg (156 µmol, 1.0 eq.) (Z)-11,12-dihydrodibenzo[c,g][1,2]diazocine-3,8-diamine (1.50) 
in 1.8 mL pyridine and 2.0 mL absolute tetrahydrofuran was kept under argon atmosphere and was cooled 
to 0 °C. To this cold solution was added dropwise a solution of 107 mg (630 µmol, 4.0 eq.) chloroacetic 
anhydride in 2.0 mL absolute tetrahydrofuran. The solution was warmed to room temperature and stirred 
for 1 hr. The solvents were removed under reduced pressure and the remaining oily residue was diluted 
with 10 mL ethyl acetate. The organic phase was washed with 2 x 10 mL water, dried with magnesium 
sulfate and evaporated. The crude product was purified through semi-preparative RP-HPLC with a 
water/acetonitrile gradient of 90:10 ⇾ 0:80 in 40 min and lyophilized to yield the product as fine yellow 
powder (25.7 mg, 65.7 umol, 42%). 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 10.2 (s, 2H, H-NH), 7.11 (dd, J = 8.2, 2.2 Hz, 2H, H2, H9), 
7.08 (d, J = 2.1 Hz, 2H, H4, H7), 6.96 (d, J = 8.2 Hz, 2H, H1, H10), 4.10 (s, 4H, H-CH2Cl) and 2.67 (m, 
4H, H13, H13’). 
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 130.8 (C1, C10), 118.4 (C2, C9), 109.0 (C4, C7), 44.0 (CH2Cl) 
and 30.8 (C13).  
IR: ν [ppm] = 3292 (m), 3003 (w), 2956 (w), 1657 (s), 1582 (s), 1520 (s), 1401 (s), 1276 (m), 1251 (m), 
1138 (w), 970 (w), 878 (m), 844 (m), 776 (s), 699 (m). 
HRMS (+ESI) m/z (rel. intensity): calc. for C18H20O2N5Cl2
+ [M+NH4]
 +: 408.0994; found: 408.0990 (100). 
Calc. for C18H17O2N4Cl2
+ [M+H]+: 391.0723; found: 391.0726 (46). 
Rt (an. RP-HPLC, Luna column, water/acetonitrile gradient 90:10 ® 0:80 in 40 min): t [min] = 25.6 min. 
Melting point: 233 – 236 °C. 
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1.3.1.20 (E)-1,2-BIS(6-NITROBENZO[D]THIAZOL-2-YL)DIAZENE (1.52) 
 
A suspension of 1.00 g (2.60 mmol, 1.0 eq.) 2-amino-6-nitrobenzothiazole (1.51) in 50 mL sodium 
hypochlorite solution (13%) was heated to 60 °C for 1 hr. The reaction could cool down and the red 
precipitate was filtered off, washed with 3 x 50 mL water and 3 x 50 mL diethyl ether and dried. The crude 
red product was received as red solid (830 mg, 2.15 mmol, 90%) and due to the low solubility, it was 
directly used in the next reaction. 
IR: ν [ppm] = 3098 (w), 1566 (m), 1511 (s), 1347 (s), 1279 (m), 1198 (m), 1122 (m), 1042 (w), 915 (m), 
896 (m), 839 (m), 752 (m), 720 (m). 
HRMS (+EI) m/z (rel. intensity): calc. for C14H7N5O3S2
+ [M-NO+H] +: 356.9990; found: 357.9819 (35). 
Melting point: >300 °C. 
1.3.1.21  (E)-2,2'-(DIAZENE-1,2-DIYL)BIS(BENZO[D]THIAZOL-6-AMINE) (1.58) 
 
To a solution of 2.00 g (5.18 mmol, 1.0 eq.) (E,Z)-1,2-bis(6-nitrobenzo[d]thiazol-2-yl)diazene (1.52) in 125 
mL tetrahydrofuran was added 5.02 g (41.4 mmol, 8.0 eq.) sodium sulfide in 20 mL water. The solution 
was heated to 80 °C and stirred for 3 hrs. After cooling the solution was made basic with 200 mL sodium 
hydrogencarbonate solution (10%) and the precipitate was filtered off, washed with 2 x 200 mL water and 
dried. The received product was a dark blue solid (1.46 g, 4.47 mmol, 86%) and was used directly in the 
next reaction without further purification. 
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 7.79 (d, J = 8.9 Hz, 2H, H8), 7.04 (d, J = 2.3 Hz, 2H, H5), 
6.89 (dd, J = 9.0, 2.0 Hz, 2H, H7) and 6.40 (s, 4H, H-NH2). 
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 151.5 (C2), 146.2 (C4-q), 138.6 (C6-q), 126.7 (C8), 117.2 
(C7) and 103.6 (C5).  
IR: ν [ppm] = 3406 (w), 3306 (w), 3200 (w), 1631 (m), 1592 (m), 1544 (m), 1475 (m), 1428 (m), 1337 (m), 
1280 (s), 1202 (s), 1131 (s), 915 (s), 850 (s), 804 (s), 695 s). 
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HRMS (+EI) m/z: calc. for C14H10N4S2
2+ [M-2NH2+2H]
2+: 298.0336; found: 298.0313. Calc. for C14H10N6S2
+ 
[M]+: 326.0408; found: 326.0395. 
Melting point: >300 °C. 
1.3.1.22  (E)-N,N'-(DIAZENE-1,2-DIYLBIS(BENZO[D]THIAZOLE-2,6-DIYL))BIS(2-CHLOROACETAMIDE) (1.30) 
 
100 µL (1.25 mmol, 4 eq.) of chloroacetyl chloride in 5 mL dimethylformamide was cooled to 0 °C. A 
solution of 100 mg (0.31 mmol, 1.0 eq.) (E)-2,2'-(diazene-1,2-diyl)bis(benzo[d]thiazol-6-amine) (1.58) in 
5 mL DMF and 173 µL triethylamine (1.25 mmol, 4.0 eq.) was added dropwise to the cooled first solution. 
The reaction could warm to room temperature and was subsequently stirred for 2 hrs. The reaction was 
stopped by addition of 50 mL water and the solution was acidified with 2 M HCl. The precipated product 
was filtered off, washed with 2 x 50 mL water and dried. The crude product was purified through flash 
chromatography on silica (eluent 0 ⇾ 50% EtOAc/DCM) and the pure product was received as a dark 
purple solid (92.0 mg, 0.21 mmol, 64%).  
1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 10.8 (s, 1H, H-NH), 8.57 (d, J = 8.2, 2.2 Hz, 2H, H8), 8.17 (d, 
J = 9.0 Hz, 2H, H5), 7.67 (d, J = 9.0, 2.2 Hz, 2H, H7) and 4.32 (s, 4H, H-CH2Cl). 
13C-NMR (100 MHz, DMSO-d6): δ [ppm] = 172.4 (C2), 165.6 (C=O), 149.8 (C9), 139.9 (C6), 136.6 (C4), 
126.5 (C8), 120.7 (C7), 112.3 (C5) and 44.0 (CH2Cl).  
IR: ν [ppm] = 3256 (w), 1684 (s), 1602 (s), 1567 (s), 1529 (s), 1480 (s), 1402 (s), 1336 (m), 1289 (m), 1253 
(m), 1130 (s), 869 (m), 816 (m), 784 (m), 689 (m). 
HRMS (+ESI) m/z (rel. intensity): calc. for C18H13Cl2N6O2S2
+ [M+H]+: 478.9913; found: 478.9920. 
Melting point: >300 °C. 
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Chemical Formula: C18H12Cl2N6O2S2
Exact Mass: 477.98
Molecular Weight: 479.35
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1.3.2 SPECTRAL DATA 
1.3.2.1 1H- AND 13C-NMR SPECTRA OF AMPP, 3-[3-(AMINOMETHYL)PHENYLAZO]-PHENYLACETIC ACID 
(1.26) 
 
 
N N COOHFmocHN
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1.3.2.2 1H- AND 13C-NMR SPECTRA OF TERT-BUTYL 2-(4-((BROMOTRIPHENYLPHOSPHANEYL)-
METHYL)PHENYL)ACETATE (1.38) 
 
PPh3  Br
COOt-Bu
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1.3.2.3 1H- AND 13C-NMR SPECTRA OF TERT-BUTYL 2-(4-(4-CYANOSTYRYL)PHENYL)ACETATE (1.39) 
 
COOt-Bu
NC
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1.3.2.4 1H- AND 13C-NMR SPECTRA OF TERT-BUTYL 2-(4-(4-(AMINOMETHYL)PHENETHYL)-PHENYL)-ACETATE 
(1.55) 
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1.3.2.5 1H- AND 13C-NMR SPECTRA OF 2-(4-(4-((2,5-DIOXOPYRROLIDIN-1-YL)METHYL)-
PHENETHYL)PHENYL)ACETIC ACID (1.40) 
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1.3.2.6 1H- AND 13C-NMR SPECTRA OF 2-(4-(4-((2,5-DIOXOPYRROLIDIN-1-YL)METHYL)-2-
NITROPHENETHYL)-3-NITROPHENYL)ACETIC ACID (1.41) 
 
 
COOH
N
O
O
NO2
O2N
P A R T  I  –  C H A P T E R  1 :  E X P E R I M E N T A L    P A G E  | 46 
1.3.2.7 1H- AND 13C-NMR SPECTRA OF M-BDCA, (Z)-N,N'-(11,12-DIHYDRODIBENZO-[C,G][1,2]-
DIAZOCINE-3,8-DIYL)BIS(2-CHLOROACETAMIDE) (1.29) 
 
N N NH
N
H
O
Cl
O
Cl
P A R T  I  –  C H A P T E R  1 :  E X P E R I M E N T A L    P A G E  | 47 
1.3.2.8 1H- AND 13C-NMR SPECTRA OF ACTA, (E)-N,N'-(DIAZENE-1,2-DIYLBIS(BENZO-[D]THIAZOLE-2,6-
DIYL))BIS(2-CHLOROACETAMIDE) (1.30) 
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PART II 
PHOTOPHARMACOLOGY 
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PART II: PHOTOPHARMACOLOGY AND TETHERED PHARMACOLOGY 
The world as we know it today would not exist if it was not for the invention and advancement of 
pharmacotherapy7,97. It improves the everyday life of millions of people and is a major driving force for 
medicinal development and progress. Despite significant improvements to drug reliability, selectivity and 
therapy over the preceeding centuries, there are still many issues remaining in pharmacotherapy that need 
to be addressed. Two major complications are the low selectivity of many therapeutically used drugs98 and 
the risk of forming drug resistance5,99,100. Especially the latter, in view of mankinds failure of a sustainable 
use of antibiotics leading to raising numbers of resistant bacteria strains, has increasingly become a public 
and governmental health care focus99,101,102. The low selectivity of drugs can lead to severe side effects, 
limits the desired efficacy at the targeted site of action and raises challenges for drug administration17,98. 
Moreover, it causes a lowered toxicity threshold and leads to narrowing of the therapeutic window, which 
in turn prevents usage of optimal drug dosage5,103. This has far-reaching consequences for present drug 
development, as an estimated 85% of small molecule drugs are discarded due to insufficient selectivity104. 
This means many pharmaceuticals, although attractive and powerful candidates for pharmacotherapy, are 
not considered for further development only due to their low selectivity. Furthermore, recent systems 
biology studies also suggest the rethinking of pharmaceuticals as exquisitely selective compounds, but as 
multitarget network drugs simultaneously acting on several sites and tissues. Multitargeting drugs were 
shown, although case dependent, to exhibit higher clinical efficacy compared to single target drugs8. These 
polypharmacology findings complicate future developments in pharmacotherapy once more, as they show 
the demand for dynamically-selective, multiple system targeting drugs, which orchestrate complex 
physiological responses without triggering side effects.  
The reason for poor drug selectivity often lies in their affinity for other targets and uncontrolled drug activity 
in space and time, e.i. antibiotic activity outside the desired field of action. Although there are ways to 
reach higher selectivity, i.e. local administration of the drugs like in ophthalmology105, or choosing targets 
which are exclusively expressed in selected tissues or overexpressed in certain diseases17,106, these 
approaches are not generally amenable. The targeted systems are normally expressed in several organs 
throughout the organism and disease related overexpression of drug targets is not a reliable drug targeting 
device, as seen for the severe side effects caused by many cancer therapeutics107–109.  
Currently, there are three major fields that utilize light to control physiological responses and/or drug 
actions, namely optogenetics3,110,111, photodynamic therapy112,113 and photopharmacology4,5,17 (Figure II.1). 
Optogenetics makes use of natural occurring photoresponsive proteins such as bacteriorhodopsins, 
halorhodopsins or flavoproteins36,114,115. This method was sucessfully used to restore visual responses in 
blind retinae6 and to control the brain function3,116 and the movement of animals37,117. Since genetic 
manipulation is a necessity for optogenetics, they are currently limited to being research tools for the 
understanding of biological processes. Photodynamic therapy deploys photosensitive dyes that transfer 
energy from their excited triplet states after illumination with visible light to triplet oxygen, to generate 
singlet oxygen (3O2 ® 1O2). The formation of singlet oxygen as reactive oxygen species (ROS) leads to cell 
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hemoglobin and the longer-wavelength absorption of water120–122. A further decisive factor is the 
penetration depth of light into the tissue, which is limited by absorption through endogeneous 
chromophores or light scattering5. The predicted penetration depths of light of 630 or 800 nm are 1 and 2 
cm, respectively123. This shows the limitation and challenges of non-invasive photopharmacology towards 
easily light accessible targets such as skin or eyes. However, the accessibility for photopharmacotherapy 
on subjacent tissue was also demonstrated through light delivery by an optical fibre inserted through a 
small incision124.  
But not all relevant drug targets are amenable to a photopharmological approach. The recently introduced 
term photodruggability17, which was inspired by the term druggability, describes the different accessibilities 
and responsiveness of drug targets125. It furthermore prescribes rules for the choice of targets and classifies 
them into five categories. The targets thereby must bei i) accessible by light, ii) be responsive to the light 
induced structural changes of the pharmacophore and iii) should be localized in a way to benefit from the 
spatiotemporal precision of light. Based on these conditions and the existing categorization for 
photodynamic therapy, photodruggable targets can be classified into five groups (Table II.1)17.  
Table II.1: Different classes of photodruggable targets. 
Class 1: easy accessible, e.i. skin126 and ophthalmology127 
Class 2: accessible by endoscopy, e.i. gastrointestinal tract128, mouth and throat129, respiratory system130, 
biliary tract131 and bladder132,133 
Class 3: accessible through the skin without incision, e.i. testicles134, thyroid135 and lymph nodes 
Class 4: accessible through a minor incision, e.i. pancreas136, prostate137, liver138, blood vessels, glands, 
muscles and bones 
Class 5: only accessible through a major incision, e.i. brain139 and bone marrow 
 
There are different methods and modes of application postulated for photopharmaceuticals that are 
dependent on the target class, duration of the treatment/therapy and the type of the pharmacophore used. 
Administration scenarios depict the behavior of a drug in the body and comprise four time frames: i) 
distribution, ii) action, iii) clearance and iv) environment (Figure II.2))5,7. These scenarios can be split into 
two groups; the first group comprises photoswitchable drugs with binary attributes (Figure II.2 A-E), and 
the second group implies photoswitchable drugs with controllable half-lifes (Figure II.2 F-J)5. The binary or 
bistable chromophores belonging to the first group can be discretely switched between an “ON” and “OFF” 
state. This facilitates the administration of an inactive compound, which is then activated at the target site, 
stays active during the action period and is then inactivated for clearance from the body to the environment 
(Figure II.2 C).  
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Figure II.2:  Photopharmaceutical administration scenarios. Activity profiles for A-E) Binary photoswitchable drugs 
and F-J) photoswitchable drugs with controlled half-lifes. A) Non-metabolisble drug. B) Metabolisble drug. C) 
Photopharmacophore with selective light-induced activation at the site of action and deactivation after the action 
phase for clearance. D) Photoswitchable drug which is pre-illuminated before use and deactivated after activity phase 
for clearance. E) Inactivation of a photoswitchable drug before administration, activation at the site of action followed 
by inactivation for clearance. F) Pre-activation of a photopharmacophore with defined half-life of the active isomer 
prior to administration. G) Activation of a photopharmacophore with defined half-life of the active isomer at the active 
site. H) Continuous cycled activation of a photoswitchable drug with short lived stability during action phase. I) 
Inactivation of a photoswitchable drug before administration, which returns to its active state before the action phase. 
J) Inactivation of a photoswitchable drug before administration, which returns to its active state before the action phase 
and is inactivated thereafter again for clearance. The illustration of the activity profiles was adapted and alternated 
based on ref. 5. 
Further possibilities are the use of slowly backrelaxing preactivated or inactivated drugs, which can then 
be activated at the target site and inactivated after the action period (Figure II.2 D, E). The use of 
preactivated compounds is in general not desirable, as it can lead to off-target effects that should be 
circumvented through photopharmacology. However, this is also strongly dependent on the target tissue. 
Examples for bistable photoswitchable drugs are the chromopeptides AzoANP140 and LirAzo16, which are 
stable in their cis-state for several hours and thus can be administered as active or inactive compounds. 
The situation is different for chromophores with short-lived half-lives, as one can activate the drug prior to 
administration or directly at the target site without the need for inactivation before clearance. This is 
benifical for preventing the build up of active compounds in the environment (Figure II.2 F, G). For 
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compounds with very short-lived active states this auto-inactivation means that they must be repeatedly 
switched “ON” or kept active through constant illumination (Figure II.2 H). Compounds that can be 
inactivated prior to administration offer the possibility to distribute inactive compound to the target, which 
then slowly turns “ON” (Figure II.2 I) or can be turned “OFF” again for clearance (Figure II.2 J). However, 
in the sense of preventing the build-up of drugs in the environment after clearance, the latter two 
administration scenarios are less desirable.  
Based on these scenarios many therapeutically valuable targets have been developed and evaluated for a 
photopharmaceutical or optogentical approach and corresponding photoswitchable drugs, for example 
photochromic ligands (PCLs) and photoswitchable tethered ligands (PTLs)4. While the former act as normal 
ligands that bind, and dissociate from the orthosteric site of the target receptor, PTLs are covalently bound 
to the receptor in close proximity of the active site and reversibly stimulate or inhibit receptor signaling. 
The PTL approach thereby offers high precision of targeting because the bioconjugation motif, often an 
engineered cysteine for attachment of the PTL via reaction with a maleimide, can be genetically encoded 
on the target protein and expressed in cells of interest141,142. Since this cysteine-maleimide approach is very 
unselective towards native cysteine groups, and maleimide tends to hydrolyze and bind to glutathione 
under physiological conditions, novel more precise bioconjugation techniques have been developed 
recently.  
 
Figure II.3:  Principle of SNAP- and CLIP-tag bioconjugation for simultaneous labeling and imaging. The SNAP-tag 
functionalized protein of interest 1 (POI 1) can be labeled with BG-derivatives carrying the label of interest (compound 
1) through nucleophilic attack of the reactive cysteine located on the SNAP-tag on the benzylic BG position. Similarly, 
CLIP-tag functionalized POI 2 can be labeled with BC-derivatives carrying the label of interest (compound 2). If 
compound 1 and 2 are different fluorescent dyes simultaneous fluorescence imaging is possible. Adapted and modified 
based on ref. 143. 
These approaches mainly utilize self-labeling tags, self-labeling proteins or enzyme-mediated labeling of 
tags to covalently attach the labeling compound to the protein of interest142. Especially the self-labeling 
proteins are of great interest for tethered photopharmacology, because this approach is not only applicable 
to many receptor types, but also allows usage of labeling techniques including fluorescent labeling to 
monitor conformational dynamics of GPCRs144 and receptor trafficking145. The widely-used SNAP-tag is a 
20 kDa engineered version of the human O6-alkylguanine DNA alkyltransferase (AGT) DNA repair protein 
domain146. It can be attached to the protein of interest, for example at the extracellular N-terminal end of 
transmembrane receptors, and binds selectively to labeling compounds bearing a O6-benzylguanine group 
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(BG-derivatives). Similarly, the more recent CLIP-tag functions likewise as AGT-based tag, but binds 
selectively to O2-benzylcytosine groups (BC-derivatives)143. This allows the simultaneous labeling and 
fluorescent imaging of two proteins of interest and enables the concurrent determination of cellular 
localization and the monitoring of different generations of proteins (Figure II.3). Other self-labeling protein 
domains comprise the Halo-tag147, an engineered haloalkane dehalogenase which binds to chloroalkane 
derivatives, and amino acid sequences which can be modified using external enzymes148.  
As previously described in PART I: PHOTOSWITCHES, there is a large variety of azobenzene based 
photoswitchable drugs, and tuning of the tightly correlating switching wavelengths and thermal reversion 
rates is a tricky task. In principle, the perfect spectral parameters for two isomers of a photopharmacophore 
would be red-shifted (>600 nm), distinct absorption wavelengths with high molar extinction coefficients. 
Ideally, the high conversion rates would lead to complete depletion of one isomer upon illumination and 
vice versa, yielding 100% of the absorbing isomer in the photostationary state (PSS). Normal conversion 
rates are between 80-95% for the absorbing isomer in the PSS, with quantum yields in the range of 0.2-
0.54. However, low PSS conversion rates, for example 50/50 or even 40/60, do not necessarily render these 
compounds unsuitable as photoswitchable drugs. This is due to the nonlinear nature of biological systems, 
where already single stimulations can trigger largely amplified signaling cascades and small changes in 
receptor activation upon ligand switching can lead to altered physiological responses149. This applies 
particulary to neuronal systems, but also to single cells and GPCR signaling cascades4. Although no 
photopharmacophore has yet been developed to take the next step towards preclinical treatment 
evaluation, a prerequisite for successful photoswitchable drugs will be an easy amenability and a cost-
effective synthesis to meet the challanges of a large-scale drug synthesis. 
Some prominent examples of optogenetic and photopharmacological research tools and drug candidates 
comprise PCLs and PTLs for the photocontrol of ionotropic (permeable to ions such as K+, Na+ and Ca2+) 
and metabotropic (membrane receptors activated by ligands, e.i. GPCRs and receptor tyrosine kinases) 
receptors. The transmembrane channel proteins are important for the generation of action potentials and 
thus control and propagate neuronal communication150. An example for the control of neuronal signaling 
is presented by PTL MAQ II.1 (maleimide-azobenzene-quaternary ammonium)15, a photoswitchable 
tethered potassium channel blocker (Figure II.4). This photoswitch, which comprises a quaternary 
ammonium unit that is known to block potassium channels by binding to the extracellular side of the pore 
and to the channel of the so called “inner pore”, was attached to a genetically engineered Shaker potassium 
channel (pdb: 18l8)151 via cysteine-maleimide coupling. This synthetic photoisomerizable azobenzene-
regulated K+ channel (SPARK) was successfully used to optically control neuronal firing in dissociated 
neurons heterlogously expressing the receptor, and was one of the first publications in the field of 
optogenetics15. Further examples for the optical control of ion channels are the PCLs 4-GluAzo II.2 (ref. 
152) and ATA-3 II.3 (ref. 153), both agonists for the ionotropoic kainate and AMPA receptors. The II.4 
design is based on the crystal structure of the ligand 4-(R)-methyl glutamate bound to the clamshell-like 
ligand binding domain of the kainate receptor GluK2 (pdb: 1sd3). It behaves as an agonist in its trans-form 
in the dark-adapted state or with 500 nm irradiation and becomes inactive upon cis-isomer accumulation 
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with 380 nm light. This functions by changing the degree of closure of the clamshell lips, which defines 
receptor activation. In its stretched trans-form the azobenzene moiety of II.2 points out of the closed 
clamshell lips, while it forces them to open in its angled cis-form. Thus, this small molecular switch enables 
control over the whole receptor4,152. II.3 is a photochromic ligand for the AMPA receptor GluA2 that was 
also designed based on the ligand-bound receptor crystal structure and shows a similar receptor control 
mechanism153. Another striking example is the optical control of insulin secretion using the PCL JB253 II.4 
(ref. 38). This photochromic sulfonylurea targets the ATP-sensitive potassium channels (KATP) that control 
K+ efflux in pancreatic beta cells. Upon activation with blue light and accumulation of the cis-form the KATP 
channels are blocked, which results in the depolarization of the cell, opening of voltage-dependent Ca2+ 
channels (VDCC) and Ca2+ influx into the cell. This triggers various downstream signaling processes which 
ultimately lead to the exocytosis of insulin. The beforehand mentioned pharmacophore JB558 1.8 is a red-
shifted version of II.4 and allows to remotely control pancreatic beta cell activity10. 
 
Figure II.4:  Examples for PCLs and PTLs for photopharmocoligcal applications. Shown are the PTL MAQ II.1 (ref. 15) 
with maleimide and quaternary amino unit, the ionotropic glutamate receptor PCLs 4-GluAzo II.2 (ref. 152) and ATA-
3 II.3 (ref. 153) and the photochromic sulfonylurea JB253 II.4 (ref. 38). 
There are many more azobenzene based PCLs and PTLs addressing various targets, and this growing library 
of photopharmaceuticals has not only contributed to the understanding of biological signaling, but also 
helped to promote the feasibility of these molecular machines. In the subsequent chapters of this work the 
reader will find our newest advances and developments in the field of photoswitchable hormones and 
tethered ligands. 
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2 OPTICAL CONTROL OF THE NATRIURETIC PEPTIDE RECEPTOR A USING A 
PHOTOSWITCHABLE HORMONE (AZOANP) 
 
This work has been submitted to Chemical Science on the 15th November 2016.  
 
The term hormone describes signaling molecules produced by and secreted from the endocrine gland, 
which releases the substances into the bloodstream. Hormones can be divided into three main classes: 
lipid-derived, amino acid-derived and peptide hormones. Animal organisms use these molecules to 
communicate between different organs to control and regulate physiological responses and behavioral 
actions. In this way, they affect many vital functions such as metabolism, digestion, sleep, respiration, 
growth, movement and reproduction, just to name a few. Endogeneous peptide hormones are short 
peptides or small proteins and among which one can find many familiar representatives such as insulin, 
oxytocin, vasopressin, and the three natriuretic peptides ANP (atrial natriuretic peptide), BNP (B-type 
natriuretic peptide) and CNP (C-type natriuretic peptide). While ANP and BNP act as endocrine hormones 
with natriuretic, diuretic and vasorelexant properties, CNP functions in an autocrine/paracrine fashion to 
induce vasorelaxation and vascular remodeling, and to regulate bone growth154,155. The natriuretic peptides 
target the three natriuretic peptide receptors A, B and C (NPR-A, NPR-B and NPR-C). NPR-A, which is 
targeted by ANP and BNP, as well as NPR-B, targeted by CNP, are membrane-bound guanylyl cyclases 
and belong to the class of receptor-linked enzymes. By contrast, NPR-C is a clearance receptor without 
intracellular guanylyl cyclase domain to which all three natriuretic peptides bind.  
The activators of receptor-linked enzymes are normally small to medium sized proteins, with few known 
small molecule effectors, which makes these enzymes hard to conquer from a photopharmocological point 
of view. Nevertheless, the following manuscript describes the design and synthesis of a small library of 
photoswitchable atrial natriuretic peptides (AzoANPs), with one lead compound TOP271 2.1. This 
photochromic ANP derivative allows the optical control of NPR-A signaling and cGMP generation and 
was used to control vasoactive responses in mouse aorta and beta cell activity in Islets of Langerhans.
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Optical	control	of	a	receptor-linked	guanylyl	cyclase	using	a	
photoswitchable	peptidic	hormone	
Tom	Podewin,‡,a	Johannes	Broichhagen,‡,a,b	Christina	Frost,c	Dieter	Groneberg,d	Helena	Meyer-
Berg,a	Nicholas	H.	F.	Fine,e,f	Andreas	Friebe,d	Martin	Zacharias,c	David	J.	Hodson,e,f	Dirk	Trauner,*a	
and	Anja	Hoffmann-Röder*a	
The	optical	control	over	biological	function	with	small	photoswitchable	molecules	has	gathered	significant	attention	in	the	
last	decade.	Herein,	we	describe	 the	design	and	 synthesis	of	 a	 small	 library	of	photoswitchable	peptidomimetics	based	
upon	 human	 atrial	 natriuretic	 peptide	 (ANP),	 in	 which	 the	 photochromic	 amino	 acid	 [3-(3-
aminomethyl)phenylazo]phenylacetic	acid	(AMPP)	is	incorporated	into	the	peptide	backbone.	The	endogeneous	hormone	
ANP	 signals	 via	 the	 natriuretic	 peptide	 receptor	 A	 (NPR-A)	 through	 raising	 intracellular	 cGMP	 concentrations,	 and	 is	
involved	in	blood	pressure	regulation	and	sodium	homeostasis,	as	well	as	 lipid	metabolism	and	pancreatic	function.	The	
cis-	and	trans-isomers	of	one	of	our	peptidomimetics,	 termed	TOP271,	exhibit	a	 four-fold	difference	 in	NPR-A	mediated	
cGMP	synthesis	 in	vitro.	Despite	this	seemingly	small	difference,	TOP271	enables	large,	optically-induced	conformational	
changes	 ex	 vivo	 and	 transforms	 the	 NPR-A	 into	 an	 endogenous	 photoswitch.	 Thus,	 application	 of	 TOP271	 allows	 the	
reversible	generation	of	cGMP	using	light	and	remote	control	can	be	afforded	over	vasoactivity	in	explanted	murine	aortic	
rings,	as	well	as	pancreatic	beta	cell	 function	 in	 islets	of	Langerhans.	This	 study	demonstrates	 the	broad	applicability	of	
TOP271	 to	 enzyme-dependent	 signalling	 processes,	 extends	 the	 toolbox	 of	 photoswitchable	molecules	 to	 all	 classes	 of	
transmembrane	receptors	and	utilizes	photopharmacology	to	deduce	receptor	activation	on	a	molecular	level.	
Introduction	
Controlling	 biological	 function	 with	 light	 has	 been	 achieved	
using	 two	 general	 approaches,	 viz.	 optogenetics,1	 and	
photopharmacology.2,3	 While	 the	 first	 relies	 on	 the	 genetic	
introduction	 of	 light-responsive	 proteins,	 the	 latter	 describes	
the	 exogenous	 use	 of	 small	 photochromic	 molecules	 that	
interact	 with	 a	 specific	 target.	 The	 advantage	 of	
photopharmacology	 is	 the	 precise	 control	 of	 cell	 signalling	
through	 native	 receptors,	 without	 necessarily	 introducing	
foreign	 genes.	 While	 optogenetics	 has	 successfully	 targeted	
the	receptor-linked	enzyme	(RLE)	class,4	 in	particular	receptor	
tyrosine	kinases,5,6	photopharmacology	has	not	kept	pace.	One	
reason	 is	 that	RLE	 ligands	are	usually	 large	peptides	with	 few	
known	small	molecule	activators,	making	it	a	challenge	to	find	
a	 suitable	 “azologable”3	 pharmacophore.	 However,	 we	 and	
others	 recently	 reported	 the	 optical	 control	 of	 cell	 function	
with	 photoswitchable	 peptides,7,8	 an	 approach	 that	 is	 highly	
applicable	to	RLEs.		
Accordingly,	we	focused	on	the	natriuretic	peptide	receptor	A	
(NPR-A),	with	its	endogenous	agonist	atrial	natriuretic	peptide	
(ANP),	 as	a	 suitable	 target	 for	RLE	photocontrol	 (Fig.	1a).	 The	
physiological	 actions	 of	 ANP	 are	 widespread	 and	 range	 from	
blood	pressure	 regulation	 and	 sodium	homeostasis	 to	 effects	
on	fat	metabolism	and	pancreatic	beta	cell	function/survival.9–
11	 ANP	 is	mainly	 expressed	 and	 stored	 as	 inactive	 proANP	 in	
atrial	 cardiac	 myocytes,	 with	 lesser	 concentrations	 found	 in	
the	 ventricles	 and	 kidneys.6	 Upon	 secretion,	 primarily	
controlled	 by	 mechanical	 stimulation	 following	 atrial	 wall	
stretching,12,13	proANP	is	rapidly	cleaved	by	the	cardiac	serine	
protease	corin	to	release	the	active	28	amino	acid	ANP.14		The	
active	 form	 comprises	 a	 central	 17	 amino	 acid	 macrocycle	
linked	 by	 a	 disulfide	 bridge	 between	 Cys7	 and	 Cys23.	 Upon	
ligand	activation	of	NPR-A,	the	membrane-proximal	regions	of	
2.1 MANUSCRIPT: OPTICAL CONTROL OF A RECEPTOR-LINKED GUANYLYL CYCLASE USING A 
PHOTOSWITCHABLE PEPTIDIC HORMONE 
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the	 monomeric	 receptor	 units	 undergo	 a	 global	
conformational	 change,	 triggering	 guanylyl	 cyclase	 activity.	
This	 leads	 to	 generation	 of	 cGMP,	 a	 major	 player	 in	
intracellular	cell	signalling.12		
Dysregulated	 ANP	 secretion	 has	 been	 linked	 to	 different	
cardiovascular	 diseases,	 i.e.	 atrial	 fibrillation,15	
hypertension16,17	 and	 heart	 failure.18,19	 Moreover,	 genetic	
variants	 in	or	close	to	the	ANP	gene	(NPPA)	 locus,	which	 lead	
to	 increased	 circulating	 levels	 of	 plasma	ANP,	were	 shown	 to	
lower	 blood	 pressure	 and	 the	 risk	 of	 hypertension	 in	 healthy	
individuals.20,21	Moreover,	 individuals	 harbouring	 one	 copy	 of	
the	G	allele	of	rs5068	have	lower	likelihood	of	diabetes,22	and	
ANP	 has	 been	 shown	 to	 increase	muscle	 insulin	 sensitivity,23	
although	 whether	 insulin	 release	 itself	 is	 stimulated	 is	 more	
debated.10,24,11	 Such	 fundamental	 and	 pleiotropic	 actions	 of	
ANP	 have	 made	 its	 receptors	 an	 important	 pharmacological	
target,	 resulting	 in	 recently	 introduced	 therapies	 for	 the	
treatment	 of	 cardiovascular	 disease.25,26	 Despite	 this,	 many	
facets	of	ANP	 function	and	action	remain	elusive.	Thus,	novel	
tools	 for	 unravelling	 and	 controlling	 ANP/NPR-A-stimulated	
signalling	processes	would	be	a	valuable	asset.		
To	 address	 this,	 we	 report	 the	 synthesis	 of	 a	 photochromic	
ligand	based	on	human	ANP	that	enables	the	photocontrol	of	
RLE	 activity	 (Fig.	 1a).	 The	 NPR-A	 was	 endowed	 with	 light-
sensitivity	by	incorporation	of	the	photoswitchable	amino	acid,	
[3-(3-aminomethyl)phenylazo]phenylacetic	 acid	 (AMPP)27,28	
into	 ANP,	 which	 along	 with	 related	 derivatives,29,30,8,31	 has	
proven	 to	 be	 a	 valuable	 building	 block	 for	 photocontrol	 of	
peptide	conformation	and	activity	(Fig.	1b).	One	out	of	nine	of	
our	 synthesized	 photochromic	 ANPs	 (AzoANPs),	 termed	
TOP271,	 allowed	 optical	 control	 to	 be	 exerted	 over	 NPR-A	
activity,	 intracellular	 cGMP	 levels,	 and	downstream	processes	
using	UV	and	blue	light.	
Results	and	discussion	
Our	 initial	 design	 approach	was	 based	 on	 the	 substitution	 of	
amino	acids	in	ANP	by	AMPP,	more	precisely	into	the	peptidic	
backbone	 to	 induce	 maximal	 structural	 changes	 upon	
photoisomerization.	 Nine	 different	 photochromic	 AzoANP	
peptides	(dubbed	TOP263-271)	were	designed	and	synthesized	
to	 obtain	 a	 small	 library	 (Fig.	 1c),	 whereby	 AMPP	 replaced	
either	 two,	 three	 or	 four	 amino	 acids	 in	 ANP.	 The	
substitutions,	following	a	circular	permutational	fashion,	were	
located	 either	 near	 the	N-	 or	 C-terminus	 or	 facing	 the	 Cys7-
Cys23	disulfide	bridge	in	the	native	17	amino	acid	cycle	of	ANP	
(see	SI	for	details	on	synthesis	and	characterization).		
At	 this	point,	 it	 is	worth	noting	 that	 initial	 screening	of	 cGMP	
accumulation	 returned	 a	 single	 compound,	 i.e.	 TOP271,	 as	
being	 the	 most	 active	 and	 most	 isomer-dependent	 peptide.	
Thus,	we	focused	on	characterization	and	investigation	of	this	
lead	 compound.	 Further	 details	 on	 the	 cGMP	 assays	 can	 be	
found	under	“optical	control	of	cGMP	generation”.	
Photophysical	properties	of	AzoANP	peptides	TOP263-271	
The	 photochromic	 AzoANP	 peptides	 including	 native	 human	
ANP	 (hsANP)	 were	 synthesized	 through	 solid-phase	 peptide	
synthesis	 (SPPS),	 characterized	 by	 high	 resolution	 mass	
spectrometry,	 and	 their	 purity	 assessed	 by	 reverse-phase	
HPLC:	 all	were	<3.7	ppm	of	 the	 calculated	mass	and	RP-HPLC	
revealed	 high	 purity	 (see	 SI	 for	 MS	 and	 HPLC	 data).	 The	
switching	 kinetics	 of	 all	 azologued	 peptides	were	 determined	
by	UV/Vis	 spectroscopy	 (TOP271	Fig.	2a-c,	TOP263-270	SI	Fig.	
1-3	 and	 SI	 Tab.	 3,4).	 Starting	 with	 compounds	 in	 the	 dark-
adapted	 state	 (vide	 infra),	 a	 decrease	 in	 the	 π-π*	 and	 an	
increase	in	the	n-π*	band	was	observed	in	response	to	UV	light	
Fig.	1:	ANP	receptor	and	AMPP.	(a)	The	ANP	receptor	links	binding	of	and	activation	
by	a	photoswitchable	peptide	 to	guanylyl	 cyclase	activity,	 that	 is	 cGMP	generation	
and	 subsequent	 vasodilation	 in	 its	 UV-light	 adapted	 cis-state.	 (b)	 The	 photoswitch	
AMPP	can	be	toggled	between	its	trans-	and	cis-isomer	with	blue	(460	nm)	and	UV-
light	(365	nm),	respectively.	(c)	The	structure	of	ANP	is	characterized	by	a	macrocycle	
that	 is	 formed	 by	 a	 disulfide	 bond	 between	 Cys7	 and	 Cys23.	 Replacement	 of	 two,	
three	or	four	amino	acids	along	the	ring	 structures	 leads	to	TOP263–271.	(d)	 Initial	
assessment	 of	 AzoANP	 peptides	 TOP263-271	 potency	 towards	 cGMP	 synthesis	
focuses	on	TOP271,	where	four	amino	acids	are	replaced	on	the	C-terminal	 side	of	
the	macrocycle.	
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(l	=	365	nm)	(Fig.	2a),	with	reversion	of	this	switching	process	
in	response	to	blue	light	(l	=	460	nm).	
As	 expected	 for	 an	 electron-poor	 azobenzene,	 all	 peptides	
were	 bistable	 (TOP271	 Fig.	 2c,	 TOP263-270	 SI	 Fig.	 3).	 This	
advantageous	 trait	allows	samples	 to	be	pre-illuminated	prior	
to	 application	 rather	 than	 needing	 constant	 illumination.	We	
determined	 the	 thermal	 cis®trans	 relaxation	 rate	kobs	 in	 PBS	
buffer.	This	was	performed	at	room	temperature,	and	because	
the	 compounds	were	 bistable,	 the	 initial	 back-relaxation	was	
obtained	as	a	linear	function	(pseudo-first	order)	from	the	first	
30	 min	 after	 ceasing	 illumination.	 Peptides	 TOP263-270	
showed	 kobs	´	 10
-4	 a.u.330nm/min	 between	 0.28-2.83,	with	 the	
most	potent	 compound	TOP271	being	0.98	a.u.330nm/min	 (see	
SI	 Table	 4,	 compare	 with	 kobs	 =	 3.58	 ´	 10
-4	 a.u./min	 for	
unsubstituted	 azobenzene	 in	 benzene	 at	 0	 °C).32	 To	 examine	
the	 structural	 relations	 between	 ANP	 and	 both	 isomers	 of	
TOP263-271,	 CD	 spectra	 were	 recorded	 in	 40%	 buffered	
aqueous	 2,2,2-trifluoroethanol	 (TFE)	 solutions.	 TFE	 is	 needed	
for	 the	 peptides	 to	 form	 stabilized	 secondary	 structures	
instead	 of	 random	 coils,33	 and	 the	 optimal	 TFE	 concentration	
of	 40%	 was	 determined	 with	 ANP	 in	 different	 aqueous	
buffered	 mixtures	 (SI	 Fig.	 4).	 The	 spectra	 of	 the	 peptides	
TOP263-271	 showed	 differences	 between	 their	 cis/trans-
isomers,	 but	 remained	 similar	 to	 that	 of	 native	 ANP,	with	 no	
observable	trend	(SI	Fig.	5-7).	TOP271	was	subjected	to	further	
characterization	 for	 both	 its	 cis-	 and	 trans-form	 by	 NMR	
spectroscopy	 alongside	 ANP.	 The	 spectra	 were	 recorded	 in	
35%	 aqueous	 TFE-d3	 solutions	 to	 suppress	 signal	 broadening	
and	 aggregation	 (see	 SI	 for	 NMR	 data	 on	 ANP	 and	 cis/trans-
TOP271).	 The	cis-TOP271	NMR	 spectrum	 showed	overlapping	
signals	 and	 thus	 could	 not	 be	 resolved.	 Nevertheless,	 the	 1H	
and	 13C	 chemical	 shift	 values	 of	 the	 trans-TOP271	 peptide	
could	be	unambiguously	identified,	showing	the	incorporation	
of	 AMPP	 into	 the	 backbone	 of	 the	 peptide	 and	 the	 overall	
correct	structure.		
Optical	control	of	cGMP	generation	
To	assess	the	most	suitable	peptide	for	further	analysis,	cGMP	
generation	 was	 measured	 in	 HEK293t	 cells	 transiently	
transfected	with	NPR-A.34	cGMP	is	a	major	effector	of	cellular	
metabolism,35	with	effects	on	adipose	tissue,36–38	liver39,40	and	
the	brain.41	Alongside	nitric	oxide,	the	natriuretic	peptides	are	
the	major	potentiators	of	cGMP	generation,	with	downstream	
signalling	 effects	 on	 phosphodiesterases	 (PDEs),42	 cGMP-
dependent	proteinkinases	(PKGs)43	and	cyclic	nucleotide-gated	
channels	 (CNGs).44	 ANP	 induces	 smooth	 muscle	 relaxation	
through	increases	in	intracellular	cGMP	levels	and	activation	of	
PKGI,	which	subsequently	leads	to	a	decrease	in	cytosolic	Ca2+	
levels	 and	 reduced	 Ca2+-sensitivity	 of	 the	 contractile	
system.45,46,12	 Furthermore,	 depleting	 cGMP	 levels	 leads	 to	
depolarization	in	rods	of	the	retina,	triggering	action	potentials	
that	transduce	signals	to	perceive	light.47	
For	testing	of	cGMP	synthesis,	each	peptide	was	applied	as	the	
trans-	or	cis-isomer	by	keeping	them	either	in	the	dark	or	pre-
illuminating	 with	 UV	 light	 (λ	 =	 365	 nm)	 for	 15	 minutes,	
respectively.	 Using	 this	 approach,	 TOP271,	 i.e.	 the	 ANP	
analogue	 where	 AMPP	 replaces	 four	 amino	 acids	 at	 the	 C-
terminal	end	of	the	ring,	was	identified	as	the	most	promising	
candidate	 due	 to	 its	 highest	 binding	 affinity.	 In	 addition,	 a	
trend	 in	 the	activity	of	 these	azobenzene-containing	peptides	
was	revealed:	activity	towards	cGMP	synthesis	was	higher	the	
more	 amino	 acids	 were	 replaced	 and	 the	 closer	 their	
substitution	 was	 located	 to	 the	N-terminus	 (Fig.	 1d).	 Besides	
TOP271,	 only	 three	 further	 peptides	 from	 our	 small	 AzoANP	
library,	TOP264,	-265	and	-268,	showed	NPR-A	activation	in	the	
µM	range	(SI	Fig.	8).	The	low	potency	of	these	compounds	and	
the	 inactivity	 of	 the	 remaining	 photochromic	 ANP	 peptides	
(TOP263,	 -266,	 -267,	 -269	 and	 -270)	 likely	 stems	 from	 the	
substitution	 of	 residues	 crucial	 for	 receptor	 binding,	 such	 as	
Phe8.48,49	
Having	identified	TOP271	as	the	lead	candidate,	we	attempted	
to	access	light-dependent	NPR-A	activity.	The	measured	cGMP	
dose-responses	showed	that	both	TOP271	isomers	had	similar	
potency	 to	 native	 ANP	 (EC50,ANP	 =	 2.0	±	 0.4	 nM)	 (Fig.	 2d),	 but	
cis-TOP271	(EC50,cis	=	126.6	±	10.9	nM)	was	roughly	 four	times	
more	 potent	 than	 the	 trans-isomer	 (EC50,trans	 =	 467.9	 ±	 59.4	
nM).	 It	 should	 be	 noted	 that,	 although	 the	 increase	 in	 EC50	
seems	 small,	 signal	 integration	 and	 amplification	 of	 cGMP	
leads	 to	more	pronounced	 responses	 in	 cellulo.50	With	 this	 in	
mind,	 we	 decided	 to	 progress	 TOP271	 through	 to	 more	
relevant	studies	ex	vivo.		
Optical	control	of	smooth	muscle	tone	and	pancreatic	beta	cell	
function	
Fig.	2:	Photodynamics	and	cGMP	dose-response	of	TOP271.	(a)	UV/Vis	spectra	of	cis-	
and	trans-TOP271.	(b)	Reversible	switching	of	TOP271	with	UV	(365	nm)	and	blue	(460	
nm)	light.	(c)	Bistability	of	TOP271	when	 switched	to	the	cis-isomer	by	means	of	UV	
light	(365	nm)	and	subsequently	 left	 in	the	dark.	(d)	Dose-response	of	cis-	and	trans-
TOP271	 in	NPR-A	transfected	HEK293t	 cells	 assessed	by	 cGMP	HTRF.	EC50	 values	 for	
ANP	=	2.0	±	0.4	nM,	cis-TOP271	=	126.6	±	10.9	nM	and	trans-TOP271	=	467.9	±	59.4	nM	
correspond	to	two	independent	assays.	Values	represent	the	mean	±	SEM.	
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We	next	 sought	 to	address	whether	TOP271	would	allow	 the	
optical	 control	 of	 cGMP-dependent	 processes	 in	 a	
physiologically-relevant	system,	i.e.	the	aortic	ring	preparation.	
The	 treatment	of	 constricted	aortic	 rings	with	ANP	 leads	 to	a	
potent	 vasodilation,	 corresponding	 to	 the	 blood	 pressure	
reducing	 effect	 of	 ANP.51	 Accordingly,	 we	 predicted	 that	
TOP271	 would	 allow	 reversible,	 light-controlled	 vasoactive	
responses,	 with	 cis-TOP271	 being	 the	 stronger	 effector	 at	
specific	 concentrations.	 Dose-response	 curves	 were	 obtained	
for	 vasodilation	 in	 pre-constricted	 aortic	 rings	 following	
exposure	 to	 pre-illuminated	 cis-	 (l	 =	 365	 nm)	 and	 trans-
TOP271	 (l	 =	460	nm),	 and	 showed	 increased	potency	 for	 the	
former	 isomer	 in	the	100	nM	to	1	µM	range	(Fig.	3a,	SI	Fig.	9).	
Although	 this	dose-response	 indicated	a	 significant	difference	
in	 receptor	 activation	 for	 100	 nM	TOP271,	we	 decided	 to	 use	
400	 nM	 TOP271	 to	 trigger	 a	 stronger	 isomer-dependent	
vasodilation.	 Thus,	 the	 application	 of	 dark-adapted	 trans-
TOP271	 led	 to	 strong	 vasodilation,	 which	 was	 enhanced	
following	 UV	 (l	 =	 365	 nm)	 illumination	 to	 induce	 cis-
isomerization,	and	again	reversed	after	blue	light	(l	=	460	nm)	
exposure	to	induce	trans-accumulation	(Fig.	3b	and	d).		
Conversely,	 to	 examine	 the	 cis	®	 trans	®	 cis	 isomerization	
cycle,	 pre-illuminated	 (l	 =	 365	nm)	 cis-TOP271	was	 added	 to	
the	organ	bath,	leading	to	a	potent	vasodilation	(Fig.	4b	and	e,	
SI	Fig.	10).	Subsequent	trans-isomer	accumulation	by	exposure	
to	 blue	 light	 (l	 =	 460	 nm)	 elicited	 vasoconstriction,	 which	
again	 could	 be	 reversed	 by	 UV	 (l	 =	 365	 nm)	 illumination.	
Notably,	 the	 speed	 of	 the	 initial	 vasodilation	was	 1.5x	 higher	
for	 cis-	 compared	 to	 trans-TOP271,	 with	 the	 former	 being	
analogous	to	ANP	(Fig.	3c).	
Insulin-secreting	pancreatic	beta	cells	express	NPR-A,	and	ANP	
action	 is	 thought	 to	 provide	 a	 potential	 explanation	 for	 the	
association	 between	 cardiovascular	 and	 metabolic	
dysregulation.52,53	 We	 observed	 that	 native	 ANP	 dose-
dependently	 (0.1-100	 nM)	 suppressed	 beta	 cell	 function	 at	
physiologically-elevated	 glucose	 (8	mM)	 levels,	 as	 shown	by	 a	
reduction	in	the	amplitude	of	intracellular	Ca2+	fluxes	in	intact	
islets	 of	 Langerhans.	 These	 findings	 could	 be	 replicated	 using	
Fig.	 3:	 TOP271	 allows	 photocontrol	 of	 aortic	 tissue.	 (a)	 Dose-response	 curves	 for	
trans-	 and	 cis-TOP271.	 (b)	 Aortic	 relaxation	 for	 cycles	 in	 a)	 and	 b).	 (c)	 τ	 of	 aortic	
relaxational	 responses	 for	 17	 nM	 ANP	 compared	 to	 400	 nM	 trans-	 and	 cis-TOP271.	
(d,e)	Reversible	photocontrol	over	aortic	 tension	by	application	 of	 trans-TOP271	 (d)	
and	 cis-TOP271	 (e)	 with	 UV-/blue	 and	 blue/UV-light	 (365	 and	 460	 nm)	 cycles,	
respectively.	All	experiments	were	 conducted	in	the	presence	of	200	µM	N-ω-nitro-L-
arginine	methyl	 ester	 (L-NAME)	and	3	µM	Diclofenac.	PE	=	phenylephrine;	 IBMX	=	3-
iso-butyl-1-methylxanthine.	 (n	 =	 6	 aortic	 rings	 from	 4	 animals)	 (*P<0.05,	 **P<0.01,	
repeated	measures	Student’s	t-test).	Values	represent	the	mean	±	SEM.	
	
Fig.	 4:	 TOP271	allows	photocontrol	of	pancreatic	beta	 cell	 function.	 (a-d)	ANP	dose-
dependently	 suppresses	 Ca2+	 response	 in	 beta	 cells	 (representative	 traces	 shown	
(scale	bar	25	µM)	(n	=	4	-	6	islets	for	each	concentration)	(**P<0.01,	one-way	ANOVA).	
(g-h)	 cis-TOP271	 dose-dependently	 inhibits	 Ca2+	 spike	 amplitude,	 whereas	 trans-
TOP271	 is	 less	 effective	 at	 all	 concentrations	 tested	 (representative	 traces	 shown)	
(scale	bar	25	µM)	(n	=	4	-	6	islets	for	each	concentration)	(**P<0.01,	two-way	ANOVA).	
(i-j)	 TOP271	allows	 reversible	photocontrol	of	beta	 cell	 function,	with	blue	 (458-488	
nm)	light	partially	restoring	Ca2+	responses	(n	=	5	 islets)	(*P<0.05,	repeated	measure	
one-way	ANOVA).	Values	represent	the	mean	±	SEM.	
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UV	pre-illuminated	(l	=	365	nm)	cis-TOP271	(Fig.	4e-h),	which	
also	robustly	suppressed	Ca2+	rises	from	1-100	nM.	By	contrast,	
dark-adapted	 trans-TOP271	 induced	 only	 a	 small	 decrease	 in	
beta	cell	Ca2+-spiking	activity	(Fig.	4e-h).	Reversibility	could	be	
achieved	 by	 applying	 cis-TOP271	 and	 then	 illuminating	 with	
blue	light	(l	=	458-482	nm)	to	induce	trans-isomerization	(Fig.	
4i).	Restoration	of	beta	cell	 function	was	only	partial	 (Fig.	4j),	
however,	 possibly	 due	 cGMP-mediated	 sequestration	 of	 Ca2+	
into	internal	stores	such	as	the	endoplasmic	reticulum.54	
Pancreatic	beta	cells	have	been	shown	to	express	NPR-A,	and	
links	exist	between	ANP	and	diabetes	risk.55	Indeed,	ANP	gene	
expression	 is	 increased	 in	 the	 ventricles	 of	 rats	with	 reduced	
beta	cell	mass,	and	ANP	levels	are	elevated	during	diabetes.52	
We	were	able	to	show	that	ANP	dose-dependently	inhibits	the	
amplitude	of	beta	cell	Ca2+	rises,	with	significant	effects	at	10-	
and	100	nM	of	the	peptide.	Whereas	trans-TOP271	was	largely	
without	effect,	cis-TOP271	suppressed	cytosolic	Ca2+	fluxes	and	
beta	 cell	 activity,	 and	 this	 could	 be	 partially	 reversed	 by	
ceasing	 UV	 illumination.	 The	 effects	 of	 ANP	 on	 beta	 cell	
function	 are	 complex	 and	 controversial.	 While	 some	 studies	
have	 shown	 that	 ANP	 inhibits	 Ca2+	 levels	 and	 insulin	
secretion,10,24	 others	 have	 shown	 stimulatory	 effects.11,56	 This	
likely	 reflects	 differences	 in	 the	 time	 course	 of	 application,	
preparation	 under	 examination	 (i.e.	 dissociated	 vs.	 intact	
islets),	 stimulation	 state	 (i.e.	 low	 vs.	 high	 glucose)	 and	
concentration.		
This	likely	reflects	differences	in	the	time	course	of	application,	
preparation	 under	 examination	 (i.e.	 dissociated	 vs.	 intact	
islets),	 stimulation	 state	 (i.e.	 low	 vs.	 high	 glucose)	 and	
concentration.	 With	 regards	 to	 the	 latter,	 we	 were	 able	 to	
show	 a	 bimodal	 relationship	 where	 low	 doses	 of	 ANP	
preferentially	affect	Ca2+	oscillation	frequency	without	altering	
amplitude,	 whereas	 high	 doses	 do	 the	 opposite	 (SI	 Fig.	 11).	
Thus,	 TOP271	 may	 provide	 an	 important	 tool	 to	 allow	 ANP	
receptor	conformation	and	signalling	 to	be	understood	 in	 the	
context	of	beta	and	other	cell	(dys)function.	
Molecular	dynamics	simulations	of	ANP	and	cis/trans-TOP271	
Atomic-level	 modelling	 in	 explicit	 solvent	 was	 conducted	 to	
better	 understand	 the	 structure/activity	 relationships	 of	
isomer-dependent	 NPR-A	 activation.	 We	 focused	 on	 the	 in	
silico	 structure	 of	 native	 ANP	 peptide	 and	 cis/trans-TOP271,	
both	 in	 aqueous	 solution	 and	 bound	 to	 the	 NPR-A	 receptor.	
The	extra-cellular	domains	were	modelled	based	on	the	NPR-A	
crystal	 structure	 (pdb:	 1t34,	 in	 complex	 with	 rat	 ANP	
(rnANP)),48	 while	 the	 receptor-bound	 ANP	 peptide	 and	 the	
cis/trans-TOP271	 isomers	 where	 based	 on	 the	 NPR-C	 crystal	
structure	 (pdb:	 1yk0,	 in	 complex	with	hsANP).49	We	used	 the	
latter	 for	 our	 structural	 peptide	modelling	 to	 account	 for	 the	
Met12/Ile12	difference	between	ANP	and	rnANP,	respectively.		
In	 a	 first	 step,	 the	 cis/trans-TOP271	 isomers	 were	 simulated	
for	200	ns	 in	 the	absence	of	 the	NPR-A	receptor.	To	compare	
the	 affinity	 of	 both	 isomers	 to	 adopt	 the	 bound	 ANP	 ring	
structure,	 distance	 restraints	 with	 respect	 to	 the	 ANP	 crystal	
structure	were	 applied	 between	 all	 Cα-atom	 pairs	within	 the	
ring,	 neglecting	 the	 two	 terminal	 tails.	 The	 resulting	 restraint	
energy	 distributions	 show	 a	 clear	 difference	 between	 the	
Fig. 5: MD simulations of ANP and TOP271. (a) Restraining energy distribution obtained from MD simulations (200 ns) of cis- and trans-TOP271 in solution, including restraints 
to keep the sampled conformations close to native ANP (see methods section for details). (b) Representative restrained conformations of cis- and trans-TOP271 illustrating the 
steric hindrance of trans-azobenzene to fit into the native ring structure (red: azobenzene, orange: Cys7-Cys23 disulfide bridge). (c) Mean backbone-Cα RMSD and standard 
deviation of the NPR-A dimer and the both receptor domains A and B after 1 µs simulation, calculated for bound native ANP (black), bound cis/trans-TOP271 (gray and blue, 
respectively) and apo-NPR-A (cyan). The overall receptor RMSD clearly differs between native and cis-TOP271 vs. trans-TOP271 and apo-NPR-A. (d) Center-of-mass distance 
(orange balls and arrow) of the membrane-proximal NPR-A domains after 1 µs simulation. For bound native ANP (black) and cis-TOP271 (gray) the receptor domains tend to close 
compared to trans-TOP271 and the apo-NPR-A (blue and cyan). (e, f, g) Representative NPR-A and peptide conformations for bound native ANP (e) and bound cis/trans-TOP271 
(f and g, respectively). Top row: Isomer-dependent overall receptor geometry and binding site coverage visualized by time-superposition of the disulfide-connected isomer segment 
Cys7-Cys23 (red: ≤300 ns, white ≤600 ns, blue ≤1000 ns). Middle row: zoom into the time-superposition illustrates differences in the conformational ensemble of native ANP and 
cis-TOP271 vs. trans-TOP271 (azobenzene in line design). Bottom row: Representative isomer conformations extracted from the simulated ensemble (red: azobenzene, orange: 
Cys7-Cys23 disulfide bridge).	
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isomers	 (Fig.	 5a),	 with	 the	 energy	 of	 trans-TOP271	 being	 on	
average	6.7	kcal/mol	higher.	This	 likely	derives	from	the	rigid,	
extended	 trans-azobenzene	 structure,	 which	 sterically	
prevents	adoption	of	the	native	ring	structure	(Fig.	5b).	
To	 elucidate	 the	 effect	 of	 the	 isomeric	 conformational	
differences	on	receptor	geometry,	unrestrained	simulations	of	
1	 μs	 length	 were	 performed	 for	 NPR-A	 bound	 cis/trans-
TOP271,	 ANP	 and	 apo-NPR-A.	 The	 overall	 receptor	 RMSD	
significantly	differs	for	cis-	and	trans-TOP271,	with	the	former	
matching	ANP	 and	 the	 latter	 being	 similar	 to	 apo-NPR-A	 (Fig.	
5c).	These	isomer-dependent	differences	in	receptor	geometry	
are	related	to	a	change	in	relative	orientation	of	the	two	NPR-
A	 dimers:	 while	 there	 are	 no	 ligand-dependent	 orientation	
changes	 in	 the	 membrane-distal	 domains	 (SI	 Fig.	 12),	 the	
membrane-proximal	 domains	 tend	 to	 close	 around	 ANP	 and	
cis-TOP271,	but	remain	more	open	in	the	case	of	trans-TOP271	
(Fig.	 5d-g).	 This	 is	 in	 agreement	with	 the	 crystal	 structures	of	
the	 different	 apo-	 and	 ligand-bound	 natriuretic	 peptide	
receptors,	 which	 show	 up	 to	 20	 Å	 distance	 change	 between	
the	 two	 C-terminal/membrane-proximal	 receptor	 domains	
upon	 ligand	binding.48,49	 trans-TOP271	 thereby	 resembles	 the	
apo-form,	 in	 which	 fluctuating	membrane-proximal	 distances	
shift	 the	 receptor	 towards	 an	 open	 state	 (Fig.	 5c).	 These	
changes	 in	 receptor	 geometry	 can	 be	 assigned	 to	 isomeric	
differences	 in	 the	 bound	 conformation.	 Whereas	 the	
conformations	 of	 cis-TOP271	 are	 comparable	 to	 the	 crystal	
ring	 structure	of	ANP,	 the	 conformational	 ensemble	of	 trans-
TOP271	is	narrower	and	more	hairpin-like	(Fig.	5e-g).	The	NPR-
A-bound	crystal	structure	of	ANP	also	reveals	a	central	pore	in	
the	17	amino	acid	ring	that	is	essential	for	ligand	binding;	only	
cis-TOP271	is	able	to	adapt	this	donut	like	conformation,	while	
the	trans-isomer	forms	a	closed	structure	(Fig.	5e-g).		
Lastly,	we	attempted	to	quantify	the	twist	motion	of	the	NPR-
A	membrane-proximal	 domains	 upon	 ligand	binding,	which	 is	
thought	 to	 initiate	 intracellular	 GC	 activation.48	 Here,	 we	
detected	a	less	prominent	isomer-dependency	for	the	selected	
twist	angle	of	the	ligand-bound	receptor	domains	compared	to	
apo-NPR-A	 (see	SI	Fig.	13	and	SI	Tab.	6).	While	 the	binding	of	
ANP	leads	to	a	focusing	of	the	twist	angle	distributions	in	NPR-
A,	 bound	 cis-	 and	 trans-TOP271	 show	 broader,	 shifted	
distributions	 and	 the	 apo-NPR-A	 inherits	 large	 angle	
fluctuations.	This	shows	on	the	one	hand	the	higher	similarity	
of	 angle	 distributions	 of	 ANP	 and	 cis-TOP271	 compared	 to	
trans-TOP271,	but	on	the	other	hand	also	the	flexibility	of	the	
apo-NPR-A	 membrane-proximal	 regions.	 Notably,	 crystal	
structures	 represent	 only	 a	 structural	 snapshot,	 while	 MD	
simulations	 cover	 a	 whole	 ensemble	 of	 structures	 and	 as	 a	
result	 we	 conclude	 that	 the	 reduced	 distance	 between	 the	
membrane-proximal	 domains	 in	 the	 ligand-bound	 state,	 and	
not	 the	twisting	motion	of	 the	NPR-A,	 is	 the	major	 trigger	 for	
receptor	activation.		
In	summary,	our	MD	simulations	showed	a	higher	flexibility	of	
the	 apo-NPR-A	 receptor	 as	 well	 as	 bound	 to	 trans-TOP271,	
whereas	 the	 membrane-proximal	 receptor	 domains	 tend	 to	
close	 around	 ANP	 and	 cis-TOP271.	 The	 simulations	 hence	
suggest	 an	 alternative	 regulation	 of	 the	 guanylyl	 cyclase	
activity,	in	which	the	binding	of	ANP	and	cis-TOP271	to	NPR-A	
suppresses	 dynamic	 fluctuations	 of	 the	 membrane-proximal	
domains	 of	 both	 receptor	 dimers,	 leading	 to	 defined	
ligand/receptor	 structures.	 Since	 in	 contrast	 to	 previous	
experiments	 our	 simulations	 suggest	 an	 only	 less	 prominent	
isomer-dependency	 of	 twisting	 motion	 of	 the	 membrane-
proximal	 domains,	 we	 predict	 that	 our	 dynamic	 simulations	
deliver	 a	 more	 precise	 picture	 of	 NPR-A	 activation	 than	 the	
static	crystal	structure	model.48	
Conclusions	
In	this	study,	we	present	the	design,	synthesis,	evaluation	and	
application	of	TOP271,	a	peptidic	hormone	based	on	ANP	with	
a	 photoresponsive	 azobenzene	 unit.	 Acting	 via	 the	 NPR-A	
receptor	 to	 generate	 cGMP,	 TOP271	 allows	 the	 reversible	
photocontrol	of	contraction/dilation	in	aortic	tissue,	as	well	as	
Ca2+	 oscillations	 in	 rodent	 islets	 of	 Langerhans.	 Although	
photodependent	cGMP	synthesis	was	described	earlier,	 these	
approaches	 rely	 on	 the	 genetically-encoded	 photosensitive	
proteins	 EROS57,58	 or	 BeCyclOps,59,60	 whereas	 TOP271	 allows	
the	unprecedented	photocontrolled	 cGMP	 synthesis	 in	native	
tissue.	 EROS	 and	 BeCyclOps	 are	 based	 on	 bacterial	 flavin-
containing	 photoreceptors	 and	 fungal	 rhodopsins,	
respectively,	and	can	be	used	to	induce	penile	erection	in	male	
rats	 or	 tactic	 behavior	 in	 C.	 elegans	 following	 illumination.	 A	
drawback	of	EROS	is	the	residual	cAMP	activity,	caused	by	the	
specific	 mutation	 of	 an	 adenylyl	 cyclase	 to	 an	 engineered	
guanylyl	 cyclase.	 BeCyclOps	 on	 the	 other	 hand	 utilizes	 native	
guanylyl	cyclase	activity	and	was	shown	to	specifically	engage	
only	 cGMP	 synthesis,	 but	 requires	 genetic	 introduction.	
Photochromic	 ligands	 like	 TOP271	 avoid	 these	 issues	 and	
remain	 exogenously	 applied,	 thereby	 only	 targeting	 and	
activating	the	protein	of	interest.	
With	 TOP271,	we	 could	 selectively	 and	 reversibly	manipulate	
the	NPR-A/cGMP	signalling	pathway	with	high	spatio-temporal	
precision.	 Interestingly,	 the	 4-fold	 higher	 potency	 of	 cis-
TOP271	 for	 cGMP	 generation	 detected	 in	 vitro	 in	 transfected	
HEK293t	 cells	 is	 sufficient	 to	 trigger	 a	 more	 pronounced	
vasodilation	 ex	 vivo	 in	 aortic	 ring	 tissue.	 Although	 the	 exact	
intracellular	 cGMP	 concentration	 is	 an	 active	 source	 of	
research	 efforts,	 the	 changes	 observed	 are	 in	 agreement	 to	
prior	findings,	where	small	changes	in	the	concentration	of	this	
second	 messenger	 provoke	 a	 significant	 amplification	 of	
downstream	 signals.61	 It	 also	 showcases	 the	 robustness	 and	
applicability	 of	 TOP271,	which	we	 believe	will	 enable	 precise	
control	 of	 hemodynamic	 processes,	 contributing	 to	 the	
dissection	of	vascular	function	in	health	and	disease.	
Moreover,	 TOP271	 not	 only	 demonstrates	 the	 successful	
transformation	 of	 ANP	 into	 a	 photoswitchable	 peptide,	 but	
also	extends	the	toolbox	of	photochromic	ligands	to	all	classes	
of	 transmembrane	 receptors.	 The	 incorporation	 of	
azobenzenes	into	peptides	and	proteins	has	been	achieved	in	a	
multitude	 of	 systems	 in	 the	 last	 decade,	 i.e.	 in	 proteins	 of	E.	
coli62,7	and	in	short	peptides	with	specific	secondary	structures	
such	 as	 b-sheet	 and	 b-hairpin	 motifs.63,30,29,27	 Two	 major	
possibilities	 should	 be	 distinguished:	 i)	 having	 an	 azobenzene	
as	 an	 amino	 acid	 residue	 and	 ii)	 having	 an	 azoswitch	 in	 the	
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peptide	 backbone.	 While	 the	 former	 has	 been	 used	 to	 gain	
optical	control	over	binding	affinity	of	transcription	factor	and	
cell	adhesion	molecules,62,64	the	latter	was	successfully	applied	
to	 the	 optical	 control	 of	 muscle	 contraction31	 and	 secondary	
structure	formation.65	We	envision	our	design	herein,	together	
with	AzoChig28	and	LirAzo,8	to	be	highly	applicable	to	all	kinds	
of	peptides	(e.g.	neuropeptides,	such	as	oxytocin,	vasopressin,	
kisspeptin	 etc.),	 as	 backbone	 substitution	 allows	 a	 larger	
conformational	 change	 upon	 isomerisation	 and	 therefore	 a	
larger	change	in	affinity/efficacy.	With	recent	synthetic	efforts	
in	 mind,66	 tetra-ortho-chloro-AMPP,	 exhibiting	 red-shifted	
illumination	 wavelengths	 and	 high	 bistability,	 can	 be	
envisioned	 for	 the	 incorporation	 into	 target	 peptides.	 Such	
breadth	already	encompasses	hairpin	structures,	a-helices	and	
now	macrocyclic	structures,	but	can	potentially	be	extended	to	
antibodies,	 immunogens,	 peptidic	 hormones	 and	 receptors,	
where	fine	regulation	of	protein	function	by	tertiary	structure	
stabilization/destabilization	 is	 necessary	 for	 function.67	 Thus,	
the	 present	 findings	 set	 the	 stage	 for	 photochromic	 peptides	
to	 become	 a	 mainstay	 for	 optical	 control	 of	 biological	
processes	using	photopharmacology.	
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3. Supplementary Figures and Tables 
 
Supplementary Figure 1: UV/Vis spectra of ANP (black) and the cis- (gray) and trans-
isomers (blue) of peptides TOP263-TOP270 in PBS buffer at approx. 50 µM conc.; 25 °C. 
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Supplementary Figure 2: UV/Vis switching kinetics of peptides TOP263-TOP270 in 
PBS buffer measured over abs. at 330 nm; 50 µM conc.; 25 °C. Reversible cis«trans-
isomerization was recorded by 365 (trans®cis) and 460 nm (cis®trans) illumination 
cycles (5 min).  
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Supplementary Figure 3: UV/Vis bistability measurement of peptides cis-TOP263-
TOP270 at 330 nm in PBS buffer; 25 °C. 
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Supplementary Figure 5: CD spectra of the cis/trans-isomers of peptides TOP263, 
TOP264 and TOP265 with two amino acids substituted by AMPP.  
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Supplementary Figure 6: CD spectra of the cis/trans-isomers of peptides TOP266, 
TOP267 and TOP268 with three amino acids substituted by AMPP.  
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Supplementary Figure 7: CD spectra of the cis/trans-isomers of peptides TOP269, 
TOP270 and TOP271 with two amino acids substituted by AMPP.  
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Supplementary Figure 8: cGMP dose-responses of peptides TOP263-270 recorded in 
YFP and NPR-A co-transfected HEK293t cells using a cisbio HTRF® kit. EC50 values of 
TOP264, -265 and -268 were not calculated, nor were experiments repeated due to low 
activation in the µM range. 
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Supplementary Figure 9: Representative traces for aortic ring tensometry vasodilatory 
dose-responses recorded for cis- (gray, a) and trans-TOP271 (blue, b). 
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Supplementary Figure 10: Representative traces for aortic ring tensometry illumination 
control experiments showing the reversibility of UV (365 nm) and blue (460 nm) light 
induced vasoactive responses. Rings were preconstricted with 1 µM phenylephrine (PE) 
and maximally dilated with 100 µM 3-isobutyl-1-methylxanthin (IBMX). To test the 
reversibility on dilated rings, 17 nM ANP was added in some cases. (a-d) Indirect 
illumination of the surrounding organ bath solution. (e,f) Direct illumination of the tissue. 
(a) Vasodilation with UV light (365 nm). (b) Vasodilation with blue light (460 nm). (c) 
Vasodilation with UV (365 nm) and blue light (460 nm). (d) Reversible dilational effect of 
UV (365 nm) and blue light (460 nm) on vasodilated rings (17 nM ANP). (e) Reversible 
effect of direct tissue illumination with UV light (365 nm). (f) Reversible effect of direct 
tissue illumination with blue light (460 nm). 
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Supplementary Figure 11: (a) Low (0.1 nm) but not high (10 nm) concentrations of ANP 
stimulate increases in pancreatic beta cell Ca2+ spiking frequency (n = 5-7 islets for each 
concentration). b) As for a), but cis-TOP271 (n = 4-7 islets for each concentration).
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Supplementary Figure 12: Center-of-mass distance distribution of the membrane-distal 
NPR-A domains A and B after 1 µs simulation show no significant ligand-dependence for 
bound native ANP (black), cis/trans-TOP271 (gray and blue, respectively) and apo-NPR-
A (cyan). 
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Supplementary Figure 13: Twist angle distributions of the membrane-proximal NPR-A 
subdomains with respect to the crystal structure 1t345 indicating only a slight isomer-
dependence, with the distributions of ANP and cis-TOP271 (black and gray, respectively) 
having more overlap than ANP and trans-TOP271 (blue).	
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Supplementary Table 3: Photoswitching kinetics of peptides TOP263-271. 
TOP263 t (sec) 
cis 67.2 ± 3.7 
trans 46.2 ± 2.2 
TOP264  
cis 83.6 ± 1.6 
trans 55.1 ± 1.4 
TOP265  
cis 71.3 ± 1.2 
trans 50.3 ± 0.8 
TOP266  
cis 136.6 ± 1.1 
trans 84.8 ± 0.8 
TOP267  
cis 84.8 ± 6.4 
trans 62.0 ± 4.0 
TOP268  
cis 174.3 ± 7.1 
trans 95.7 ± 2.6 
TOP269  
cis 167.8 ± 8.9 
trans 98.9 ± 3.1 
TOP270  
cis 187.0 ± 6.5 
trans 103.2 ± 2.8 
TOP271  
cis 163.2 ± 5.3 
trans 95.8 ± 0.8 
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Supplementary Table 4: kobs of thermal cis®trans relaxation of peptides TOP263-271. 
 kobs  ´ 10-4 a.u. / min 
TOP263 2.825 ± 0.008 
TOP264 0.945 ± 0.010 
TOP265 0.316 ± 0.004 
TOP266 2.726 ± 0.006 
TOP267 0.942 ± 0.010 
TOP268 2.020 ± 0.026 
TOP269 0.275 ± 0.003 
TOP270 1.620 ± 0.069 
TOP271 0.975 ± 0.010 
 
 
Supplementary Table 5: 1H/13C-NMR chemical shifts of trans-TOP271.  
Residue 1H chem. shifts [ppm] 13C chem. shifts [ppm] 
Ser1 Ha 4.09, Hb* 3.95 Ca 56.8, Cb 62.6 
Leu2 NH 8.52, Ha 4.35, Hb* 1.55,  
Hg 1.54, Hda 0.82, Hdb 0.86 
Ca 55.0, Cb 42.1, Cg 26.4,  
Cda 23.0, Cdb 23.9 
Arg3 NH 8.06, Ha 4.26, Hba 1.79, Hbb 1.69,  
Hga 1.54, Hgb 1.55, Hd* 3.07, He 7.07 
Ca 55.6, Cb 30.7, Cg 26.7, Cd 42.8 
Arg4 - - 
Ser5 NH 7.96, Ha 4.29, Hba 3.62, Hbb 3.69 Ca 58.1, Cb 63.3 
Ser6 NH 7.90, Ha 4.22, Hba 3.64, Hbb 3.59 Ca 58.4, Cb 63.1 
Cys7 NH 8.52, Ha 4.59, Hb* 2.72 Ca 53.4, Cb 38.0 
Phe8 NH 8.11, Ha 4.56, Hba 3.11, Hbb 2.96,  
Hd* 7.25, He* 7.18, Hz 7.11 
Ca 57.6, Cb 38.9, Cd* 130.8,  
Ce* 131.2, Cz 129.2 
Gly9 NH 8.18, Haa 3.73, Hab 3.71 Ca 44.8 
Gly10 NH 8.14, Haa 3.82, Hab 3.81 Ca 44.9 
Arg11 NH 7.66, Ha 4.18, Hba 1.60, Hbb 1.49,  
Hg* 1.35, Hd* 3.00, He 6.99 
Ca 55.2, Cb 30.5,  
Cg 26.7, Cd 42.7 
Met12 NH 7.57, Ha 4.44, Hba 2.00,  Ca 54.3, Cb 31.9, Cg 31.5, Ce 16.0 
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Hbb 1.91, Hga 2.47, Hgb 2.39, He* 1.98 
Asp13 NH 7.76, Ha 4.47, Hba 2.97, Hbb 2.86 Ca 57.3, Cb 38.8 
Arg14 NH 7.76, Ha 4.20, Hba 1.63, Hbb 1.52,  
Hg* 1.38, Hd* 3.02, He 7.01 
Ca 55.2, Cb 30.6, Cg 26.3, Cd 42.7 
Ile15 NH 7.82, Ha 3.99, Hb 1.76, Hg1a 1.04,  
Hg1b 1.02, Hg2* 0.75, Hd1* 0.72 
Ca 61.6, Cb 37.8, Cg1 27.0,  
Cg2 16.5, Cd1 11.8 
Gly16 NH 8.09, Ha* 3.87 Ca 44.8 
Ala17 NH 7.87, Ha 4.23, Hb* 1.31 Ca 52.4, Cb 18.5 
Gln18 NH 8.15, Ha 4.31, Hba 2.12,  
Hbb 1.98, Hg* 2.30 
Ca 55.7, Cb 29.1, Cg1 33.5 
AMPP NH 8.19, H2* 4.41, H4 7.66, H6 7.68,  
H7 7.46, H8 7.38, H12 7.73, H14 7.42,  
H15 7.49, H16 7.71, H17a 3.80, H17b 3.73 
C2 44.9, C4 123.1, C6 123.8,  
C7 131.9, C8 132.5, C12 125.1,  
C14 134.6, C15 131.9, C16 123.8,  
C17 43.9 
Cys23 NH 8.52, Ha 4.64, Hb* 2.69 Ca 53.2, Cb 38.1 
Asn24 NH 7.88, Ha 4.51, Hba 2.98, Hba 2.91 Ca 57.3, Cb 39.0 
Ser25 NH 8.24, Ha 4.42, Hba 3.88, Hba 3.74 Ca 58.1, Cb 63.5 
Phe26 NH 7.62, Ha 4.46, Hba 3.02, Hba 2.83,  
Hd* 7.13, He* 7.04, Hz 7.20 
Ca 56.7, Cb 38.1, Cd* 130.7,  
Ce* 131.2, Cz 129.3 
Arg27 - - 
Tyr28 NH 7.63, Ha 4.46, Hba 3.02, Hba 2.84,  
Hd* 7.01, He* 6.73, Hz 7.20 
Ca 58.1, Cb 38.1, Cd* 132.7,  
Ce* 117.5 
 
 
Supplementary Table 6: Average twist angle of NPR-A membrane-proximal domains upon ligand binding. 
Twist angle Mean / ° Stddev / ° 
ANP 7.56 2.37 
cis-TOP271 10.99 3.51 
trans-TOP271 15.10 3.25 
apo-NPR-A 11.07 5.58 
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2.3 ADDITIONAL COMPOUNDS AND DATA 
During this work, two additional photochromic AzoANP peptides have been designed, synthesized and 
tested, but they have not found their way into the final manuscript. In these two peptides, dubbed 
N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3, the side chain photoswitch AzoPhe 1.24 was incorporated 
instead of AMPP 1.22. This implies a completely different azologization pattern, where 1.27 substitutes 
only a single amino acid and not two, three or four, as it is the case for the nine AzoANP peptides TOP263-
270 and TOP271 2.1. As can be deduced from the compound abbreviations, sites for single amino acid 
substitutions in native ANP are Asn24 and Ser25 in peptides 2.2 and 2.3, respectively. Asn24 and Ser25, 
which are located on the C-terminal tail of ANP adjacent to the disulfide bridge, were selected based on 
the crystal structure of a truncated ANP ligand bound to NPR-A (pdb: 1yk0). This structure revealed the 
position of Asn24 and Ser25 close to a hydrophobic region comprising residues Ile188, Tyr189 and Phe191 
within the B-domain of NPR-A (Figure 2.1).  
 
Figure 2.1:  X-Ray crystal structure based design scheme for N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3. Left: X-
ray crystal structure of both homo dimers of the NPR-A receptor (subunit A light gray, subunit B dark gray) with bound 
truncated ligand ANP (green) (pdb: 1yk0). Right: zoom into the ANP and NPR-A interactions with marked AzoPhe-
substituted amino acids Asn24 (red) and Ser25 (yellow) of ANP and hydrophobic residues Ile188, Tyr189 and Phe191 
(all orange) of the homodimer B of NPR-A.  
It was anticipated that either the cis- or the trans-form of AzoPhe 1.24 would direct the exo phenyl ring of 
the azobenzene unit into the hydrophobic region, resulting in deviating binding affinities of both peptide 
isomers and a biased receptor activation. Similar to the other nine AzoANP peptides, 2.2 and 2.3 were 
initially assessed through detection of their photoswitching kinetics and through the measurement of cGMP 
synthesis dose-response curves using with NPR-A transiently tranfected HEK293t cells. Both peptides 
showed the expected cis/trans-switching with 365 nm UV light or 430 nm blue light and robust switching 
kinetics. The observed t-values for the photoconversion rates were ttrans ⇾ cis = 133.4 ± 5.8 sec and tcis ⇾ trans 
= 95.0 ± 0.2 sec for 2.2 and ttrans ⇾ cis = 116.4 ± 3.2 sec and tcis ⇾ trans = 92.9 ± 0.5 sec for 2.3, and therefore 
similar to the remaining AzoANP peptides.  
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Figure 2.2:  UV/Vis spectra and UV switching kinetics of 2.2 and 2.3. Top left: UV/Vis spectra of cis/trans-2.2. Top 
right: UV switching kinetics of 2.2 measured through the absorption at 330 nm after photoswitching with 365 nm UV 
light (trans ⇾ cis) and 430 nm blue light (cis ⇾  trans). Bottom left: UV/Vis spectra of cis/trans-2.3. Bottom right: UV 
switching kinetics of 2.3 measured through the absorption at 330 nm after photoswitching with 365 nm UV light (trans ⇾  cis) and 430 nm blue light (cis ⇾  trans). 
The EC50 values obtained for both isomers of 2.2 were EC50,cis = 72.1 ± 1.3 nM and EC50,trans = 
149.0 ± 22.5 nM. With EC50 values of EC50,cis-2.3 = 207.3 ± 9.8 nM and EC50,trans-2.3 = 894.9 ± 37.1 nM both 
isomers of 2.3 have a weaker potency towards NPR-A than 2.2 (see table 2.1 to compare with EC50 of ANP 
and TOP271 2.1). However, although 2.2 is a better agonist it shows only a roughly two-fold difference in 
NPR-A activation between both isomers, while 2.3 has an over four-fold difference in NPR-A activation 
and is comparable to TOP271 2.1. Thus, 2.1 was chosen as the lead compound based on the large 
difference in receptor activation of cis/trans-2.1, together with its higher potency. Compounds 2.2 and 2.3 
were dismissed, not least because of their different photoswitch substitution scheme. Nevertheless, the 
drop in potency and simultaneous rise in isomer-bias between 2.2 and 2.3 remains very interesting and is 
worth investigating through structural analysis of ligand-bound NPR-A structures.
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Figure 2.3:  Overview of AzoANP peptides and cGMP dose-response curves for TOP271 2.1, N24AzoPhe-ANP 2.2 
and S25AzoPhe-ANP 2.3. Left: schematic overview of the AMPP 22 substitution pattern in the AzoANP peptides 
TOP263-270 and TOP271 2.1, and dismissed compounds 2.2 and 2.3 with the AzoPhe 1.24 photoswitch. Right: dose-
response curves of both cis/trans-isomers of TOP271 2.1, 2.2 and 2.3 for cGMP synthesis in with NPR-A transiently 
transfected HEK293t cells. Values represent mean ± SEM (n = 3 technical repeats). 
Table 2.1: EC
50 
values of peptides ANP, TOP271 2.1, N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3. 
Peptide EC50 trans (nM) EC50 cis (nM) EC50 trans/cis 
ANP 2.0 ± 0.4 - - 
TOP271 2.1 467.9 ± 59.4 126.6 ± 10.9 3.7 ± 0.8 
N24AzoPhe-ANP 2.2 149.0 ± 22.5 72.1 ± 1.3 2.1 ± 0.3  
S25AzoPhe-ANP 2.3 894.9 ± 37.1 207.3 ± 9.8 4.3 ± 0.4 
 
2.4 SUMMARY AND OUTLOOK 
The natriuretic peptides are important regulatory hormones in eukaryotes and involved in maintaining 
blood and water homeostasis and blood pressure regulation. Many cardiac diseases are associated with 
dysfunctional expression of natriuretic peptides through gene defects154,156, and the plasma levels of atrial 
(ANP) and the B-type (BNP) natriuretic peptide are used as markers for the detection of atrial fibrillation, 
arythmia and heart failure157,158. Moreover, ANP is used in many preclinical trails as treatment for heart 
and renal diseases, but in part with varying effects159–161. Recently, there is also growing evidence for a gut-
heart axis and elevated ANP plasma levels are related with obesity and diabetes risk162–165. Although 
originally discovered in 1981 (ref. 166), there are many recent discoveries of the vast interactions of ANP 
and its natriuretic peptide receptor A (NPR-A) throughout the body, making this hormone and its receptor 
a worthwile target for a photopharmacological approach. This is supported through the affiliation of the 
NPR-A to the class of receptor-linked enzymes, which was not amenable to photopharmacology hitherto. 
To gain optical control over NPR-A signaling nine photochromic AzoANP peptides TOP263-270 and 
TOP271 2.1 carrying the AMPP 1.22 photoswitch, and the two peptides N24AzoPhe-ANP 2.2 and 
S25AzoPhe-ANP 2.3 with the AzoPhe 1.27 photoswitch, were synthesized. After initial assessment of all 
the AzoANP peptides and screening of cGMP synthesis in with NPR-A transiently transfected HEK293t 
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cells TOP271 2.1 was selected as most suitable candidate. This compound not only showed a merely ~63x 
times reduced potency, which is remarkable for a native compound altered with a hydrophobic 
photoswitch that substitutes four amino acids, but also showed a roughly four-fold difference in NPR-A 
activation between the more potent cis-isomer and the weaker trans-form. This difference in potency is 
enough to trigger pronounced physiological responses, which was demonstrated in murine smooth muscle 
tissue and islets of Langerhans. Thereby it was possible to optically control the smooth muscle tone by 
inducing vasoactive reponses, i.e. illumination of aortic rings with UV light led to vasodilation, while blue 
light provoked vasoconstriction. In islets of Langerhans ANP and cis-2.1 caused complete suppression of 
Ca2+ spiking, while trans-2.1 showed no inhibitory effects. The suppression through the cis-isomer could 
be abolished by blue light illumination and trans-accumulation, demonstrating the reversibility of 2.1 
action. 
However, the complete spectrum of ANP action and function throughout the body so far remains elusive, 
which can easily be recognized by the contradictory results about ANP induced stimulation167–169 or 
suppression of beta cell function170,171. Furthermore, the direct effect of ANP on heart rate and action 
potential is also being controversially discussed154,172,173. This shows the need for a tool to precisely control 
and dissect the actions of ANP in health and disease, and TOP271 2.1 is the first PCL to successfully 
facilitate optical control of NPR-A signaling and subsequent physiological actions. Moreover, it provides a 
valuable blue print for the next generation of ANP based photopharmacophores and by being available on 
gram scale through amenable photoswitch and peptide synthesis, this compound has the future to become 
a widely used photopharmocological tool. A remaining drawback for in vivo applications are the 
photoswitching wavelengths in the UV region, but this disadvantage is currently being addressed through 
the design of red-shifted AMPP 1.22 photoswitch derivatives. 
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1.6. HRMS-ESI of peptides TOP263-TOP271 
Peptid calc. mono isotopic mass found mono  
isotopic mass 
Dm/m (ppm) 
ANP [M+4H]4+ = 3084.4804 3084.4858 -1.75 
TOP263 [M+4H+H2O+3MeCN]4+ = 3273.5980 3273.5979 0.02 
TOP264 [M+5H-CH4N3]5+ = 3148.4786 3148.4780 1.87 
TOP265 [M+4H+Na]5+ = 3190.5397 3190.5281 3.68 
TOP266 [M+2H+2NH4+Na]5+ = 3148.5192 3148.5225 -1.08 
TOP267 [M+5H-NH]5+ = 3079.4411 3079.4391 0.70 
TOP268 [M+5H-NH]5+ = 3093.4447 3093.4495 0.97 
TOP269 [M+4H]4+ = 2918.3840 2918.3774 -2.29 
TOP270 [M+5H-H2O]5+ = 2948.3868 2948.3840 2.13 
TOP271 [M+5H-H2O]5+ = 3003.4300 3003.4323 2.25 
  
2.5 EXPERIMENTAL 
This chapter lists experimental details and spectroscopic and spectrometric data of the AzoANP peptides 
TOP263-270, TOP271 2.1, N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3. Details on peptide synthesis, 
chemicals and methods for compounds TOP263-270 and 2.1 can be found in the SUPPORTING INFORMATION 
on the enclosed CD. Details on peptide synthesis for 2.2 and 2.3 can be found in this chapter, chemicals 
and general methods are listed in the APPENDIX.  
2.5.1 SPECTROSCOPIC AND SPECTROMETRIC DATA OF TOP263-271 
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1.5. NMR Spectra of ANP and cis/trans-TOP271 peptides 
1.5.1. ANP 
 
 
1H- (top) and HSQC- (bottom) NMR spectra of ANP peptide. 
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1H,1H-TOCSY (top) and 1H,1H-NOESY (bottom) NMR spectra of ANP peptide. 
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1.5.2. trans-TOP271 
 
 
 
 1H- (top) and HSQC- (bottom) NMR spectra of trans-TOP271 peptide. 
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1H,1H-TOCSY (top) and 1H,1H-NOESY (bottom) NMR spectra of trans-TOP271. cis-TOP271 
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1.5.3. cis-TOP271 
 
 
1H- (top) and HSQC- (bottom) NMR spectra of cis-TOP271 peptide. 
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1H,1H-TOCSY (top) and 1H,1H-NOESY (bottom) NMR spectra of cis-TOP271. 
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Aromatic signals from 1H-NMR spectra of ANP (black) and cis/trans-TOP271 (blue/purple). Full assignment 
of chemical shifts for trans-TOP271 can be found in Supplementary Table 5.   
ANP 
trans-TOP271 
cis-TOP271 
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2.5.2 EXPERIMENTAL DATA OF ADDITIONAL COMPOUNDS N24AZOPHE-ANP 2.2 AND S25AZOPHE-
ANP 2.3 
2.5.2.1 SYNTHESIS OF PEPTIDES N24AZOPHE-ANP $2.4 AND S25AZOPHE-ANP 2.3 
The synthesis of peptides N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3 followed the general peptide 
synthesis protocol stated in the APPENDIX. Table 2.2 depicts the coupling conditions of the different building 
blocks used for the automated peptide synthesis.  
 
Table 2.2: Coupling conditions for synthesis of peptides N24AzoPhe-ANP 2.2 and S25AzoPhe-ANP 2.3. 
Amino acid(s) Coupling method Steps Time (sec) Temperature (°C) Power (W) 
Fmoc-Arg(Pbf)-OH Arg double 
coupling 
2 Step 1: 1500 
Step 2: 300 
Step 1: 25 
Step 2: 75 
Step 1: 0  
Step 2: 23 
Fmoc-Cys(Trt)-OH Single amino acid 
50 °C coupling 
1 480 50 23 
Fmoc-AzoPhe-OH 1.27 Photoswitch 
coupling 
1 1800 75  23 
Fmoc-Ala-OH, Fmoc-Asn(Trt)-
OH, Fmoc-Glu(t-Bu)-OH, Fmoc-
Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Phe-OH, Fmoc-
Ser(t-Bu)-OH, Fmoc-Tyr(t-Bu)-
OH 
Standard single 
amino acid 
coupling 
1 480 75 23 
 
  
P A R T  I I  -  C H A P T E R  2 :  E X P E R I M E N T A L    P A G E  | 94 
2.5.2.2 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF N24AZOPHE-ANP 2.2 
 
 
Figure 2.4:  HPLC spectrum of N24-AzoPhe-ANP 2.2. Analytical HPLC spectrum of 2.2 with a water/acetonitrile 
gradient 95:5 ⇾ 20:80 in 40 min. Rt,cis = 14.6 min, Rt,trans = 16.0 min.  
 
 
Figure 2.5:  HRMS spectrum of N24-AzoPhe-ANP 2.2. HRMS (+ESI) m/z: calc. for C139H213O38N45S2Na3+ [M-
NH+Na+4H]3+: 1073.8476; found: 1073.8490. Calc. for C139H214O38N45S2Na
4+
 [M-NH+Na+3H]4+: 805.6357; 
found: 805.6394. ∆m = -0.45 ppm. Calc. for C139H215O38N45S2Na
5+ [M-NH+Na+4H]5+: 644.7114; found: 644.7130. 
∆m = 0.93 ppm.   
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2.5.2.3 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF S25AZOPHE-ANP 2.3 
 
 
Figure 2.6:  HPLC spectrum of S25AzoPhe-ANP 2.3. Analytical HPLC spectrum of 2.3 with a water/acetonitrile 
gradient 95:5 ⇾ 20:80 in 40 min. Rt,cis = 14.6 min, Rt,trans = 15.9 min. 
 
 
Figure 2.7:  HRMS spectrum of S25AzoPhe-ANP 2.3. HRMS ESI from 2.3. HRMS (+ESI) m/z: calc. for 
C140H216O38N47S2K3
3+ [M+3H+3K]3+: 1115.1595; found: 1115.1806. Calc. for C140H218O38N47S2
4+
 [M+5H]4+: 
646.5120; found: 646.5130. ∆m = 1.55 ppm.    
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3 OPTICAL CONTROL OF INSULIN SECRETION USING AN INCRETIN SWITCH 
(LIRAZO) 
 
This work was published in Angew. Chem. Int. Ed. Engl. 54, 15565-15569 (2015). 
 
There are many diseases afflicting the human population and diabetes belongs to the severer and rapidly 
growing ones. In 2015 9% (415 million) of the adult population was affected by diabetes, causing 5 million 
victims every year (or one death every six seconds). The International Diabetes Foundation (IDF) predicts 
that the number of adult people with diabetes will rise to 10% (642 million) by 2040174. Moreover, every 
seventh new born child is affected by gestational diabetes and the numbers of children and young adults 
with diabetes are climbing. Most countries already spend 5-20% of their health expenditure on the 
treatment of diabetes and related diseases, which sums up to a global spending of around 650 billion USD 
in 2015, and is predicted to raise to nearly 800 billion USD by 2040. These numbers fiercely demonstrate 
the need for action against this global emergency. 
But what is diabetes, and what are the causes? There are three main types of diabetes: type 1 (T1D), type 
2 (T2D) and gestational diabetes. The less common variants comprise monogenic diabetes, which is due 
to genetic mutations, and secondary diabetes, which is triggered by complications with other diseases174. 
In T1D an auto-immune reaction leads to destruction of the insulin producing beta cells of the pancreas, 
which leaves the body completely without the hormone in charge of cellular glucose uptake and reduction 
of blood glucose levels. People with T1D need insulin administered every day. Gestational diabetes can 
affect pregnant women and elevated blood glucose levels during pregnancy can cause risks during child 
birth and trigger high blood pressure and foetal macrosomia. The most common form is T2D, and the 
following CHAPTERS 3 and 4 will focus on this type. T2D, often also referred to as type 2 diabetes mellitus, 
can be described as tandem between impaired cellular glucose uptake, i.e. insulin resistance, and deficient 
amounts of insulin produced by the body175–177. The pancreatic beta cells attempt to retain normoglycemia 
(normal blood glucose levels) and compensate the resistance by secreting more insulin, but this leads to 
enhanced insulin resistance in cells. In the end, the constantly raised blood glucose levels lead to a 
progressive death of the beta cell mass and leave the body without insulin at the final stage of T2D. The 
resulting complications are diverse and include heart, vascular, nerve and renal diseases178. Although the 
exact causes for the insulin resistance remain enigmatic, there are several risk factors related to T2D, with 
the most prominent being excess body weight, physical inactivity and poor nutrition174. 
If T2D is diagnosed in an early stage, the reduction of body weight through sport and a healthy liftestyle 
and diet, together with a life-long medication can help to delay severe effects and the need for the 
administration of insulin as in T1D. The key here is to maintain normoglycemia to protect the beta cell 
mass and thus keep up the endogenous insulin production. There are several drugs used for the treatment 
of T2D addressing various targets, with the oldest and most prevailing ones being metformin (3.1)179 (e.i. 
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Glucophageâ) and sulfonylureas180–182 (e.i. Glimeperideâ (3.2)) (Figure 3.1). The biguanide metformin 3.1 
acts through decreasing the hepatitc glucose production (gluconeogenesis) in T2D patients, which can be 
three times as high as normal183, and by improving cellular insulin sensitivity184. Although this drug is the 
most widely prescribed medicament for T2D treatment, the mechanisms of action are not completely 
understood. Sulfonylureas generally boost insulin secretion by acting via the sulfonylurea receptors (SUR-
1) in pancreatic beta cells. They block of KATP channels which leads to depolarization of the cell, Ca
2+ 
influx and insulin excretion185.  
 
Figure 3.1:  Different drugs for the treatment of T2D. Shown are the biguanide metformin 3.1, the sulfonylurea 3.2, 
the DPP-IV inhibitor sitagliptin 3.3 and the incretin mimetic liraglutide 3.5. 
Other new treatment methods comprise enzymatic inhibitors of the dipeptidyl peptidase IV (DPP-IV), e.i. 
Sitagliptinâ (3.3), and incretin mimetica such as exenatide (3.4) (Byettaâ) and liraglutide (3.5) (Victozaâ)186. 
While DPP-IV inhibitors block the enzymatic degradation of the endogenous incretin glucagon-like 
peptide 1 (GLP-1), incretin mimetica are long-acting variants thereof. The antihyperglycemic hormone 
GLP-1 is secreted in the intestinal L cells upon food intake and exerts its effects through action on the 
glucagon-like peptide 1 receptor (GLP-1R), thereby slowing gastric emptying, reducing food intake, 
boosting insulin secretion in pancreatic beta cells and suppressing glucagon secretion in pancreatic alpha 
cells187,188. The latter is important for maintaining normoglycemia after food intake, because ongoing 
secretion of glucagon would lead to continuous hepatic gluconeogenesis and high blood glucose levels. 
In this sense glucagon is the counterpart to insulin and both hormones are the main actors for controlling 
cellular energy uptake, metabolism, blood sugar levels and food intake. Upon secretion GLP-1 is rapidly 
cleaved as mentioned by the DPP-IV with a half-live of typically two min187,188. Liraglutide 3.5 as long-
acting incretin mimeticum exerts similar effects as GLP-1189, i.e. it potently augments insulin release in a 
glucose-dependent manner, induces profound weight loss, slows down beta cell failure and has a half-life 
of thirteen hours190,191, which allows the administration of a single daily dose. The feature of incretins to 
only act upon permissive glucose levels reduces the risk of hyperglycemia (critical low blood glucose 
levels), and is a great advantage over insulin-dependent therapy. However, adverse effects have also been 
reported, such as gastrointestinal disturbance and nausea192,193, but also a critical increased risk of 
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pancreatitis194,195. Since incretins are believed to become a mainstay of T2D treatment soon, a deeper 
insight into the mechanism of action and into beta cell physiology is mandatory. 
Thus, we set out to install a photoswitchable unit to liraglutide 3.5 to bestow the GLP-1R with light 
sensitivity. The resulting photoswitchable incretin mimetic dubbed LirAzo 3.6 allowed an isomer-biased 
control over GLP-1R action and is presented in the following article.  
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Supplementary Figure 2: LirAzo photoswitching kinetics. cis-Isomerization 
occurs over the minutes timescale (n = 4).Values represent mean ± S.D. 
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Supplementary Figure 3: GLP-1 bound to the GLP-1R ectodomain (pdb: 3iol)[4] 
served as an additional model for the design of LirAzo. GLP-1 binds to the GLP-
1R ectodomain through interactions of 22G-37G. Moreover, the N-terminus is 
believed to interact with the 7TM domain located in the lipid bilayer. Therefore, 
we propose that replacement of 22G-23Q (highlighted in red) with AMPP will alter 
one or both of the helical interactions, leading to divergent class B GPCR 
signaling through isomer bias. To date, no crystal structure of the full GLP-1R is 
available. However, the homologous glucagon receptor (GCGR) has been 
resolved in atomic detail and used to model GLP-1 interactions depicting binding 
to the 7TM domain.[5] Taken together, a more detailed activation model can only 
be proposed using an x-ray structure of GLP-1R that highlights the specific 
interactions with the 7TM domain.  
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Supplementary Figure 4: CD spectral data of Lira and cis-/trans-LirAzo. a) Far 
UV spectra and b) Near UV spectra of Lira (black), trans-LirAzo (blue) and cis-
LirAzo (purple) at 50 µM and 1500 µM concentrations, respectively. Lira exhibits 
two minima (λ = 205 and 223 nm) and a pronounced rise to a maximum (λ = 188 
nm), typical of α-helix possession. Consistent with this, both cis-/trans-LirAzo 
exhibit minima in the λ = 200-220 nm region. However, whereas trans-LirAzo 
displays a maximum at λ = 180 nm, cis-LirAzo only shows a weak maximum (λ = 
189 nm) after a local minimum (λ = 193 nm), consistent with (partial) helix 
unfolding. Moreover, in the near UV-region, the signal of cis-LirAzo rises to a 
maximum (λ = 326 nm) that can be assigned to the cis-azobenzene moiety in a 
chiral environment. 
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Supplementary Figure 5: Photoswitching of ionic fluxes in beta cells, and GLP-
1R- and glucose-dependency. a) Representative trace showing reversible control 
of GLP-1R signaling and Ca2+ levels (n = 4 recordings) (smoothed trace shown in 
black). b) As for a) but before-after plot showing reversal of cis-LirAzo effects 
following exposure to blue light to induce trans-isomerization (n = 4 recordings). 
c-d) Exendin 9-39 (Ex 9-39) 150 nM abolishes trans-LirAzo-stimulated Ca2+ 
oscillations (n = 9 recordings). e-f) trans-LirAzo 150 nM is unable to properly 
stimulate Ca2+ rises in the presence of low (non-permissive) glucose 
concentration (G3; 3 mM glucose) (G11; 11 mM glucose) (n = 5 recordings). g-h) 
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LirAzo allows photoswitching of Ca2+ in immortalized MIN6 beta cells subjected 
to high-throughput assays (n = 4 repeats). Lira/LirAzo were applied at 150 nM in 
the presence of permissive (> 8 mM) glucose concentration. **P<0.01 versus 
LirAzo/Lira. Values represent mean ± S.E.M. 
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Supplementary Figure 6: LirAzo-stimulated Ca2+ rises versus control (i.e. 17 
mM glucose; G17) (KCl, positive control) (n = 8).  
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Supplementary Figure 7: Photoswitching of cAMP generation in CHO-GLP-1R 
cells. Identical to Figure 2d (main text), except showing only cAMP 
concentration-responses for cis- (EC50 = 262.0 nM) and trans-LirAzo (EC50 = 
993.6 nM) (n = 3 repeats) on a contracted x-axis, for clarity. Values represent 
mean ± S.E.M. 
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Supplementary Figure 8: Isomer-dependent engagement of beta cell signaling 
pathways. a) Effects of trans-LirAzo on cytosolic Ca2+ rises in MIN6 beta cells 
are blocked by antagonists of Epac2 (HJC0350 10 µM), L-type Ca2+ channels 
(Nif, nifedipine 50 µM), KATP (Dz, diazoxide 150 µM), IP3R (XestoC, 
Xestospongin C 10 µM) and PKA (H89, 10 µM) (n = 8 repeats). b) As for a), but 
effects of cis-LirAzo are only blocked by inhibitors of Epac2, IP3R and PKA. c) 
As for a) but Lira positive control showing blockade by all inhibitors. Cells were 
retained in permissive (> 8 mM) glucose concentration and Lira/LirAzo applied at 
150 nM. cis- and trans-LirAzo were run in parallel in the same assay, and KCl 
used as a single positive control for a) and b). *P<0.05, **P<0.01 and NS, non-
significant versus LirAzo-alone. Values represent mean ± S.E.M.
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Supplementary Figure 9: LirAzo does not induce cytotoxicity in beta cells. a) 
Normal (150 nM) and high (2000 nM) concentrations of LirAzo do not alter islet 
viability (Triton X-100; positive control) (n = 20-25 islets) (Con, control). b) Lira 
and trans-LirAzo do not induce islet cell apoptosis under normal conditions (i.e. 
11 mM glucose-only), as determined using TUNEL staining (n = 8-9 islets). NS, 
Non-significant versus control (Con). Values represent mean ± S.E.M. 
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3.2.2 SUPPLEMENTARY TABLES 
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Supplementary Table 2: LirAzo photoswitching kinetics 
LirAzo τ1 (sec) τ2 (min) 
cis 51.0±2.4 11.1±4.0 
trans 32.3±1.6 7.5±3.4 
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Supplementary Table 4: EC50 values for cAMP generation in CHO-GLP-1R 
cells. *P<0.03 and $P<0.34 versus cis-LirAzo(Lira; liraglutide) (Student’s t-test). 
95% Confidence intervals are shown in brackets.  
 cis-LirAzo trans-LirAzo Lira 
EC50 (nM) 262.0 
(199.5 to 344.1) 
993.6* 
(681.6 to 1448) 
98.93$ 
(69.14 to 141.5) 
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3.3 ADDITIONAL COMPOUNDS AND DATA 
The published photoswitchable incretin mimetic LirAzo 3.6 was only one of originally three AMPP 1.22 
modified peptides, however the other two peptides LirAzo2 3.7 and LirAzo3 3.8 were necleted due a lack 
of potency and/or isomer-bias. Following the described design principles in PART I, the AMPP photoswitch 
1.22 was incorporated into liraglutide by substituting either two (3.6), three (3.7) or four (3.8) amino acids. 
While 1.22 substitutes Gly22 and Gln23 in Liraglutide 3.5, it substitutes adjacent Ala24 and Ala25 in 3.7 
and 3.8, respectively. This substitution pattern was for one reason selected based on the X-ray crystal 
structure of GLP-1 bound to the extracellular domain of GLP1-R (pdb: 3iol), as well as the NMR structure 
of liraglutide 3.5 in solution (pdb: 4apd) (Figure 3.2). The latter shows 3.5 as flexible helix with a bridged 
part connecting two helix segments. This connecting part is proximal to the cell membrane, as seen from 
the X-ray structure, and thus was selected as suitable substitution site for AMPP 1.22. Switching the 
photoswitch between its linear trans- and crooked cis-form was predicted to shift both helix parts and alter 
receptor binding and membrane permeation of the LirAzo peptides.  
 
Figure 3.2:  Design approach for LirAzo 3.6, LirAzo2 3.7 and LirAzo3 3.8. Left: X-ray crystal structure of GLP-1 (green) 
bound to the extracellular domain of GLP-1R (gray) (pdb: 3iol). Middle: zoom into substitution region, with marked 
amino acids Gly22 and Gln23 (both red), Ala24 (orange) and Ala25 (cyan). Primary sequences of liraglutide 3.5 and 
LirAzo versions 3.6, 3.7 and 3.8. Right: NMR structure of liraglutide 3.5 with marked substituted amino acids Gly22 
and Gln23 (both red), Ala24 (orange) and Ala25 (cyan) (pdb: 4apd). 
The three LirAzo versions 3.6, 3.7 and 3.8 were initially evaluated with regard to their switching kinetics 
to check photoresponsivity and bistability. All three compounds exhibited high photoconversion rates and 
robust switching without photobleaching, as published for 3.6 and shown for 3.7 and 3.8 in Figure 3.3. 
Furthermore, all three peptides were bistable, abolishing the need for constant illumination, thus enabling 
the pre-illumination of the compound and direct application to the tissue.  
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Figure 3.3:  UV/Vis spectra and UV switching kinetics of LirAzo2 3.7 and LirAzo3 3.8. Top left: UV/Vis spectra of 
cis/trans-3.7. Top right: UV switching kinetics of 3.7 measured through the absorption at 330 nm after photoswitching 
with 365 nm UV light (trans ⇾ cis) and 430 nm blue light (cis ⇾ trans). Bottom left: UV/Vis spectra of cis/trans-3.8. 
Bottom right: UV switching kinetics of 3.8 measured through the absorption at 330 nm after photoswitching with 
365 nm UV light (trans ⇾ cis) and 430 nm blue light (cis ⇾ trans). 
To determine the lead candidate, the three LirAzo peptides 3.6, 3.7 and 3.8 were assessed through cAMP 
dose-response assays in CHO cells stably expressing the GLP-1R (CHO-GLP-1R) (Figure 3.4). While 3.7 
and 3.8 showed EC50 values in the micromolar range wihout full receptor activation and any detectable 
isomer-bias, both isomers of LirAzo 3.6 showed only a slightly decreased potency, with isomer-dependent 
activation of the GLP-1R (see publication for details). For this reason, compounds 3.7 and 3.8 were 
dismissed and research was concentrated on LirAzo 3.6. 
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Figure 3.4:  cAMP dose-response curves for peptides LirAzo 3.6, LirAzo2 3.7 and LirAzo3 3.8. Dose-responses were 
obtained in CHO-GLP-1R cells and plotted against a forskolin (FSK) maximum activation. Values represent mean ± 
SEM (n = 3 technical repeats). 
3.4 SUMMARY AND OUTLOOK 
Type 2 diabetes (T2D) is the major type of diabetes and nearly 10% of the global adult population will be 
affected by 2040 (ref. 174). It can best be described as combination of increasing cellular insulin resistance 
and failure of pancreatic beta cells to adequately compensate for the excess need. The final result is 
reduction of the beta cell mass, insufficient endogenous insulin production and the need for administering 
exogenous insulin. Since prevailing risk factors comprise excess body weight and an unhealthy lifestyle, 
T2D in an early stage can be controlled through sport and diet, accompanied by medication with 
metformin, sulfonylureas, dipeptidyl peptidase IV inhibitors or incretin mimetica178. The latter are long-
acting variants of the glucagon-like peptide 1 (GLP-1) and exert the same effects, i.e. boost insulin secretion 
from pancreatic beta cells, inhibit gastric emptying, suppress hunger by acting on the brain and help to 
substantially reduce the body weight. Furthemore, they act only in presence of permissive glucose levels, 
impeding the risk of hyperglycemia after treatment. Based on these striking results and advantages, incretin 
mimetica such as exenatide 3.4 (Byetta®) and liraglutide 3.5 (Victoza®) are believed to become a mainstay 
in the treatment of T2D, despite rising concerns about adverse effects such as gastrointestinal disturbance, 
thyroid cancer and pancreatitis193,195,196. The causalities behind this and in general the mechanism and 
action of T2D drugs remain enigmatic, and research is vital in this field to understand and combat this 
global emergency. 
Incretin mimetica are valuable photopharmocological targets, as tight spatiotemporal control of drug 
activity would not only enable the reduction of adverse effects, but also deliver photochemical tools for 
the dissection and comprehension of beta physiology and control of neuronal signaling. Moreover, it was 
already shown that the pancreas, a class 4 photodruggable target, is amenable to a photopharmacological 
approach involving light38,67. Therefore, liraglutide 3.5, with 97% sequence homology being very similar 
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to native GLP-1, was selected for AMPP 1.22 photoswitch incorporation. The three peptides LirAzo 3.6, 
LirAzo2 3.7 and LirAzo3 3.8 were synthesized in which 1.22 substitutes two, three or four amino acids in 
the central bridging part between the two helix segments of 3.5. All three compounds exhibited good 
photophysical properties, i.e. showed robust switching kinetics for the 350 nm trans ⇾ cis and for the 430 
nm cis ⇾ trans induced isomerization and were bistable in their cis-forms over days. After initial assessment 
of the potency of the LirAzo peptides towards the glucagon-like peptide 1 receptor (GLP-1R) through cAMP 
dose-response curves in CHO-GLP-1R cells, LirAzo 3.6 was selected as lead candidate. This was due to 
its slightly weaker potency than native GLP-1 towards GLP-1R and a nearly four-fold difference between 
its both isomers. The GLP-1R is known to boost insulin secretion through signaling via cAMP and Ca2+, 
and LirAzo 3.6 stimulation of GLP-1R was examined for both pathways in MIN6 cells endogeneously 
expressing the receptor. It was shown that 3.6 differently engages GLP-1R signaling, i.e. the cis-isomer 
provoked higher cAMP synthesis, while solely the trans-isomer engaged Ca2+ influx into beta cells. This 
well-known signal bias of GPCR agonists is being intensively studied, as it is believed to be a possible 
actuator for drug side effects. Furthermore, insulin secretion was biased towards cis-3.6, while beta cell 
survival was prolonged after treatment with trans-3.6. Both the boosting of insulin secretion and protection 
of the beta cell mass are important effects of incretin mimetica and 3.6 can help to understand these 
processes. 
To this end LirAzo 3.6 delivers a blue print not only for next generation of photoswitchable incretin 
mimetics, but for all compounds of this class. It also showcases the complexity and variety of GPCR 
signaling and the need for further remotely controllable compounds to dissect beta cell signaling in health 
and disease. The next step will be the implementation of atomic level molecular dynamic simulations to 
gain insight into cis/trans-3.6-GLP-1R binding interactions and possibly the crystallization of both receptor 
bound isomers. To enable in vivo application the complete analogue of liraglutide 3.5, dubbed gEp-LirAzo 
3.9, which possesses the palmitoyl moiety at Lys25 has been synthesized. The fatty acid side chain 
promotes binding to serum albumin, enhances blood plasma distribution, prolongs the half-live and 
enables crossing of the blood brain barrier, facilitating drug action in the central nervous system. The next 
version gEp-LirAzo 3.9 will open the door to intensive in vivo testing and stressing of this 
photopharmacophore. Furthermore, as in case of the AMPP 1.22 modified AzoANP peptides, a red-shifted 
tetra-ortho chloro variant of this photoswitch will enable the in vivo application without the need of UV 
light. 
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3.5 EXPERIMENTAL 
3.5.1 SPECTROSCOPIC AND SPECTROMETRIC DATA OF LIRAZO 3.6 
 
 
4 
 
1.3. HPLC traces of Lira and LirAzo peptides 
 
Above are analytical HPLC traces of a) Lira and b) LirAzo using a gradient 
MeCN/H2O = 10/90 ! 100/0 within 40 min. 
 
1.4. Photoswitching of LirAzo peptide 
cis-/trans-Isomerization was assessed by UV/Vis spectroscopy following the π-
π*-band (330 nm) and double-exponential fitting of the slopes (Wavemetrics Igor 
v6.2). τ-Values are given in Supplementary Table 1 and represented in 
Supplementary Figure 2. 
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1.5. NMR Spectra of Lira and cis/trans-LirAzo peptides 
1.5.1. Lira 
 
1H- (top) and 13C- (bottom) NMR spectra of Lira peptide. 
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1H,1H-COSY (top) and 1H,1H-NOESY (bottom) NMR spectra of Lira peptide. 
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1.5.2. trans-LirAzo 
 
 
 1H- (top) and 13C- (bottom) NMR spectra of trans-LirAzo peptide. 
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1H,1H-COSY (top) and 1H,1H-NOESY (bottom) NMR spectra of trans-LirAzo.  
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1.5.3. cis-LirAzo 
 
 
1H- (top) and 13C- (bottom) NMR spectra of cis-LirAzo peptide. 
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1H,1H-COSY (top) and 1H,1H-NOESY (bottom) NMR spectra of cis-LirAzo. 
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Selected aromatic signals of 1H-NMR spectra of Lira (black) and trans-(blue)/cis-
(purple)-LirAzo (top). Protons of the substituted glutamine residue (23Q, black) 
are undetectable in cis-/trans-LirAzo. Signals emanating from AMPP (red 
asterisks) and tyrosine (19Y-Hε doublet) become more prominent for the cis-
isomer, demonstrating changes in secondary and tertiary structure of LirAzo 
upon isomerization. Numeration of AMPP atoms (bottom). See also 
Supplementary Table 3. 
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Supplementary Table 3: H and C atom chemical shift data of cis/trans-AMPP in 
trans- and cis-LirAzo peptides. 
             trans-LirAzo           cis-LirAzo 
AMPP H [ppm] C [ppm] H [ppm] C [ppm] 
2 4.46, 4.38 45.2 4.26, 4.19 44.9 
4 7.72 125.5 6.82 122.5 
6 7.64 123.6 6.48 120.7 
7 7.41 131.6 7.22 129.3 
8 7.36 132.8 7.06 129.5 
12 7.79 125.0 6.90 124.4 
14 7.44 134.3 7.12 131.1 
15 7.45 131.9 7.11 131.5 
16 7.70 123.8 6.58 120.9 
17 3.87 44.0 3.57, 3.45 43.8 
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1.6. HRMS spectra of peptides 
1.6.1. Lira 
 
HRMS (ESI): calc. for C151H232N42O474+ (M+4H)4+: 846.6767 (monoisotopic), 
found: 846.6769. 
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1.6.2. LirAzo 
 
HRMS (ESI): calc. for C159H234N42O454+ (M+4H)4+: 863.1831 (monoisotopic), 
found: 863.1833. 
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3.5.2 EXPERIMENTAL DATA OF ADDITIONAL COMPOUNDS LIRAZO2 3.8 AND LIRAZO3 3.6 
3.5.2.1 SYNTHESIS OF PEPTIDES LIRAZO2 3.7 AND LIRAZO3 3.8 
The synthesis of peptides LirAzo2 3.8 and LirAzo3 3.6 followed the general peptide synthesis protocol 
stated in the APPENDIX. Table 3.1 depicts the coupling conditions of the different building blocks used for 
the automated peptide synthesis. As resin for peptides LirAzo2 3.8 and LirAzo3 3.6 a pre-loaded Wang LL 
N-(Fmoc)-Gly resin (NovaBiochem, Darmstadt/Germany) was used. 
 
Table 3.1: Coupling conditions for synthesis of peptides LirAzo2 3.8 and LirAzo3 3.6. 
Amino acid(s) Coupling method Steps Time (s) Temperature (°C) Power (W) 
Fmoc-Arg(Pbf)-OH Arg double coupling 2 Step 1: 1500 
Step 2: 300 
Step 1: 25 
Step 2: 75 
Step 1: 0  
Step 2: 23 
Fmoc-His(Trt)-OH Single amino acid 
50 °C coupling 
1 480 50 23 
Fmoc-AMPP-OH 1.26 Photoswitch 
coupling 
1 1800 75  23 
Fmoc-Ala-OH, Fmoc-
Asp(Trt)-OH, Fmoc-Glu(t-
Bu)-OH, Fmoc-Gly-OH, 
Fmoc-Ile-OH, Fmoc-Leu-
OH, Fmoc-Lys(Boc)-OH, 
Fmoc-Phe-OH, Fmoc-
Ser(t-Bu)-OH, Fmoc-Thr(t-
Bu)-OH, Fmoc-Trp(Boc)-
OH, Fmoc-Tyr(t-Bu)-OH, 
Fmoc-Val-OH 
Standard single 
amino acid coupling 
1 480 75 23 
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3.5.2.2 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF LIRAZO2 3.8 
 
Figure 3.5:  HPLC spectrum of LirAzo2 3.8. Analytical HPLC spectrum of 3.8 with a water/acetonitrile gradient 
95:5 ⇾  0:80 in 40 min. Rt,cis = 16.4 min, Rt,trans = 17.4 min.  
 
Figure 3.6:  HRMS ESI spectrum of LirAzo2 3.8. HRMS (+ESI) m/z: calc. for C153H223O43N403+ [M+3H]3+: 1103.2170; 
found: 1103.2165. Calc. for C153H224O43N40
4+ [M+4H]4+: 827.6646; found: 827.6648. ∆m = -0.45 ppm.   
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3.5.2.3 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF LIRAZO3 3.6 
 
Figure 3.7:  HPLC spectrum of LirAzo3 3.6. Analytical HPLC spectrum of 3.6 with a water/acetonitrile gradient 
95:5 ⇾ 20:80 in 40 min. Rt,cis = 16.0 min, Rt,trans = 16.7 min.  
 
Figure 3.8:  HRMS ESI spectrum of LirAzo3 3.6. HRMS (+ESI) m/z: calc. for C156H229O44N413+ [M+3H]3+: 1126.8960; 
found: 1126.9014. Calc. for C156H230O44N41
4+ [M+4H]4+: 845.4238; found: 845.4266. ∆m = 2.83 ppm. 
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4 CONSTITUTIVE ACTIVATION OF A CLASS B G-PROTEIN COUPLED RECEPTOR 
USING TETHERED PHARMACOLOGY (EXONATIDE) 
 
This work has been submitted to Angewandte Chemie on the 30th November 2016. 
 
The previous two projects discussed in CHAPTER 2 and 3 utilized the PCLs TOP271 2.1 and LirAzo 3.6 for 
controlling receptor activation and signaling. Especially the latter project not only demonstrated 
photocontrol of the GLP-1R through isomer-biased receptor activation, but also differential triggering of 
downstream signaling events, i.e. cAMP accumulation and intracellular Ca2+ fluxes16. Although the PCL 
approach offers many advantages over PTLs, with the most concise being the evasion of genetic 
modification, tethered ligands in general have several benefits in an experimental environment. These 
comprise: i) a diffusion rate which is independent of the ligand-receptor binding and activation, ii) a 
defined ligand/receptor ratio of 1:1, iii) membrane-independent high local concentrations, iv) a negligible 
receptor pre-activation, v) eventual disturbances in vivo are only caused by the bioconjugation reaction 
and vi) fast and easy in vitro screening using a single transfected receptor construct. Given these aspects, 
we envisioned a benzyl guanine (BG) modified photoswitchable tethered incretin mimetic based on LirAzo 
3.6 to be linked to a SNAP-tag fusion protein modified GLP-1R (SNAP-GLP-1R). This PTL BG-LirAzo 4.1 
should allow constitutive activation and optical regulation of GLP-1R cAMP and Ca2+ signaling, and should 
help to detect their regulation in post-endocytotic receptor trafficking. These processes remain elusive for 
GLP-1R and in general for class B GPCRs197, and their understanding them will mark a cornerstone in 
related drug development and future disease treatment.  
The original approach involved the synthesis of the four BG-modified peptides BG-Ex4(1-39) 4.2 
(exONatide), BG-Ex4(9-39) 4.3 (exOFFatide), BG-Lira 4.4 and BG-LirAzo 4.1. While the latter two are 
based on liraglutide 3.5 and the photoswitchable LirAzo 3.6, 4.2 and 4.3 are BG-modified versions of the 
blockbuster incretin mimetic exenatide 3.4 (Ex4(1-39)). Ex4(1-39) 4.2 thereby is a full length 1-39 amino 
acid agonist, while Ex4(9-39) 4.3 is the N-terminal truncated antagonist. All four peptides were designed 
based on the same concept, that is C-terminal substitution with a cysteine followed by disulfide bridge 
linkage with the reactive BG-pyridyldithiol derivative 4.5. Although all four precursor peptides could be 
synthesized, only the agonist exONatide 4.2 and the antagonist exOFFatide 4.3 were successfully linked 
to the BG-compound. For this reason, and because 4.3 showed a lack in potency, only exONatide 4.2 was 
successfully used for the constitutive activation of SNAP-GLP-1R signaling.  
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Constitutive activation and reversible trafficking of a class B G 
protein-coupled receptor using tethered pharmacology  
Tom Podewin,[a] Johannes Broichhagen,[a,d] Nicholas H. F. Fine,[b] Daniela Nasteska,[b] Philipp Leippe,[a] 
Manuel Gailer,[a] Teresa  Buenaventura,[c] Nisha Kanda,[c] Sarah Janik,[a] Alejandra Tomas,[c] Dirk 
Trauner,[a]* Anja Hoffmann-Röder[a]* and David J. Hodson[b]* 
Abstract: Understanding the activation and trafficking of G protein-
coupled receptors (GPCRs) using conditional approaches is 
paramount to developing new disease strategies. Here, we describe 
the design, synthesis and testing of ExONatide, a benzylguanine-
linked agonist of the glucagon-like peptide-1 receptor (GLP-1R), a 
class B GPCR required for proper maintenance of glucose levels in 
humans. ExONatide covalently binds to cells expressing the SNAP-
tagged GLP-1R, leading to long-lasting cAMP generation, Ca2+ rises 
and intracellular trafficking. These effects can be readily switched 
OFF following cleavage of the introduced disulfide bridge using a 
cell-permeable reducing agent. Thus, ExONatide allows SNAP-tag-
directed constitutive activation and trafficking of a class B GPCR in a 
reversible manner. This or similar compounds may be useful for 
understanding GLP-1R signaling both in vitro and in vivo, with broad 
applicability to other transmembrane proteins including GPCRs.  
Selectively targeting and activating G protein-coupled 
receptors (GPCRs) is important for understanding their 
function/signaling. Self-labeling proteins such as SNAP-tag are 
ideal for these purposes, since they can be expressed 
conditionally both in vitro[1] and in vivo,[2] and covalently bind 
molecules possessing a benzylguanine (BG) bioconjugation 
handle. Moreover, SNAP-tags can be fused onto a variety of 
proteins including GPCRs using recombinant engineering,[3] and 
CRISPR/Cas9 genome editing approaches have opened up the 
possibility to do the same in vivo in rodents.[4] The recently 
developed bio-orthogonal (iBOLT) and photoswitchable 
orthogonal remotely-tethered (PORTL) methods address 
‘tethered pharmacology’, and form the basis of targeting 
receptors orthogonally.[5]  
The glucagon-like peptide-1 receptor (GLP-1R) is an 
excellent candidate for such approaches. Following ligand 
binding, this class B G protein-coupled receptor (GPCR) 
primarily activates adenylyl cyclase through Gs, leading to 3'-5'-
cyclic adenosine monophosphate (cAMP) accumulation[6] and 
intracellular Ca2+ fluxes.[7] These signaling processes are 
terminated by post-endocytotic receptor trafficking, where the 
GLP-1R is internalized into endosomes and lysosomes, before 
sorting and recycling to the membrane.[8] However, recent 
reports suggest that GPCR signaling continues even following 
receptor internalization into endosomes via cytosolic cAMP 
generation.[9]  
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Figure 1. Logic and synthesis of ExONatide. a) After covalent labeling of a SNAP-tag with 
ExONatide, the GLP-1R can be activated, leading to Ca2+ and cAMP rises together with 
internalization and trafficking, which can readily be terminated by reductive cleavage using E-
mercaptoethanol (BME). b) Commencing with activated disulfide BG-PEG4-SSpy obtained by 
peptide coupling, a cysteine-containing peptide S39C-Ex4 obtained by solid-phase peptide 
synthesis (SPPS) can be installed by means of disulfide exchange. 
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Figure 3. ExONatide leads to long-lasting Ca2+ and cAMP signaling. a) ExONatide induces large 
Ca2+ rises in MIN6B1-SNAP-GLP-1R beta cells similarly to Ex4(1-39), but this is only washed out 
following application of E-mercaptoethanol (BME) (n = 5-9 recordings). b) As for a), but FRET 
assays for intracellular cAMP synthesis (n = 40-71 cells from 3 experiments). c) As for a) but box 
and whiskers plot showing 5-95 percentile and median for insulin secretion (n = 8 wells) (Ex4(1-39)-
alone was used as a positive control). In all cases, BME-alone did not affect Ca2+ or cAMP levels 
vs. control. **P<0.01 and NS, non-significant; one-way ANOVA (with Bonferroni’s or Tukey’s 
posthoc test) or Kruskal-Wallis test (with Dunn’s multiple comparison test). Values are the mean ± 
SEM unless otherwise stated. 
 
How internalization and subsequent trafficking influence 
class B GPCR function is poorly understood.[10] Deciphering the 
mechanisms involved may be important for drug development 
and disease treatment, particularly regarding the GLP-1R, a 
blockbuster type 2 diabetes target,[11] which displays pleiotropic 
effects (e.g. on the brain, heart and immune system).[11-12] Key to 
this is the development of tools that allow constitutive activation 
and reversible trafficking of the GLP-1R in a highly conditional 
manner. 
Herein, we describe the development and testing of 
ExONatide, a benzylguanine-linked incretin-mimetic based upon 
Exenatide (Byetta®) that constitutively switches ‘ON’ the GLP-
1R (Fig 1a). As shown by X-ray crystallography, peptides such 
as Liraglutide (Victoza®) and Exendin-4 (Ex4(1-39)) bind to the 
GLP-1R extracellular domain with their C-terminus solvent 
exposed.[13] We therefore set out to derivatize Ex4(1-39) by 
mutating and synthesizing the S39C-Ex4 variant by means of 
solid-phase peptide synthesis (SPPS) to install a free cysteine 
bioconjugation handle as the C-terminal amino acid. Linking BG-
NH2 to a PEG4 spacer containing a pyridyl activated disulfide 
from commercially available substrates, ExONatide was 
obtained with high purity and efficiency on the milligram scale 
(see SI for details on synthesis, including RP-HPLC trace and 
HRMS for ExONatide) (Fig. 1b).  
As reported, Ex4(1-39) was able to 
increase intracellular cAMP concentrations 
with an EC50 = 39.9 r 11.5 pM, as assessed 
using LANCE TR-FRET-based assays in 
transiently transfected SNAP-GLP-1R AD293 
cells (Fig. 2a). By contrast, cAMP 
concentration-responses to ExONatide were 
slightly right-shifted (EC50 = 10.0 r 3.1 nM) 
(Fig. 2a). Suggesting that single amino acid 
substitutions can affect potency, the EC50 
values for S39C-Ex4 and ExONatide were 
almost identical (EC50 = 4.9 r 0.8 nM) (Fig. 
2a). Nonetheless, maximal cAMP responses 
were almost 100% (vs. 10 PM FSK) for all 
compounds tested, implying full agonism (Fig. 
2a).   
SNAP-tag binding was determined by 
pre-incubating SNAP-GLP-1R transfected 
AD293 cells with ExONatide for 30 min 
before washing the cells and adding TMR-
Star (λEx = 554 nm; λEm = 580 nm), a fast 
SNAP-labeling fluorophore. Increasing 
concentrations of ExONatide exponentially 
reduced TMR-Star intensity with a half-
maximal binding concentration (BC50,30min = 
0.30 r 0.03 µM) suggestive of near-
quantitative SNAP-tag labeling (Fig. 2b) (Fig. 
S1). 
 We next sought to investigate whether 
ExONatide would allow constitutive 
activation of GLP-1R signaling in a 
physiologically more relevant system. This 
was done by following GLP-1-induced Ca2+ 
fluxes using confocal microscopy. Both 
Ex4(1-39) and ExONatide induced large 
cytosolic Ca2+ rises in Fluo8-loaded MIN6 beta cells stably 
expressing SNAP-GLP-1R (MIN6B1-SNAP-GLP-1R) (Fig. 3a). 
While resting baseline Ca2+ levels could be completely restored 
following a washout period for Ex4(1-39), this was not the case 
for ExONatide (P<0.01 vs. Ex4(1-39)). However, addition of 
reducing agent allowed ExONatide effects to be subsequently 
reversed by washout (Fig. 3a) (non-significant vs. Ex4(1-39)). E-
Mercaptoethanol (BME) was used for reductive cleavage, since 
it is cell permeable and the GLP-1R undergoes rapid 
internalization following activation.[14] Similar results were 
observed in MIN6 using the FRET-based cAMP biosensor 
Epac2-camps,[15] providing evidence for reversible signaling 
through the two main GLP-1R activation pathways (Fig. 3b). 
While MIN6 endogenously express GLP-1R that may give rise to 
background adenylyl cyclase activity, this did not appear to be a 
major issue here, since cAMP responses to ExONatide were 
reduced to almost control levels by BME. Moreover, an effect of 
reducing agent per se is unlikely, as Ca2+ and FRET responses 
to Ex4(1-39) remained normal in the presence of BME (Fig. 3a 
and b). In line with the Ca2+ and cAMP data, insulin secretory 
responses to ExONatide could only be washed out following 
reductive cleavage (Fig. 3c).   
In response to binding, the GLP-1R undergoes 
Figure 2. ExONatide signaling and binding. a) ExONatide, S39C-Ex4 and Ex4(1-39) all induce 
sigmoidal cAMP dose-response curves in AD293 cells transiently-transfected with SNAP-GLP-1R 
cells (n = 3). b) Pre-incubation of the same cells with increasing concentrations of ExONatide 
exponentially decreases TMR-Star binding/fluorescence (n = 60-120 cells from 4 experiments). c) 
As for b), but representative images of cells pre-incubated with and without a high concentration (1 
PM) of ExONatide (scale bar = 33 µm). Values are the mean ± SEM. 
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internalization before organellar (endosomal/lysosomal) sorting, 
ligand removal and either recycling back to the membrane or 
degradation.[9b, 10] To examine the effects of constitutive 
activation on trafficking, MIN6B1-SNAP-GLP-1R cells were 
treated with either Ex4(1-39) or ExONatide before 
immunohistochemistry for GLP-1R localization using a 
monoclonal antibody against the extracellular domain. Both 
Ex4(1-39) and ExONatide induced internalization, as shown by 
a decrease in cell surface GLP-1R expression and an increase 
in punctate intracellular staining (Fig. 4a-d). However, this was 
only reversed by the specific antagonist Ex4(9-39) for the native 
agonist, with no significant membrane recycling detected for  
ExONatide (Fig. 4a-d).[16] Supporting a role for SNAP-tag-
binding in irreversible internalization, almost complete recycling 
of the GLP-1R to the plasmamembrane was seen following 
addition of both BME and Ex4(9-39)  (Fig. 4b and d). As for Ca2+ 
and cAMP signaling, BME-alone did not alter intracellular 
trafficking (Fig. S2).  
 In the present study, we describe an incretin-mimetic 
termed ExONatide that allows constitutive activation and 
internalization of the GLP-1R, a class B GPCR, when N-
terminally fused to a SNAP-tag. Constitutive activation of class B 
GPCRs has been described previously by means of cloning 
activating peptides onto the N-termini[17] and by co-expression of 
membrane-anchored peptides for probing ion channel or GPCR 
function.[18] However, using a SNAP-tagged receptor in 
conjunction with a BG-linked ligand bears several advantages: i) 
the ligand/receptor ratio is defined as 1:1 in terms of binding and 
potency; ii) local concentration can be considered high[19] and 
does not rely on membrane fluctuations; iii) pre-activation during 
expression and culture is absent; iv) disturbances in vitro and in 
vivo are limited by sole SNAP-tag fusion, i.e. it is highly 
conditional; and v) it is bidirectional and can be switched ‘ON’ 
and ‘OFF’ by virtue of the incorporated cleavage site.  
Compared to native Ex4(1-39), the potency of ExONatide 
for cAMP generation was almost 250-fold lower, but still lying in 
the low nanomolar range. The reasons for this are unknown, but 
may reflect the single amino acid substitution rather than the 
presence of the PEG linker, since a similar right-shift of the 
concentration-response was detected for the S39C variant of 
Ex4(1-39). Indeed, single amino acid mutations on the 
extracellular face of the GLP-1R were reported to have a large 
effect on affinity and signaling bias,[20] and may similary underlie 
diversity in peptide hormone binding. Importantly, the ligand 
concentration required for orthosteric activation was 10-fold less 
than that required for full SNAP-tag labeling, meaning that 
ExONatide bound to to SNAP-GLP-1R fusion is always active. 
Suggesting that activation of the GLP-1R may occur in a 
cooperative manner, the Hill coefficient was 1.90 ± 0.50 and only 
minimal cAMP generation was observed at 10 nM ExONatide, 
despite ~50% SNAP-tag occupancy. Notably, ExONatide 
induced long-lasting GLP-1R re-distribution to the intracellular 
compartment that could only be reversed following addition of 
cell permeable reducing agent. Although SNAP-labeled 
fluorophores with cell surface-restricted disulfide cleavage sites 
have been reported,[21] they still rely on receptor activation by 
native ligand. By contrast, ExONatide provides a 
physiologicallyrelevant tool for probing how class B GPCRs such 
as the GLP-1R signal within organelles (e.g. endosomes), as 
well as how alterations in kinetics may influence second 
messenger recruitment (i.e. signal bias), all based upon 
intracellular manipulation. Moreover, it is becoming increasingly 
apparent that the GLP-1R has broad-ranging physiological 
functions. While conditional knockout mouse models exist,[22] 
methods for constitutively activating the receptor are lacking. In 
combination with SNAP-GLP-1R animals, ExONatide may 
provide a powerful platform for dissecting out the role of GLP-1R 
signaling in a cell–specific manner in vivo.  
In summary, ExONatide provides a template for the 
design and production of agonists, antagonists and modulators 
that allow constitutive yet reversible activation of cell surface 
receptor proteins, such as GPCRs, bearing a fused SNAP-tag. 
ExONatide and its congeners thus promise to open up new 
avenues of exploration for extracellular activation, including its 
kinetics and intracellular signaling.  
Experimental Section  
Experimental details including solid-phase peptide synthesis, 
spectroscopic and spectrometric characterization and biological 
Figure 4. Constitutive trafficking by ExONatide in MIN6B1-SNAP-GLP-1R 
beta cells. a) Representative images showing that application of the agonist 
Ex4(1-39) at high glucose concentration (11 mM; G11) causes GLP-1R 
internalization, which can be reversed with the antagonist Ex4(9-39) (scale 
bar = 10 µm). b) As for a), but following application of ExONatide. Note that 
GLP-1R internalization can only be reversed by Ex4(9-39) following 
application of BME. c) Surface GLP-1R expression is significantly reduced 
following application of Ex4(1-39), and this is reversed by application of 
Ex4(9-39). d) Surface GLP-1R expression is significantly reduced following 
application of ExONatide, but this is not reversed by application of Ex4(9-39). 
e) As for d), but showing plasmamembrane recycling of GLP-1R following 
treatment with BME. **P<0.01 and NS, non-significant versus G3 (one-way 
ANOVA with Tukey’s posthoc test). In c) and d), samples were run in parallel, 
hence the same control value (n = 3-7 experiments). Values are the mean ± 
SEM. 
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experiments can be found in the Supporting Information. ExONatide is 
available from the Trauner, Hoffmann-Röder and Hodson labs for 
academic use free of charge.  
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4.2 SUPPLEMENTARY FIGURES 
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5 Supporting Figures and Tables 
  
Supporting Figure 1: Logarithmic plot of concentration-dependent ExONatide binding to 
AD293-SNAP-GLP-1R cells. 
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Supporting Figure 2: Control of BME influence on trafficking in MIN6B1-SNAP-GLP-1R 
cells. a) Representative images showing that application of BME to native agonist Ex4(1-39) 
stimulated cells has no influence on trafficking (scale bar = 10 µm). b) Plotted data from a), 
showing that there is no significant difference in BME- and non-BME-treated cells. NS, non-
significant; Student’s t-test. Values are the mean ± SEM unless otherwise stated. 
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4.4 SUMMARY AND OUTLOOK 
The incretin mimetic exenatide 3.4 (Byetta®) is a GLP-1R agonist and a blockbuster drug for the treatment 
of T2D. Like the native agonist GLP-1, it i) increases insulin secretion in a glucose-dependent manner, ii) 
decreases glucagon secretion and iii) suppresses hunger, i.e. reduces food intake201. The signaling of GLP-
1R that leads to the boosting of insulin secretion has been intensively studied, but signal termination and 
receptor trafficking remain obscure202,203. The established paradigm for GPCR endocyctic trafficking 
describes a rapid receptor desensitization after the ligand-bound receptors have signaled via heterotrimeric 
G-proteins204. This desensitization is mediated by GPCR kinases (GRKs), which selectively phosphorylate 
activated ligand-bound receptors. The phosphorylation triggers the recruitment of  b-arrestin, which 
prevents G-protein interaction with the receptor thus terminating G-protein mediated signaling, and 
secondly it can bind the coat structure of clathrin coated pits, thus initiating the endocytosis of the b-
arrestin-bound receptors. Subsequent post-endocytic fates after receptor internalization comprise the i) 
recycling of the receptor back to the plasma membrane, ii) lysosomal degradation or iii) a resting state in 
the endosomes204. The GLP-1R was shown to be rapidly internalized and recycled upon agonist 
stimulation, which contributes to receptor resensitization. Studies showed that prolonged treatment of GLP-
1R with the agonists GLP-1, exenatide 3.4 and liraglutide 3.5 leads to a decline of the internalization 
maximum, which was suggested to correlate with the loss of a small pool of receptors due to degradation203. 
This can be interpreted as a receptor downregulation in a self-defense mode to prevent overstimulation 
through chronical treatment. This is an important finding, particulary in respect of the life-long treatment 
of T2D with incretin mimetics. Studies also showed that GLP-1Rs cycle for a prolonged period and exhibit 
prolonged cAMP signaling, which was linked to continuous signaling of internalized GPCRs205,206. In 
contrast, a recent study utilized new time-resolved fluorescence resonance energy transfer (TR-FRET) 
techniques to monitor real-time internalization of GLP-1R in HEK293t and connected the prolonged cAMP 
signaling to continuous cycling and resensitziation of GLP1-Rs after agonist stimulation203. This controvers 
discussion shows the need for research tools to dissect the trafficking and post-endocytic fate of GLP-1Rs. 
With exONatide 4.2 we hope to deliver such an instrument, extending the tethered ligand toolbox to the 
GLP-1R by applying the powerful SNAP-tag bioconjugation technology. 4.2 enables unprecedented 
activation of GLP-1R signaling and trafficking, and the constitutional receptor activation allows the 
monitoring of internalization and recycling of the continuously bound ligand-receptor complex. Thereby 
first trafficking studies showed that the covalently bound ligand prevents receptor recycling to the cell 
surface and resensitization, revealing a crucial role for the dissociation of the ligand-receptor complex in 
endosomal sorting. In depth analysis of internalized and constitutional activated GLP-1Rs will give 
information about whether endosomal cAMP signaling205,206, or fast receptor recycling are the reason for 
prolonged cAMP signaling of GLP-1R after stimulation203. Moreover, the fast progression in developing 
mice ubiquitously expressing the SNAP-tag on target proteins, will soon allow to test exONatide 4.2 in 
vivo, facilitating valuable insights into the treatment of T2D with incretin mimetica.  
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4.5 EXPERIMENTAL 
4.5.1 SPECTROSCOPIC AND SPECTROMETRIC DATA OF EXONATIDE 4.2 
 
6 
 
2.2 S39C-Ex4 peptide 
Peptide sequence:  
H2N-HGEG TFTS DLSK QMEE EAVR LFIE WLKN GGPS SGAP PPC-CONH2  
 
The peptide S39C-Ex4 was synthesized according to the generalized peptide synthesis protocol 
in chapter 1.2.  
 
 
 
Analytical HPLC spectrum of peptide S39C-Ex4 with a water/acetonitrile (+0.1% TFA) gradient 
90:10 o 20:80 in 40 min. Retention time of the peptide: 20.1 min. 
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HR +ESI-mass spectrum of peptide S39C-Ex4. M(C184H284N50O58S2) = 4201.0078; calc. mass 
for C184H288N50O58S24+ [M+4H]: m/z = 1015.5101, found: m/z = 1051.5122, 'm = 2.19 ppm. 
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2.3 Synthesis of ExONatide 
Peptide sequence:  
H2N-HGEG TFTS DLSK QMEE EAVR LFIE WLKN GGPS SGAP PPC(PEG4_BG)-CONH2  
 
To a solution of 6.35 mg (1.50 Pmol, 1 equiv.) S39C-Ex4 in 595 PL buffer (100 PM Na2PO4, 150 
PM NaCl, 1 mM EDTA and 0.02% NaN3) was added 205 PL (1.8 Pmol, 1.2 equiv.) of a 8.7 mM 
stock solution of BG-PEG4-SSpy in DMSO. The solution was mixed gently, sparged with argon 
and agitated in a thermocylcer at 37 °C for 48 h. The mixture was filtered and directly injected 
on to a semi-preparative HPLC column. Lastly, the purified product was lyophilized from 
H2O/MeCN 60:40 with 0.1% TFA to afford 3.35 mg (693 nmol, 46%) of ExONatide. 
 
 
Analytical HPLC spectrum of peptide ExONatide with water/acetonitrile gradient 90:10o 
20:80 in 40 min. Retention time of the peptide: 20.2 min. 
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HR +ESI-mass spectrum of peptide ExONatide. M(C211H319N57O66S3) = 4805.2857; calc. mass 
for C211H323N57O66S3 [M+4H]4+: m/z = 1202.3219, found: m/z = 1202.3218, 'm = 0.05 ppm. 
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4.5.2 EXPERIMENTAL DATA OF ADDITIONAL COMPOUNDS S39C-EX4(9-39) 4.7, EXOFFATIDE 4.3, 
G36C-LIRA 4.8 AND G36C-LIRAZO 4.9 
4.5.2.1 SYNTHESIS OF PEPTIDES S39C-EX4(9-39) 4.7, EXOFFATIDE 4.3, G36C-LIRA 4.8 AND G36C-
LIRAZO 4.9 
The synthesis of peptides S39C-Ex4(9-39) 4.7, exOFFatide 4.3, G36C-Lira 4.8 and G36C-LirAzo 4.9 
followed the general peptide synthesis protocol stated in the APPENDIX. Table 3.1 depicts the coupling 
conditions of the different building blocks used for the automated peptide synthesis. As resin for peptides 
S39C-Ex4(9-39) 4.7 and exOFFatide 4.3 a preloaded TentaGel® S-RAM N-(Fmoc)-Ser(t-Bu) resin (Rapp 
Polymere, Tübingen/Germany) was used. As resin for peptides G36C-Lira 4.8 and G36C-LirAzo 4.9 a 
preloaded Wang LL N-(Fmoc)-Gly resin (NovaBiochem, Darmstadt/Germany) was used. 
 
Table 4.1:  Coupling conditions for synthesis of peptides S39C-Ex4(9-39) 4.7, exOFFatide 4.3, G36C-Lira 4.8 and 
G36C-LirAzo 4.9. 
Amino acid(s) Coupling method Steps Time (s) Temperature (°C) Power (W) 
Fmoc-Arg(Pbf)-OH Arg double 
coupling 
2 Step 1: 1500 
Step 2: 300 
Step 1: 25 
Step 2: 75 
Step 1: 0  
Step 2: 23 
Fmoc-His(Trt)-OH Single amino acid 
50 °C coupling 
1 480 50 23 
Fmoc-AMPP-OH 1.26 Photoswitch 
coupling 
1 1800 75  23 
Fmoc-Ala-OH, Fmoc-Asp(t-
Bu)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Glu(t-Bu)-OH, 
Fmoc-Gly-OH, Fmoc-Ile-
OH, Fmoc-Leu-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Met-
OH, Fmoc-Phe-OH, Fmoc-
Ser(t-Bu)-OH, Fmoc-Thr(t-
Bu)-OH, Fmoc-Trp(Boc)-
OH,  
Standard single 
amino acid 
coupling 
1 480 75 23 
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PART III 
STRUCTURAL BIOLOGY OF AZOCHIG 
AND RELATED DERIVATIVES 
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PART III: STRUCTURAL BIOLOGY OF AZOCHIGNOLIN AND RELATED 
DERIVATIVES 
One of the most intriguing secrets of cellular biology and function is how proteins self-assemble into their 
designated native structures. Only correctly folded proteins are capable of evoking correct actions, such 
as biological activity, trafficking and regulation of cellular growth and differentation27,207. The complexity 
and diversity in which various of these self-assembling molecular systems have evolved throughout many 
organisms is fascinating, as it demonstrates natures elegant way in forming precise molecular systems for 
performing specific functions208. The correct molecular assembly not only brings functional groups in close 
structural proximity, for example to form active sites of receptors, but also is the key feature allowing high 
molecular concentrations in cells209. The ability to maintain this solubility was a critical key step in the 
formation of complex organisms, and loss of this ability can lead to molecular aggregation. Protein 
misfolding is the actuator for many age-related and degenerative diseases, including Alzheimer’s and 
Creutzfeldt-Jakob’s disease, as well as T2D and bovine spongiform encephalopathies (BSE)210,211. The fact 
that these amyloidoses or “protein misfolding diseases” are often age related, supports the association of 
protein aggregation with divergent protein behavior in biological systems under conditions, which 
alternate in a faster pace than set by evolution212. While the ageing human organism interferes with 
evolutionary tightly adapted cellular processes, overtaking and challenging the speed of evolutionary 
adaption, humanity itself disrupts the global homeostasis of biochemical processes. This can best be 
examplefied with the recent disturbing uprise of multidrug resistant bacteria, which was and still is driven 
by over- and misuse of antibiotics over the last decades213,214. Science has already made great progress in 
unraveling such biochemical and biological nexuses, helping to expand health and wealth of the global 
population. However, due to the dazzling complexity and multiciplictiy of these biological patterns, a 
lion’s share remains opaque. Most of the conducted studies are focused on understanding biological 
complextity of proteins, as they are the dominating class of molecules involved in literally all reactions 
taking place in living organisms208. Moreover, they are accessible for both theoretical and experimental 
investigations and descriptions, allowing the merging of this two often detached fields215,216. In respect of 
rising computational power and the development of super computers and artificial intelligence, the 
validation of growing sets of theoretical descriptions with experimental data will become an important task 
in the future. 
But how can one study complex protein folding processes in experimental and theoretical detail? A feasible 
way to reduce complexity is to breakdown huge molecular systems into simplified and smaller units, which 
then can be studied separately in detail and at the end the obtained results and relationships can be 
transposed into a bigger picture. Thereby the smallest of these units in proteins is the amino acid sequence 
(primary structure), which is a combination of different lengths and sequences of the 20 proteinogenic 
amino acids. This is the principle protein code, and it contains the complete information on the folding 
process of the protein217. Divergences and mutations in the native sequence can cause inactivity, 
misfolding and altered trafficking. Climbing the ladder in biological complexity there are secondary 
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structures, for example a-helices, b-sheets and b-loops, followed by the three-dimensional protein folding 
or tertiary structure, and the formation of subunits or quaternary protein structures (Figure III.1). Especially 
aberrations in the three-dimensional structure of proteins can lead to misfolding and aggregation, causing 
cellular toxicity and disease. By further increasing the biological complexity one passes the levels of 
macromolecular assemblies, cellular and tissue processes and in the end, comes to trying to understand 
whole organisms and the mystery of life itself208.  
 
Figure III.1:  Breakdown of complex protein structures. The full-scale protein folding is subdivided into four stages: 
primary structure (amino acid sequence), secondary structure (secondary structure motifs, i.e. a-helix or b-sheet), 
tertiary structure (three-dimensional protein fold) and quarternary structure (global native structural protein formation 
with different subunits). Illustrated using the X-ray crystallographic structure of the extracellular domain of GLP-1R 
(pdb: 3iol) for the left, middle left and middle right figure. In the right figure the extracellular domain of GLP-1R (pdb: 
3iol) was merged to the 7TM domain of the β2AR receptor (pdb: 2RH1) to illustrate the arrangement of different 
subunits. 
The pathway of protein folding follows similar steps, gradually increasing complexity through structural 
formation (Figure III.2). After the transcription of the genetic information stored in the DNA and protein 
synthesis on the ribosome, the resulting polypeptide chain can either be folded i) co-translational, ii) folded 
directly in the cyctoplasm or iii) is transported for folding into specific compartments, i.e. mitochondria or 
the endoplasmic reticulum218–220. These folding steps are crucial for correct folding, as important protein 
regions that are buried in the native structure are inevitably solvent exposed, which could promote 
inappropriate reactions with other molecules in the crowded cellular environment27,209. For this reason, 
cells have developed quality control mechanisms that detect incorrectly folded proteins and trigger 
degradation in the ubiquitin-proteasome system221. The following steps of protein folding comprise the 
formation of intermediate states with secondary structures, which facilitate the formation of the native 
protein fold. In these intermediate states the formation of unstructured soluble oligomers, or pre-fibrillar 
aggregates, sparks the organization of larger aggregates, or protofilaments, which exhibit high kinetic 
stability and thus can exist for long periods. Interestingly, biological systems have avoided the use of 
alternating hydrophobic and polar residues that favor b-sheet formation as seen in amyloid fibrilles, to 
prevent the formation of such material222. 
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Figure III.2:  Schematic representation of possible protein structures. After synthesis on the ribosome proteins are 
folded through intermediate states into their native protein structure. Following this way, they reversibly traverse via 
intermediate states and disordered aggregates, or are recognized by cellular quality control as misfolded proteins and 
are subsequently degraded in the ubiquitin-proteasome system. Formation of intermediate states can also lead to the 
formation of amyloid fibrilles, which can only slowly disaggregate and are the actuators of amyloidosis diseases. In 
the end, proteins in their native structure can form higher molecular systems, as exemplified through the molecular 
assembly of the homodimeric NPR-A receptor (pdb: 1yk0) and oligomeric ubiquitin structures (pdb: 5go8). The scheme 
was adapted and modified based on ref. 208. 
For decades, it was assumed that protein folding follows the Levinthal’s paradox, which states that a random 
search for the native protein structure upon the myriads of possible conformations would take an 
astronomical length of time223,224. This falsely led to the conclusion that folding events must occur through 
intermediate structures, like chemical reactions, which guide the folding to the native structure. Today we 
know that folding is a stochastical trial and error process comprising free energy minimization along a 
small explorational pathway216,225. Thereby the inherent movement of the flexible polypeptide chain allows 
even distal functional groups to get close to each other. This enables a small number of amino acids to 
form one or several critical cores, i.e. nucleation sites from which the folding is driven through the 
remaining protein structure215,226. These nucleation sites often form secondary structures, i.e. small a-helical 
or b-sheet and b-turn motifs, as was shown through the study of a series of small proteins (60-100 residues) 
through different spectroscopic techniques227,228. Particularly b-hairpins, the basic elements of anti-parallel 
b-sheets, are believed to be initiators of protein folding and thus small model systems representing this 
secondary structure motif have become a mainstay in the experimental and computational research of 
protein structural folding and unfolding processes199,229–231. Thereby these self-contained model peptide 
systems offer enough detail while exhibiting a reasonable amount of complexity.  
b-turns are the most widely distributed type of turns and belong to the class of reversed turns, which also 
includes the lesser distributed g- and a-turns (and others)232. They usually contain three or four residues in 
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the turn segment, with the most common four-residue b-turns being classified as Types I and II233. b-
Hairpins are b-turns flanked by two b-sheets and the structural dynamics and features have been 
extensively studied over the last decades. They are stabilized by effects of their turn propensities, as well 
as through cross-strand interactions between the two flanking sequences. These cross-strand interactions 
include aromatic-aromatic, aromatic-polar, hydrogen-bonding, hydrophobic and salt-bridge 
interactions26,232,234,235. Regarding these interactions three main models for the mechanism of hairpin folding 
have been developed: the zipper, the hydrophobic collapse and the broken-zipper model236 (Figure III.3). 
The zipper mechanism is a statistical mechanic model based on observations of a single kinetic barrier 
separating folded and unfolded states237–240. It thus describes folding using minimal numbers of parameters: 
loss of conformational entropy, backbone stabilization through hydrogen bonding and formation of a 
stabilizing hydrophobic cluster. The mechanism comprises the following steps: formation of a bend 
structure with generation of intitial hydrogen bonds in the turn region, which then progress towards the 
end of the two strands and, as the name implies, zip up the hairpin. After the establishment of the hydrogen 
bond network in the first step, the second step comprises formation of hydrophobic interactions, stabilizing 
the final hairpin structure241. Although this model seems reasonable and is the most prevailing one, there 
are arguments against turn nucleation through the strong contribution of hydrogen bonds236,242–244. In 
contrast, the hydrophobic collapse model predicts that folding is initiated by an choatic formation of as 
many hydrophobic interactions as possible, which then rearrange to form a hydrophobic core. This core 
then serves as starting site for the formation of hydrogen bonds propagating in all directions245,246. This 
mechanism accounts for the importance of non-polar side chains in the structural formation of the hairpin, 
because they can stabilize hydrogen bonds by wrapping themselves around involved groups and thus 
shield off competing water molecules. However, this model omits the incipient formation of a turn 
nucleation site and hydrogen bonds possess a supreme proportion of structural stabilization. The broken-
zipper model in principle is a combination of the two preceeding models and involves the following steps: 
first the turn sequence initiates interactions between non-polar residues close to the turn region, which 
then invites distal hydrophobic interaction partners to join in and promote the growth of the hydrophobic 
core. An interesting feature of this model is that the unfolding process is not just a reversion of the folding, 
but it requires hydrophobic interactions proximal to the turn region to break first, followed by the rest of 
the hydrophobic core. All three models are still being critically discussed and it is not clear, whether there 
is a general folding mechanism applicable to all possible b-hairpin folding processes, or if every sequence 
folding mechanism is unique. This shows the need for further model systems, new techniques and more 
detailed experimental and theoretical data sets to eventually establish a universel folding mechanism. 
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Figure III.3:  Different models for b-hairpin formation in peptides. Shown are the zipper, hydrophobic collapse and 
broken-zipper models suggested for the folding mechanisms of b-hairpin secondary structure motifs. Figure elements 
are the peptide chain (gray), hydrogen bonds (cyan lines), non-polar residues (green balls) and hydrophobic 
interactions (green lines). The figure was adapted and modified based on ref. 241. 
The monitoring of folding and unfolding events in small peptides can be done experimentally by several 
techniques, including circular dichroism (CD), NMR spectroscopy and differential scanning calorimetry 
(DSC)199,229,241,243,247. A drawback in all these experimental assessments of model systems is the need to 
chemically or mechanically induce the folding transitions, i.e. by regulating pH and salt conditions or with 
denaturing concentrations and reagents, which limits them to the supra microsecond timescale248. To reach 
the domain of nanoseconds additional time-resolved techniques have been developed, such as the 
temperature jump (T-jump) experiment and direct energy transfer through raman processes249. While the 
former uses the energy absorption of a dye by irradiation to induce a temperature rise of up to ten degrees 
and trigger peptide unfolding, the latter relies on energy excitation through raman scattering. However, the 
dyes used for the T-jump experiments tend to interact with the tested molecules causing artefacts, while 
raman excitation is often to slow for the monitoring of the ultra-fast protein folding processes. The bypass 
of these issues is the use of optical-pump probe spectroscopy, which harnesses the speed of light through 
modern laser techniques and allows to explore the limits of time-resolution on the sub-nanosecond 
timescale20. Using this method, the changes in peptide structure are induced using ultra-fast conformational 
switches, as this is the rate limiting step for detection. Azobenzene photoswitches are exquisitely suited for 
this task because, as described in PART I, their reversible photoconversion happens on the timescale of a 
few hundred femtoseconds. Furthermore, with the pump/excitation pulse for the photoswitch being in the 
near UV region, any feasible wavelengths in the visible or infrared spectrum can be used for detection. 
Intriguingly, photoconversion of azobenzene in the UV region is in this case an advantagoues trait, and 
contrasts the general red-shifting efforts for chromophores used in photopharmacology. A prevailing 
method developed to detect b-hairpin folding events comprises the monitoring of changes in the absorption 
wavelengths of the amide-I bands in the IR region through infrared spectroscopy23,250,251. The amide-I bands 
correspond to carbonyl-stretching vibrations and are sensitive to changes in the backbone conformations 
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of peptides, i.e. they can be used to detect shifts in the hydrogen bonding pattern. Hydrogen bonded 
carbonyl groups have lower energy vibrational modes compared to higher energy bands in the solvated 
state, and thus show red-shifted absorption bands in the IR spectrum. Since the detectable changes are 
relatively small, differential IR spectra are used for visualization (Figure III.4). 
A variety of photoswitchable b-hairpin peptide model systems has been developed in the last decade, and 
folding and unfolding events have been extensively studied using the above mentioned experimental and 
theoretical techniques251–253. A prominent example is the Azobenzene-Tryptophan-Zipper peptide 
(AzoTrpZip, ATZ, III.1), consisting of two strands with two aromatic tryptophan amino acids each (the 
zipper motif), which are connected through the AMPP 1.22 photoswitch23,80,253. This peptide adopts 
hairpin-like conformations when the photoswitch is in its cis-state, which are stabilized by cross-strand 
hydrogen bonds and by hydrophobic interactions between the two opposing tryptophan pairs. Unfolding 
into an ensemble of stabilized globular structures occurs upon irradiation and formation of the trans-
peptide. The rigid trans-photoswitch prevents tight interactions between the N- and C-terminal tails as 
observed in the cis-peptide. Detailed mechanistic studies revealed the energetic landscape and structural 
intermediates of the folding and unfolding processes, and describe a high energetic barrier of 48 kJ mol-1 
between the two structures23,254. Moreover, they suggest a hydrophobic collapse model for the folding of 
this b-hairpin and indicate the formation of the hydrophobic core as rate limiting step. However, the 
obtained results can only be applied to this specific peptide and other model systems eventually provide 
different results. This shows the need to expand the existing model peptide systems library to understand 
the dynamics of protein folding and formulate universel mechanisms for future experimental and 
theoretical applications.  
 
Figure III.4:  Different shifts of the peptide amide-I band in continuous wave IR spectra. The absorption bands in the 
continuous wave (cw) IR spectra of peptide backbone carbonyls depend on whether they are hydrogen bonded or 
exposed to the solvent. They are red-shifted in case of hydrogen bonded carbonyls as they display lower energy 
vibrational modes compared to carbonyls interacting with the solvent.  
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A part of this work was published in Chem. Commun. 51, 4001-4004 (2015). 
 
Most of what we know today about the structural formation of b-hairpins is based on studies about the 
GB1 and the Peptide 1 hairpin, with the former being a small 16-residue peptide derived from the C-
terminal end of the B1 domain of protein G from streptococcus bacteria, and the latter being an artificial 
15-residue peptide255–257. The GB1 peptide was the first natural sequence found to fold autonomously in 
aqueous solution, and together with the designed Peptide 1 it has granted deep insight into structural 
relations, diversity of the turn region and details on hairpin folding mechanics. A relatively new model 
system is the artificial decapeptide chignolin 5.1, which is also based on the central part of the GB1 
hairpin258. This peptide was designed during the search for autonomous elements (AEs) in proteins, which 
can be defined as small native protein segments with high foldability stabilized by local interactions with 
neighbouring amino acids. They have their origin in the fragment assembly method for protein structure 
analysis that implies that small AE segments in proteins function as folding nucleus and dictate the folding 
of the rest of the passive regions259,260. Furthermore, it is believed that AEs represent early ancestoral 
proteins, which were much smaller than their present-day relatives, and that these have evolved from their 
early predecessors by assembly of small AE pieces or gradual elongation261,262.  
The primary structure GYDPETGTWG of chignolin 5.1 has emerged from a statistical method, in which 
the eight central amino acids of the GB1 hairpin were selected based on comparison of over 100 non-
homologous proteins for stable b-hairpin analogs258,263. Chignolin 5.1, besides sharing a ∼60% sequence 
homology with the blueprint GB1 hairpin, has also ∼50% sequence homology with turn segments in other 
proteins, e.i. hyaluronate lyase, galactose oxidase and the retinoic acid receptor g1258. The two terminal 
Gly1 and Gly10 residues function as terminal spacers to prevent any accidental charges interfering with 
the folding of the remaining eight residues. The central four amino acids Pro4, Glu5, Thr6 and Gly7 form 
the turn region and thus 5.1 is classified as Type II 4:4 b-hairpin, the same as the GB1 hairpin264,265. 
Initially it was found that the native hairpin structure of 5.1 is stabilized through five hydrogen bonds 
between Asp3 and Glu5, Thr6, Gly7 and Thr8 proximal to the turn region, and through hydrophobic 
interactions between Tyr2 – Pro4 and Tyr2 – Trp9 (Figure 5.1). A large body of work has focused on 
dissecting the folding steps involved in the formation of the hairpin and to determine the driving and 
stabilizing forces. Recent simulations predict a turn-centric hydrophobic collapse model255; this means that 
the intitial step of folding is the formation of the turn sequence through hydrogen bond formation between 
the central amino acids Glu5-Thr6, joined by the rearrangement of Pro4. Subsequent formation of two 
more hydrogen bonds is followed by the rearrangement of Gly7 into the turn region, which brings the C- 
and N-terminal strands closer together. This in turn enforces the hydrophobic interactions between Tyr2 
and Trp9, followed by formation of the remaining hydrogen bonds. It should be noted that Pro4 is an 
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important contributor to the initial hairpin folding process, by forcing Asp3 into a conformation that 
supports the formation of the native hydrogen bond cluster255,266. Furthermore, weak intrastrand Tyr2 – 
Pro4 help to maintain the hairpin structure during the folding process. The proposed mechanism agrees 
with studies on the GB1 hairpin and Peptide 1, which also support a dominant role for turn formation in 
initiating the folding240,256,267. However, the role of hydrophobic interactions remains ambiguous, as the 
initial driving forces after turn formation in all models is the formation of native or supportive non-native 
hydrogen bonds, with loose hydrophobic contacts contributing marginally to the hairpin folding. 
Moreover, if native intrastrand Tyr2 – Pro4 hydrophobic contacts miss to form, non-native Pro4 – Trp9 
interactions can occur that delay folding due to packing frustration for the correct Tyr2 – Trp9 cross-strand 
packing255.  
 
Figure 5.1:  Stabilizing interactions in the chignolin 5.1 b-hairpin. Left: schematic representation of 5.1 residues and 
interactions stabilizing the b-hairpin. The hydrophobic interactions between Tyr2 – Pro4 and Tyr2 – Trp9 are shown 
as red arrows. The hydrogen bonds between Asp3:N – Thr8:O,  Glu5:N – Asp3:Oδ, Gly7:N – Asp3:O, Thr6 – Asp3:Oδ 
and Thr8:N – Asp3:O are presented as blue arrows. Right: three representative rotations of the crystal structure of 
chignolin 5.1 (pdb: 1UAO). 
The remaining questions drive the search for answers in new experimentel model systems that have altered 
turn regions, hydrogen bonding networks and hydrophobic interactions, and allow either the confirmation 
and extension of existing data and mechanisms, or challenge present ideas about protein folding. Peptides 
comprising azobenzene conformational switches as optical responsive turn elements, as for example in 
the ATZ peptide III.1 or cyclic protein disulfide isomerase compounds, made it possible to control folding 
and unfolding events80,96,254,268,269. Moreover, they shifted the focus away from turn nucleation driven 
folding contemplation towards a more general view of hairpin formation, enforced by stabilizing hydrogen 
networks and hydrophobic interactions. Although one can argue that folding events in these unnatural 
systems are not representative for natural proteins, they do facilitate experimental monitoring of folding 
events with high spatio-temporal precision. As chignolin 5.1 represents one of the smallest proteins with 
b-hairpin structure available hitherto, we aimed to transform 5.1 into a photoswitchable model system by 
introducing AMPP 1.22 into the central turn sequence. The resulting AzoChignolin peptides AzoChig1 5.2, 
AzoChig2 5.3 and AzoChig3 5.4 and their folding dynamics are described in the following communication. 
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Photocontrolled chignolin-derived b-hairpin
peptidomimetics†
T. Podewin,a M. S. Rampp,b I. Turkanovic,b K. L. Karaghiosoﬀ,a W. Zinth*b and
A. Hoﬀmann-Ro¨der*a
The synthesis of novel, chignolin-derived peptides comprising the
azobenzene photoswitch [3-(3-aminomethyl)phenylazo]phenylacetic
acid (AMPP) is reported. Reversible photoswitching behavior led to
folding into b-hairpin-like structures, as unequivocally demonstrated by
CD, FT-IR and NMR spectroscopy.
Understanding the mechanisms, by which particular sequences of
amino acids are folded into well-defined three-dimensional protein
structures, is a challenging problem in the field of molecular
biology. The complexity of possible conformational transitions
and diﬀerent timescales of folding prevents accurate predictions
and simulations for larger amino acid ensembles. Moreover, it is
believed that certain key secondary motifs, e.g. b-hairpins and
b-sheets, serve as nucleation sites for protein folding, providing
insight into the early events of secondary structure formation. In
particular b-hairpin-forming peptides have receivedmuch attention
as model systems for both experimental and theoretical studies
of the initial folding steps.1–4 For instance, light-triggered folding
of two amino acids strands into a b-hairpin peptide has been
investigated by means of azobenzene photoswitches,5–10 such as
[3-(3-aminomethyl)phenylazo]phenylacetic acid11–13 (AMPP). Upon
incorporation into the peptide backbone, the latter offers the
possibility to control the hairpin structure by initiating a reversible
folding (cis-form) or unfolding (trans-form) transition.
Herein, we present a peptidomimetic model system for photo-
controlled reversible b-hairpin formation based on chignolin14 and
AMPP. The decapeptide chignolin (GYDPETGTWG) was designed by
Honda et al. on the basis of the central part of the GB1 hairpin14–17
and is the smallest b-hairpin known to be stable in solution. As such
and in combination with ultrafast initiation of structural changes
upon photoswitching, chignolin derivatives are particularly attractive
targets for folding studies of protein nuclei. Therefore, the peptide
AzoChig1 (GYDP-AMPP-GTWG) was designed, in which the two
central amino acids Glu5 and Thr6 of chignolin’s four-residue
turn sequence were substituted by AMPP (Fig. 1). Besides, peptido-
mimetic AzoChig2 (GYDP-AMPP-GT(5FW)G) with a 5-fluoro-L-
tryptophan (5FTrp, 5FW) residue instead of Trp9 was synthesized
to enhance key hydrophobic interactions between aromatic Tyr2 and
Trp9. Fluorinated amino acid residues are known to be tolerated by
a variety of proteins without introducing much steric perturbation
and usually favor protein folding and stability due to their increased
hydrophobicity.18,19 For instance, the hydrophobicity of 5FTrp,
derived from 1-octanol–water partitioning experiments, is signifi-
cantly higher than that of native Trp.20,21 However, systematic
studies towards structure-guiding effects of fluorinated amino acids
have mostly focused on a-helical systems19,22 and only a limited
number of approaches for fluorination of specific b-sheet positions
have been reported, so far.23 Finally, since both peptides AzoChig1
and AzoChig2 showed high solubility only in polar solvents like
MeOH and MeCN, AzoChig3 ((TEG)GYDP-AMPP-GTWG), equipped
Fig. 1 Representative schematic illustration of reversible cis # trans
isomerization of AzoChig peptides at 350 and 430 nm, respectively.
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with an additional, N-terminal triethylene glycol residue, was pre-
pared to furnish a photoswitchable and water-soluble chignolin
derivative. Key aminoacidbuildingblocks for the solid-phase peptide
synthesis (SPPS)ofphotocontrolledchignolin-derivedb-hairpinswere
prepared, as follows (ESI†): Fmoc-protected AMPP derivative was
synthesized in seven steps according to the known strategy of Renner
et al.12 Thus, (9H-fluoren-9-yl)methyl-(3-aminobenzyl)carbamate,
derived fromFmoc-protectionof3-(aminomethyl)aniline,was reacted
with 2-(3-nitrosophenyl)acetic acid under Mills conditions to afford
the AMPP building block in 59% yield.
Fmoc-protection of commercially available 5FTrp yielded the
requisite fluorinated building block, while the Fmoc-TEG derivative
was synthesized in five steps starting from triethylene glycol.24 The
chignolin-derived peptides were assembled in an automated
microwave-assisted CEM Liberty 1 peptide synthesizer on a pre-
loaded Fmoc-Gly-Wang LL resin (Novabiochem).
After Fmoc-deprotection by piperidine in N-methylpyrrolidone
(NMP), the standard amino acid couplings were performed using
HBTU–HOBt and diisopropylethylamine in DMF for activation.
In contrast, incorporation of the non-standard building blocks
required modified coupling procedures and the use of the more
reactive HATU–HOAt–N-methylmorpholine cocktail. Release from
the resin with simultaneous deprotection using TFA–H2O mixtures
(95 : 5) followed by preparative RP-HPLC, finally provided the
targeted chignolin-derived peptidomimetics with yields of 10–33%.
Photomodulation of b-hairpins with azobenzene derivatives
as backbone elements mostly relies on an ultrafast trans# cis
isomerization, which can be induced by light of diﬀerent
wavelengths and involves large changes in geometry and dipole
moments.25,26 For instance, cis-AMPP-TrpZip peptides forming
a b-hairpin-like structure can rapidly unfold within 1 ns by
photoisomerization of AMPP to its trans-isomeric state.12,27,28
In chignolin, the b-hairpin conformation is stabilized by H
bonds of Asp3:N-Thr8:O, Gly7:N-Asp3:Od, Thr8:N-Asp3:O,
Glu5:N-Asp3:Od and Thr6:N-Asp3:Od, as well as by hydrophobic
interactions between Tyr2:Pro4 and Tyr2:Trp9.29 The newly
synthesized AzoChig derivatives should retain most of the
aforementioned stabilizing interactions, and in particular
AzoChig2 comprising the 5FTrp residue should reveal enhanced
hydrophobic interactions between Tyr2 and Trp9 (vide supra).
RP-HPLC analyses and NMR spectroscopy demonstrate the
structural integrity and purity of the assembled AzoChig1–3
Fig. 2 (A) Schematic structure of cis-AzoChig2 with observed NOE cross peaks (gray) between Tyr2, Pro4, AMPP5,6 and Trp9; (B) 19F-NMR spectra of
cis-(black) and trans-AzoChig2 (grey) peptides in MeOH-d4 at 26 1C, c = 2 mM; (C)
1H,1H-ROESY-NMR spectra of AzoChig2 in MeOH-d4 at 26 1C,
c = 2 mM; (D) 1H,1H-ROESY-NMR section from 7.5–6.5 and 5.0–2.4 ppm. Marked NOE cross peaks: Tyr2/H3,H52 Pro4/Ha (red) and AMPP5,6/H82
Gly7/Ha,Ha0 (purple); (E) 1H,1H-ROESY-NMR section from 7.4–6.4 and 7.4–6.5 ppm. Marked NOE cross peaks: Tyr2/H2,H6 2 Trp9/H6 (purple),
AMPP5,6/H72 AMPP5,6/H16 (orange), AMPP5,6/H72 Trp9/H4 (dark green) and AMPP5,6/H162 Trp9/H4 (green); (F) 1H,1H-ROESY-NMR section
from 4.7–1.9 and 7.5–3.5 ppm. Marked NOE cross peaks: Pro4/Ha2 Gly7/Ha,Ha0 (red).
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mimetics (ESI†). To elucidate the three-dimensional solution struc-
tures of cis-/trans-AzoChig1–3, 1H and 13C, as well as correlation
(COSY), hetero nuclear single quantum (HSQC) and hetero nuclear
multiple bond (HMBC) NMR spectra were recorded in 10 mM
MeOH-d4 solutions at 400 and 600 MHz.
30 Unfortunately though,
AzoChig3 aggregates strongly in solution, which leads to heavy
signal broadening and precludes any precise signal assignments.
In contrast, sharp 1HNMR signals, unequivocally assignable were
obtained for cis-/trans-AzoChig1 and 2, enabling their application
to total correlation (TOCSY) and rotating-frame nuclear Over-
hauser enhancement (ROESY) spectroscopy at 400 MHz in
MeOH-d4 (Fig. 2C–F). All samples were kept in the dark for two
days before measurement, yielding trans-configured peptides.
The 1H NMR spectra of AzoChig1 and AzoChig2 peptides show
distinct peak oﬀsets for the aromatic residues Tyr2, AMPP5,6 and
Trp9 (8.0!6.5 ppm) upon cis # trans isomerizations. Moreover,
NOE cross-peaks detected between Tyr2:Trp9, Pro4:Gly7, AMPP5,6:
Gly7 and AMPP5,6:Trp9 in the ROESY spectra of cis-AzoChig1 and
cis-AzoChig2, depict the expected formation of folded structures for
both derivatives (Fig. 2D–F), with NOE signals between aromatic
Tyr2, AMPP5,6 and Trp9 moiety, pinpointing the presence of turns
stabilized by hydrophobic interactions. The 19F NMR spectra of cis-
and trans-AzoChig2 finally reveal distinct downfield shifts of the
fluorine signals (Fig. 2B), indicating significant changes in the
electronic structure and interactions upon isomerization.
To substantiate the presence of unfolded trans-conformations
and their conversions into the desired b-hairpin structures upon
azobenzene trans-to-cis isomerizations, UV/Vis, FT-IR, and CD
spectroscopic measurements were performed. Therefore, 1 mM
stock solutions of AzoChig1–3 peptides in MeOH were prepared
and stored in the dark at room temperature for two days,
furnishing trans-configured peptides. Using these stock solutions,
peptide samples with concentrations of c = 76 mM (AzoChig1),
77 mM (AzoChig2) and 78 mM (AzoChig3) were prepared through
dilution with MeOH to record stationary UV/Vis absorption spectra
before and after illumination at appropriate wavelengths (Fig. 3A).
Irradiation of the trans-peptides at l = 350 nm for 180 s led to
reversible formation of photostationary states comprising in each
case 84% of the cis-conformer. The UV spectra of trans-AzoChig1
and trans-AzoChig3 are very similar and show characteristic maxima
at 322 nm and 291 nm due to the p - p* trans-azobenzene
transition and the absorptions by Trp9 and Tyr2. The latter maxi-
mum is shifted towards 299 nm in the AzoChig2 spectrum as a
result of the presence of the 5FTrp moiety.
Stationary FT-IR spectra of the trans-AzoChig peptides were
recorded using 5 mM solutions in MeOH-d4, which were kept again
in the dark for two days. MeOH–H2O mixtures were spared to avoid
the undesired aggregation of the peptidomimetics. The spectra of
all peptides are similar featuring the characteristic bands of the
azobenzene chromophore and the peptide backbones (amide I and
II bands around 1655 cm!1 and 1450 cm!1, respectively, Fig. 3B).
The peak at 1675 cm!1 originates from traces of TFA used during
preparation of the samples. The difference spectra were recorded
for trans - cis and cis - trans isomerizations (Fig. 3C). Most
prominent in the difference spectra is the dispersive line shape in
the range of the amide I band, which points to a change in the
H-bonding pattern upon isomerization of the azobenzene. In the cis-
isoform there is an excess of strong H bonds, red-shifted relative to
weaker H bonds, which were found preferentially in the trans-form
of the peptides. This feature, similar to the one observed previously
in ATZ,12,27,28 points to a change of the peptide structure with
an open trans-form to a compact cis-form. Latter thereby shows
Fig. 3 (A) UV/Vis spectra of cis-/trans-AzoChig1–3 at 25 1C, c = 76–78 mM; (B) representative FT-IR absorption spectrum of AzoChig1 at 25 1C in MeOH-
d4, c = 5 mM; (C) absorption difference spectra of AzoChig1 induced by irradiations at 350 nm (trans- cis, green curve) and 430 nm (cis- trans, purple
curve) in MeOH-d4, c = 5mM; (D) CD spectra of cis-/trans-AzoChig1–3 at 5 1C inMeOH, c = 76–78 mM; (E) solvent-dependent CD spectra of cis-AzoChig1
(red hatched band) and trans-AzoChig1 (blue hatched band) at 5 1C in MeOH–H2O ratios reaching from 100% MeOH - MeOH–H2O 10/90 with
c = 82–112 mM. The gray crossed band represents overlapping spectra; (F) solvent-dependent CD spectra of cis-AzoChig2 (red hatched band) and trans-
AzoChig2 (blue hatched band) at 5 1C in MeOH–H2O ratios reaching from 100%MeOH-MeOH–H2O 10/90 with c = 84–102 mM. The gray crossed band
represents overlapping spectra.
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additional stronger, presumably interstrand H bonds pointing to a
b-hairpin-like structure.
CD spectra in the 195–250 nm range were determined for
trans-AzoChig1–3 peptides at concentrations of c = 76–78 mM in
MeOH at 5 1C (vide supra). Solvent-dependent CD spectra of
AzoChig1 and AzoChig2 where recorded at concentrations of
c = 82–112 mM in MeOH–H2O mixtures at 5 1C. For the cis-azo
isomers, CD spectra were recorded after irradiation at 350 nm
for 180 s, i.e., at the cis-photostationary state (Fig. 3D). All three
cis-azo peptides feature distinct maxima at 231 nm – assigned
to stacking of Trp9 to Tyr2 – as well as minima at 212 nm and
200 nm, and pronounced positive signals below 195 nm.
Hence, they strongly resemble the spectra of native chignolin
suggesting a folded, hairpin-like structure. The enhanced
hydrophobic interactions between Tyr2 and 5FTrp9 in AzoChig2
become visible by the increase of the CD signal in the 231 nm
range. Temperature-dependent CD spectra of cis-AzoChig1 and cis-
AzoChig2 in the 5–60 1C range (data not shown, see ESI†) reveal a
thermal unfolding process to be working at higher temperatures,
similar to native chignolin. The CD spectra of trans-AzoChig1–3
display small maxima at 231 nm andminima at 213 nmbut deviate
in the 200 nm range. The deep minimum found for AzoChig2 at
200 nm can be tentatively interpreted in terms of a better ordering
of the peptide part due to the increased hydrophobic interaction of
5FTrp9 with Tyr2.
Moreover, solvent-dependent CD measurements were per-
formed using mixtures of MeOH–H2O (Fig. 3E and F, see ESI†),
with ratios from 10–100% MeOH. The MeOH–H2O spectra of
the cis-/trans-AzoChig1 and cis-/trans-AzoChig2 peptidomi-
metics show increasing values for the maximum around
230 nm and deeper minima at 200 nm with increasing water
amounts. Presumably, the hydrophobic turn region of the cis-
peptides becomes more stabilized by hydrophobic interactions
between Tyr2:Trp9 in aqueous surroundings, which leads to the
observed increase in molar ellipticity at 230 nm. Furthermore,
interstrand interactions are stabilized by water-mediated
hydrogen bonding as reflected by the decreased ellipticity
around 200 nm. Finally and at higher water ratios, the observed
CD signals of AzoChig1 and AzoChig2 approximate nicely the
reported molar ellipticity characteristics of the parent peptide
chignolin.14
We have presented a novel class of photoswitchable b-hairpin
model peptides derived from the designer mini protein chignolin
by substitution of two central amino acids from the turn
sequence by the known azobenzene chromophore AMPP. The
resulting AzoChig1–3 peptidomimetics were assembled by SPPS
and carefully characterized at both photoisomeric states using
UV/VIS, IR, CD, and NMR spectroscopy. In the trans-state of
AMPP, the peptides mostly exhibit a disordered structure, while
trans- cis photoisomerization of the azobenzene chromophore
induces folded b-hairpin-like structures.
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5.2 SUPPLEMENTARY FIGURES 
S20 
 
4  UV/Vis, CD and FT-IR spectra of AzoChig1-3 peptides 
4.1 UV/Vis spectra of AzoChig1-3 peptides 
 
 
Figure 17: UV/Vis spectra of cis/trans-AzoChig1-3 peptides in methanol, c = 77 μM AzoChig1, c = 77 μM AzoChig2 and 
c = 78 μM AzoChig3.  
 
4.2 CD spectra of AzoChig1-3 peptides 
 
 
Figure 18: CD spectra of cis/trans-AzoChig1-3 peptides in methanol, c = 77 μM AzoChig1, c = 77 μM AzoChig2 and 
c = 78 μM AzoChig3.  
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Figure 12: Solvent dependent CD spectra of cis-AzoChig1 (dashed lines, red to purple) and trans-AzoChig1 (solid lines, 
green to blue) peptides in methanol/water ratios from 100% methanol to 10:90% methanol/water. The CD spectra were 
measured at 5 °C with concentrations of c = 82-112 μM. 
 
 
Figure 13: Solvent dependent CD spectra of cis-AzoChig2 (dashed lines, red to purple) and trans-AzoChig2 (solid lines, 
green to blue) peptides in methanol/water ratios from 100% methanol to 10:90% methanol/water. The CD spectra were 
measured at 5 °C with concentrations of c = 84-102 μM. 
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Figure 14: Temperature dependent CD spectra of the cis-AzoChig1 peptide in methanol, c = 76 μM. 
 
 
Figure 15: Temperature dependent CD spectra of cis-AzoChig2 peptide in methanol, c = 77 μM.  
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4.3 FT-IR spectra of AzoChig1-3 peptides 
 
 
Figure 16: Top: FT-IR spectrum of AzoChig1 peptide in methanol-d4, c = 5.0 mM; Bottom: IR differential spectra of the cis 
→ trans (purple) and trans → cis (green) isomerization of AzoChig1 peptide in methanol-d4, c = 5.0 mM. 
 
 
Figure 17: Top: FT-IR spectrum of AzoChig2 peptide in methanol-d4, c = 5.0 mM; Bottom: IR differential spectra of the cis 
→ trans (purple) and trans → cis (green) isomerization of AzoChig2 peptide in methanol-d4, c = 5.0 mM. 
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Figure 18: Top: FT-IR spectrum of AzoChig3 peptide in methanol-d4, c = 5.0 mM; Bottom: IR differential spectra of the cis 
→ trans (purple) and trans → cis (green) isomerization of AzoChig3 peptide in methanol-d4, c = 5.0 mM. 
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5.3 ADDITIONAL COMPOUNDS 
5.3.1 AZOCHIGNOLIN-RELATED MUTANTS 
The native chignolin 5.1 b-hairpin structure is stabilized through a hydrogen bonding network and 
hydrophobic interactions between Tyr2, Pro4 and Trp9. Most of these interactions are presumably retained 
in the AzoChignolin peptides, as the photoswitch only subtitutes the central Glu5 and Thr6 amino acids, 
not altering the important hydrogen contributor Asp3. To test the contribution of hydrophobic interactions 
to folding and stabilization of the hairpin, we initially synthesized AzoChig2 5.3 with a more hydrophobic 
5-fluoro-Trp9 residue. Indeed, 5.3 exhibited a higher exciton coupling of Tyr2 – Trp9 in the CD spectrum, 
indicating a stronger hydrophobic stacking of both aromatic residues. This exciton coupling is 
characteristic for cross-strand coupling between Trp – Trp, Tyr – Trp and Tyr – Tyr aromatic pairs and can 
be used to monitor cross-strand interactions and estimate folded hairpin content243,270,271. The Tyr2 – Trp9 
pair in chignolin 5.1 generates a strong negative band at 200 nm and a prominent positive band at 230 
nm, whereby the latter is more particular. While the AzoChig1 5.2 and AzoChig2 5.3 peptides both show 
the band at 230 nm, 5.2 lacks the negative band at 200 nm. This can be explained with the relative 
orientation of the Tyr2 to Trp9 in 5.2, because intensity and exact wavelengths of the exciton coupling 
bands are strongly dependent on the two coupling partners and their relative orientation to each other272. 
As was shown for AzoChig1 5.2 and AzoChig2 5.3, the exciton coupling bands at 230 nm (and 200 nm 
for 5.3) of the Tyr2 – Trp9 pair are reduced upon isomerization of the folded cis- to the unfolded trans-
form and vice versa. Furthermore, in 5.3 this band was more prominent than in 5.2, showing the enhanced 
hydrophobic contact in the fluorinated compound. Although this finding is hard to directly translate into a 
quantitative assertion about hairpin content, it is a good indicator for interstrand interactions and folding. 
 
Figure 5.2:  Predicted influence of substituents on hydrophobic interactions in AzoChignolin peptides. Introduction 
of hydrophobic 5-fluoro-L-trypophan (5FTrp) in 5.3 and Trp2 in 5.5 increase cross-strand hydrophobic interactions and 
stabilize the hairpin. Substitution of Tyr2 with Val2 in 5.6 and Pro4 with Thr4 in 5.7 reduce hydrophobic interactions 
leading to an impaired stabilization of the hairpin. 
To assess the dominant sort of hydrophobic interactions in AzoChig1 5.2, i.e. whether hydrophobic contact 
and/or hydrophobic stacking are the major stabilizing forces, two mutant compounds were synthesized in 
which Tyr2 was replaced by tryptophan and valine (Figure 5.2). It was anticipated that these two peptides 
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Y2W-AzoChig 5.5 and Y2V-AzoChig 5.6 exhibit reinforced hydrophobic interactions, i.e. hydrophobic 
contact and stacking, between Trp2 – Trp9 in 5.5, and solely hydrophobic contact without stacking 
between Val2 – Trp9 in 5.6. The initial assessment via CD spectroscopy showed a weak positive band at 
230 nm and two slight and equal minima at 202 and 214 nm for the exciton coupling between Trp2 – Trp9 
in unfolded trans-5.5 (Figure 5.3). In cis-5.5 the extrema at 214 and 230 nm are amplified, while the 
minimum at 202 nm remains the same. This corresponds to the CD signals in the cis-/trans-AzoChig1 5.2 
peptide, which show small extrema at 216 and 230 nm in the trans-peptide and enhanced signals in the 
cis-form. Although the amplitude of the extrema in both isomers seems significantly stronger in 5.2 than in 
5.5, this does not necessarily indicate reduced hairpin stabilization of the latter. Since the intensity of the 
extrema is dependent on the electronic properties and relative orientation of the exciton coupling partners 
to each other, it rather allows a qualitative judgement over folded hairpin contents for the cis-/trans-isomers 
of 5.5. In contrast, both cis-/trans-Y2V-AzoChig 5.6 peptides exhibit very similar spectra with a strong 
minimum at 200 nm and no maximum at 230 nm, as a result of the missing exciton coupling between 
Val2 – Trp9 (Figure 5.3). Here, the CD spectra resemble random-coiled structures, and the similarity 
between both spectra indicates a diminished hairpin stability and restricted folding events in the cis-/trans-
peptides. This correlates with Tyr2 being the major contributor to hydrophobic interactions and 
consequently substitution with a hydrophobic, but non-aromatic valine residue abolishes the important 
hydrophobic stacking between Tyr2 – Trp9 as well as the minor intrastrand stabilization by Tyr2 – Pro4.  
The folding and unfolding dynamics of the Y2W-AzoChig 5.5 and Y2V-AzoChig 5.6 peptides were 
primarily detected with differential IR spectroscopy (Figure 5.3). This method helps to detect minimal 
differences in the cw IR spectra for peptidic cis-/trans-isomers and has been also applied to the AzoChig1 
5.2 and AzoChig2 5.3 peptides. The IR spectra of 5.5 and 5.6 both show a pronounced peak at 1674 cm-
1 and a broad shoulder at 1655 cm-1, with smaller additional signals at 1456 cm-1 and lower wavelengths, 
corresponding to the amide-II bands. Most prominent in the differential IR spectra of cis-/trans-5.5 and -
5.6 is the dispersive line shape in the region of the amide-I band, with peak shifts from 1659 to 1634 cm-1 
for trans ⇾ cis 5.5 and 1659 to 1631 cm-1 for trans ⇾ cis 5.6. The weaker absorption changes at smaller 
wavenumbers correspond to changes in the amide-II band and of the AMPP 1.22 photoswitch. Similar to 
5.2 the red-shifting of the amide-I band to lower wavenumbers in 5.5 and 5.6 shows a change in the 
hydrogen bonding pattern towards formation of stronger hydrogen bonds in the cis-form, whereas weaker 
hydrogen bonds are present in the trans-peptides. Since these changes occur in a spectral region 
characteristic for b-sheets and b-hairpins1,2, the results for 5.5 and 5.6 indicate increased hairpin contents 
of the cis-peptides. The direct comparison of the differential spectra of 5.5 with 5.6 shows higher signal 
differences between both isomers in the former peptide. This agrees with the expected enhanced 
hydrophobic interactions in 5.5 and supports their role in hairpin stabilization. However, substitution of 
Tyr2 with valine in 5.6 abolishes the intrastrand stabilization between Tyr2 – Pro4, which was identified 
crucial for the correct folding pathway in native chignolin 5.1. To rule out this effect and assess the 
contribution of the Tyr2 – Trp9 interaction to hairpin stabilization, a W9V-AzoChig peptide should be 
synthesized, since this mutant would retain hydrophobic contact between the C- and N-terminal strand, 
but simultaneously abolish the hydrophobic clustering as in 5.1. Meanwhile, time-resolved IR spectra of 
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5.5 and 5.6 will be conducted and will allow to i) monitor the folding and unfolding events on a picosecond 
timescale, ii) dissect the contribution of hydrogen bonds and hydrophobic interactions to the hairpin 
formation process and iii) deliver an experimental control for the established folding mechanisms of 5.1 
and related peptides. 
 
Figure 5.3:  CD and IR spectra of Y2W-AzoChig 5.5 and Y2V-AzoChig 5.6. Top left: CD spectra of chignolin 5.1 and 
the cis-/trans-isomers of the AzoChignolin peptides 5.2, 5.5 and 5.6. Top right: zoom into CD spectra of cis-/trans-5.2, 
-5.5 and -5.6. CD spectra of 5.2, 5.5 and 5.6 were recorded in methanol at 5 °C. The CD spectrum of 5.1 was recorded 
at 5 °C in 20 mM PBS pH 5.5. Bottom left: on top are shown the FT IR spectra of cis-/trans-5.5 in deuterated methanol 
at 25 °C, on the bottom are shown the differential FT IR spectra of the folding (trans ⇾ cis) and unfolding (cis ⇾ trans) 
processes of 5.5. Bottom right: on top are shown the FT IR spectra of cis-/trans-5.6 in deuterated methanol at 25 °C, 
on the bottom are shown the differential FT IR spectra of the folding (trans ⇾ cis) and unfolding (cis ⇾ trans) processes 
of 5.6. The FT IR spectra shown here are not methanol and TFA corrected.  
Moreover, we wanted to elucidate the role of Pro4 in the AzoChignolin peptides. In chignolin 5.1 the intra-
strand Tyr2 – Pro4 interaction is crucial for locking the N-terminal strand in a native-like conformation and 
Pro4 bends the peptide backbone, directing Asp3 to the required position for the formation of a hydrogen 
bonding network. In the AzoChignolin peptides the AMPP 1.22 photoswitch generates a different turn, and 
thus we were curios about whether the Pro4 bend is still needed for hairpin formation. Therefore, the P4T-
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AzoChig 5.7 peptide in which Pro4 is substituted by a threonine was synthesized. Threonine, offering an 
ideal O-glycolisation site, was chosen in respect of another project that focuses on the introduction of 
glycosylated amino acids into the AzoChignolin hairpin, to evaluate the effect of glycolisation patterns on 
hairpin folding. Alas, peptide 5.7 proved to be completely insoluble in water, acetonitrile and methanol, 
preventing any in-depth characterization by spectroscopic methods. Nevertheless, it is interesting that the 
bend and fixation of the N-terminal strand by Pro4 remains essential for the formation of the hairpin in 
AzoChignolin peptides, even though the central native turn sequence has been modified.  
5.3.2 THE Y2AZOPHE-CHIG PEPTIDE 
In the AzoChignolin peptides the photoswitch AMPP 1.22 substitutes the central amino acids Glu5 and 
Thr6. Although this was sucessfully used to photocontrol hairpin formation, the substitution of two amino 
acids and 20% sequence alteration still represents an invasive method. To maintain the original peptide 
sequence, we decided to develop a photochromic chignolin in which the photoswitch is located in the 
side-chain of the peptide. Therefore, the peptide Y2AzoPhe-Chig 5.8 comprising the photoswitchable 
amino acid AzoPhe 1.24 (AP2) as a substitute for Tyr2 was synthesized and evaluated (Fig. 5.4). In this 
compound the isomerization of the side-chain azobenzene moiety of AP2 was predicted to cause hairpin 
folding and unfolding through several possible factors, i.e. i) switching between a lengthy and rigid trans-
form and a more compact cis-structure, ii) changes in the hydrophobic surface area between a weaker cis- 
and stronger trans-form and iii) alteration of the dipole moments. 
 
Figure 5.4:  Predicted interactions in Y2AzoPhe-Chig 5.8. The different hydrophobic surface areas and structures of 
the cis-/trans-isomers of the AzoPhe2 (AP2) where predicted to induce structural rearrangements between the cis- and 
trans-5.8 peptide.  
As consequence of retaining the native turn sequence with the polar residues Glu5 and Thr6 Y2AzoPhe-
Chig 5.8 is soluble in aqueous media, a major prerequisite for folding experiments under physiological 
conditions. Although recent MD simulations of AzoChig1 5.2 show no severe differences between hairpin 
folding in aqueous or organic solvents, folding studies conducted in organic solvents are criticized for not 
being representative for folding processes in natural environments. Thus, the solubility in aqueous buffered 
solutions displays a great advantage of 5.8. The photophysical properties of 5.8 were as expected fast and 
robust, with switching kinetics of ttrans ⇾ cis = 42.7 ± 1.4 s and tcis ⇾ trans = 52.7 ± 2.0 s (Figure 5.5). The AP2 
photoswitch showed no signs of bleaching or degradation after several switching cycles and the cis-form 
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Figure 5.6:  NMR spectra in the aromatic region of chignolin 5.1 and cis-/trans-Y2AzoPhe-Chig 5.8. Top: overview 
of the aromatic region in the 1H-NMR spectra of peptides 5.1 and cis-/trans-5.8. Bottom: detailed view of the aromatic 
region between 8.8 – 6.6 ppm. NMR spectra were recorded at 25 °C with 3 mM concentrations in aqueous phosphate 
buffered solution (pH 5.5, 20 mM PBS) supplemented with 10% D2O and 4,4-dimethyl-4-silapentane-1-sulfonic acid 
(DSS) as internal standard. 
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Table 5.1:  1H NMR CIS values in the aromatic region of 5.1 and cis-/trans-Y2AzoPhe-Chig 5.8. Listing of CIS values 
for the 1H NMR signals in the aromatic region of peptides 5.1 and cis-/trans-5.8 with Δ5.1/cis-/trans-5.8 for comparing 
the different signal shifts. ↑ Represents upfield and ↓ downfield shifts. 
Residue Proton 
5.1 
(ppm) 
cis-5.8 
(ppm) 
Δ5.1/ 
cis-5.8 
(ppm) 
trans-5.8 
(ppm) 
Δ5.1/ 
trans-5.8 
(ppm) 
Tyr2 NH 8.24 
 Hδ,δ’ 6.59 
Hε,ε’ 6.64 
AP2 NH 
 
8.26 
 
8.19 
 
H4,4’ 6.60 6.78 
H5,5’ 6.63 7.51 
H9,9’ 7.37 7.81 
H10,10’ 6.90 7.55 
H11 7.31 7.55 
Asp3 NH 8.65 8.64 ↑	0.01 8.74 ↓ 0.09 
Glu5 NH 8.05 8.09 ↓ 0.04 7.83 ↑	0.22 
Thr6 NH 7.59 7.57 ↑	0.02 7.23 ↑	0.36 
Gly7 NH 8.30 8.24 ↑	0.06 8.08 ↑	0.22 
Thr8 NH 7.47 7.50 ↓ 0.03 7.45 ↑	0.02 
Trp9 NH 8.51 8.43 ↑	0.08 8.52 ↓ 0.01 
Hδ1 7.32 7.21 ↑	0.11 7.28 ↑	0.04 
Hε3 7.64 7.57 ↑	0.07 7.60 ↑	0.04 
Hζ2 7.41 7.28 ↑	0.13 7.28 ↑	0.13 
Hζ3 7.17 7.08 ↑	0.09 7.10 ↑	0.07 
Hη2 7.22 7.10 ↑	0.12 7.11 ↑	0.11 
Gly10 NH 8.12 8.08 ↑	0.04 8.05 ↑	0.07 
 
Table 5.2:  1H NMR CIS values of the Ha	protons of 5.1 and cis-/trans-5.8. Listing of CIS values for the 1H NMR 
signals of the Hα protons of peptides 5.1 and cis-/trans-5.8 with Δ5.1/cis-/trans-5.8 for comparing the different signal 
shifts. ↑ Represents upfield and ↓ downfield shifts, bold values mark changes >= 0.10 ppm. 
Hα 5.1 (ppm) cis-5.8 (ppm) Δ5.1/ cis-5.8 (ppm) trans-5.8 
(ppm) 
Δ5.1/ trans-5.8 
(ppm) 
Gly1 3.81 3.79 ↑ 0.02 3.85 ↓ 0.04 
Tyr2 / AP2 4.93 4.90  4.90  
Asp3 4.26 4.31 ↓ 0.05 4.37 ↓ 0.11 
Pro4 4.13 4.19 ↓ 0.06 3.92 ↑ 0.21 
Glu5 4.24 4.25 ↓ 0.01 4.13 ↑ 0.11 
Thr6 4.34 4.34 → 0.00 4.26 ↑ 0.03 
Gly7 3.97, 3.84 3.96, 3.79 ↑ 0.04 3.78, 3.57 ↑ 0.22 
Thr8 4.48 4.41 ↑ 0.07 4.51 ↓ 0.03 
Trp9 4.76 4.74 ↑ 0.02 4.80 ↓ 0.04 
Gly10 3.93, 3.88 3.89, 3.86 ↑ 0.03 3.92, 3.88 ↑ 0.01 
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Figure 5.7:  CD and FT IR spectra of cis-/trans-Y2AzoPhe-Chig 5.8. Top left: CD spectra of chignolin 5.1 and cis-
/trans-5.8 at 5 °C in 20 mM PBS pH 5.5. Top right: FT IR spectra of AzoChig1 5.2 and 5.8 and differential FT IR spectra 
of the trans ⇾ cis and cis ⇾ trans isomerization of 5.8. Bottom left: temperature dependent differential FT IR spectra of 
the trans ⇾ cis isomerization of 5.8. Bottom right: ultra-fast FT IR spectrum of the trans ⇾ cis isomerization of 5.8. All 
the FT IR spectra were recorded in deuterated methanol at 25 °C at approx. 5 mM concentrations. 
Next, CD and FT IR spectroscopy were conducted to assess the secondary structure content of the cis-
/trans-isomers of Y2AzoPhe-Chig 5.8 (Fig. 5.7). The CD spectra of both isomers show strong positive values 
below 200 nm, accompanied by two minima at 202 and 215 nm or 200 and 218 nm for the trans- and the 
cis-peptide, respectively. The positive band below 200 nm is more pronounced in the cis-isomer, which is 
very similar to chignolin 5.1. Both minima in the CD spectrum of the cis-isomer are weaker, which would 
point to a diminished AP2 – Tyr2 interaction in this isomer. However, both CD spectra lack the prominent 
band at 230 nm, because the necessary stacking conformation between AP2 and Trp9 causing the 
prominent exciton coupling band is not possible. Due to the high similarity of the CD spectra between 
both isomers it is not possible to distinguish whether the desired peptide folding dynamics upon 
isomerization occur, or subsequent structural rearrangements of the AP2 moiety lead to the the observed 
changes. To detect alterations in the hydrogen bonding network upon formation of cis- or trans-5.8, 
differential spectra for the trans ⇾ cis and cis ⇾ trans isomerization were recorded, along with melting 
curves and ultra-fast time-resolved IR spectra of the former isomerization process (Fig. 5.7). Unfortunatly, 
the differential spectra only show marginal shifts of the amide-I band, which are also close to the detection 
limit of 0.005 mOD. Furthermore, the melting curves for the trans ⇾ cis isomerization show bleaching of 
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bands in the amide-I region, rather than shifting what usually would be expected for a folding or unfolding 
process. Furthermore, the ultra-fast time-resolved IR spectra for the trans ⇾ cis isomerization show a very 
fast signal decay and rise in the amide-I band region at 1621 and 1639 cm-1, which is completed after 7 ps. 
Below 1600 cm-1 the spectrum shows some slower processes, which are completed after 50 ps. Alas, the 
retrieved CD and FT IR data is not sufficient to enable a clear statement on the folding dynamics of the 5.8 
peptide. However, the IR spectra suggest that sterical rearrangements of AP2 lead to small conformational 
shifts in the peptide structure, albeit insufficient to trigger further folding or unfolding processes. 
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5.4 SUMMARY AND OUTLOOK 
In the recent decades, various small peptide model systems for the study of the structure and folding of 
protein secondary structure elements have been developed26,276. Chignolin 5.1, an artificial decapeptide 
designed by statistical analysis of turn sequences in native proteins, was extensively studied as a model for 
the formation of b-hairpin segments258. Particularly, this structural element is believed to serve as a 
nucleation site for folding of proteins and thus a deeper understanding of the folding dynamics constitutes 
an important step in deciphering the mystery of protein folding and misfolding27,211. Although there is an 
abundant amount of experimental and theoretical data available, a general folding mechanism, if there is 
any, remains elusive. The three proposed mechanisms – the zipper, the hydrophobic collapse and the 
broken-zipper model – differ in the contribution of hydrogen bonds and hydrophobic interactions to the 
stabilization of the hairpin structure, and the succession of the single folding steps. Although the steadily 
rising computing power has enabled more sophisticated theoretical models, they still often lead to 
deviating observations when compared to experimental results. This shows the need for additional model 
peptide systems that act as experimental and theoretical playgrounds, and enable the convergence of both 
approaches. 
To contribute to this task, we developed the AzoChignolin peptides AzoChig1 5.2 and AzoChig2 5.321. 
They are based on chignolin 5.1 and possess the photoswitch AMPP 1.22 as an optical responsive turn 
element, substituting the central turn residues Glu5 and Thr6 in the native chignolin 5.1. The reversible 
cis ⇿ trans isomerization of 1.22 enables the optical control over folding and unfolding of the b-hairpin 
structure of the AzoChignolin peptides, and thus represents a useful experimental tool to study folding 
dynamics with high temporal solution. The desired folding and unfolding events upon azobenzene 
isomerization were initially demonstrated through NMR, CD and FT IR spectroscopy, and the focus now 
lies on in-depth studies of the intrinsic folding events. Therefore, ultra-fast FT IR spectroscopy and atomic 
resolution MD simulations are currently being conducted to provide a more precise picture of the 
contribution and succession of hydrophilic and hydrophobic interactions in the AzoChignolin peptides. 
To further expand the AzoChignolin model system and to alter cross-strand hydrophobic interactions, the 
two variants Y2W-AzoChig 5.5 and Y2V-AzoChig 5.6 were synthesized in which the central hydrophobic 
interaction partner Tyr2 was substituted by tryptophan and valine. As expected, the CD spectra of 5.5 and 
5.6 revealed hairpin folding and unfolding processes in the former peptide, which where abolished in the 
latter peptide. Likewise, the differential FT IR spectra monitored for both compounds show greater shifts in 
the amide-I band region for 5.5, while 5.6 exhibited only minor changes. As with the original AzoChignolin 
peptides, ultra-fast FT IR spectroscopy and MD simulations are currently underway to elucidate the role of 
individual hydrophobic interactions in this hairpin system. However, it remains unclear whether the 
abolished hydrophobic stacking between Tyr2 and Trp9, or rather the lack of intrastrand hydrophobic 
contact between Tyr2 and Pro4 are responsible for the diminished hairpin contents in the valine modified 
peptide 5.6. To clarify this, a new variant T9V-AzoChig will be synthesized and together with 5.5 and 5.6 
it should deliver more insight into folding contributions of the hydrophobic interactions in this system. 
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A different approach was chosen for the Y2AzoPhe-Chig 5.8 peptide, where the photoswitch AzoPhe 1.24 
was incorporated as a side-chain modification by subsitituting Tyr2. Thereby, the turn sequence remains 
unchanged, which facilitates native turn nucleation and folding instead of turn formation through 
azobenzene isomerization as in the former AzoChignolin peptides. Although 5.8 was envisioned to shift 
between a folded and unfolded state driven by structural changes in the side-chain azobenzene of the AP2 
residue upon isomerization, no such transition was detected. The CD spectra of both cis-/trans-isomers are 
very similar, showing only slightly shifted and reduced extrema in the cis-form. The differential FT IR 
spectra show no significant changes in the amide-I band region, which would necessarily occur if there 
where noticeable changes in the hydrogen bond network upon AP2 isomerization, i.e. if folding or 
unfolding processes take place. Moreover, the ultra-fast FT IR spectra of the trans ⇾ cis isomerization of 
5.8 show two time constants with 7 and 50 ps, respectively. These times are too fast for protein folding 
processes, which are typically on a timescale of several hundred nanoseconds or microseconds. On the 
contrary, the NMR spectra of cis-/trans-5.8 show distinct chemical shift values for the Ha and NH peptide 
backbone protons, with the signals of the trans-peptide exhibiting larger deviations to chignolin 5.1 than 
the those in the corresponding cis-isomer. Nevertheless, these results point to small sterical rearrangements 
of the peptide residues induced by the cis ⇿ trans AP2 isomerization, rather than large conformational 
shifts of the whole hairpin. MD simulations that are currently being executed will hopefully help to shed 
light on the nature of these sterical effects.  
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5.5 EXPERIMENTAL 
5.5.1 SPECTROSCOPIC AND SPECTROMETRIC DATA OF AZOCHIG1 5.1, AZOCHIG2 5.2 AND AZOCHIG3 
5.3 
S6 
 
3  Analysis of peptides AzoChig1-3 
3.1 AzoChig1 peptide 
The peptide AzoChig1 was synthesized according to the previously stated peptide synthesis strategy. After 
global deprotection and cleavage from the resin and subsequent diethyl ether precipitation, the peptide was 
purified by RP-HPLC with a water/acetonitrile (80:10 Æ 40:60) gradient. The product was obtained upon 
lyophilisation with a water/acetonitrile (60:40) mixture. HR ESI-MS (positive), m/z: found 1103.4572 
[C54H63O14N12+H]+, calc.: 1103.4508. HR ESI-MS (negative), m/z: found 1101.4420 [C54H61O14N12-2H]2-, calc.: 
1103.4508. 
 
 
Figure 1: Analytical RP-HPLC spectrum of AzoChig1 peptide. Retention time cis isomer = 13.9 min, trans isomer = 
15.5 min. 
 
 
  
Figure 2: Numbering of certain H and C atoms in the AzoChig1 peptide. 
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Table 2: 1H- and 13C-NMR chemical shifts of trans-AzoChig1 peptide. All NMR spectra where recorded in CD3OD, thus no 
NH and OH signals were recorded. 
trans AzoChig1 H [ppm] m J [Hz] C [ppm] trans AzoChig1 H [ppm] m J [Hz] C [ppm] 
G01/NH2 - - - - AMPP56/C11 - - - 154.1 
G01/Hα,Hα' 3.63 dd 16.0, 5.0 41.4 AMPP56/H12 7.96 s - 125.1 
G01/CO - - - 167.7 AMPP56/C13 - - - 138.0 
Y02/NH - - - - AMPP56/H14 7.46 d 7.8 133.2 
Y02/Hα 4.65 t 7.5 56.2 AMPP56/H15 7.47 t 7.8 133.4 
Y02/Hβ,Hβ' 2.98, 2.83 dd 13.9, 7.9 38.3 AMPP56/H16 7.79 d 7.8 122.2 
Y02/C1 - - - 128.3 AMPP56/H17,H17' 3.73 s - 43.2 
Y02/H2,H6 7.01 d 8.3 131.4 AMPP56/CO - - - 174.4 
Y02/H3,H5 6.68 d 8.3 116.2 G07/NH - - - - 
Y02/C4 - - - 157.5 G07/Hα,Hα' 3.85 dd 16.5, 10.4 44.0 
Y02/OH - - - - G07/CO - - - 172.1 
Y02/CO - - - 172.8 T08/NH - - - - 
D03/NH - - - - T08/Hα 4.29 d 4.1 60.2 
D03/Hα 4.93 dd 8.7, 5.5 49.1 T08/Hβ 4.08 dq 6.2, 5.3 68.2 
D03/Hβ,Hβ' 3.01, 2.61 dd 17.3, 4.7 37.0 T08/Hγ 1.05 d 6.5 19.9 
D03/COOH - - - 174.9 T08/OH - - - - 
D03/CO - - - 171.6 T08/CO - - - 172.3 
P04/N - - - - W09/NH - - - - 
P04/Hα 4.46 dd 8.9, 3.5 62.2 W09/Hα 4.70 dd 8.0, 5.5 55.6 
P04/Hβ,Hβ' 2.20, 2.07 d 8.3 30.8 W09/Hβ,Hβ' 3.32, 3.13 m - 28.6 
P04/Hγ,Hγ' 1.97 bs - 25.4 W09/NH - - - - 
P04/Hδ,Hδ' 3.75, 3.60 m - 48.6 W09/H2 7.13 s - 124.8 
P04/CO - - - 174.2 W09/C3 - - - 110.9 
AMPP56/NH 8.31 t 6.1 - W09/C3a - - - 128.8 
AMPP56/H2,H2' 4.52, 4.41 d 15.5 43.5 W09/H4 7.29 d 8.4 112.3 
AMPP56/C3 - - - 141.3 W09/H5 7.00 t 7.9 119.8 
AMPP56/H4 7.78 s - 121.6 W09/H6 7.06 t 7.9 122.4 
AMPP56/C5 - - - 154.2 W09/H7 7.56 d 7.9 119.3 
AMPP56/H6 7.76 d 7.8 123.2 W09/C7a - - - 137.9 
AMPP56/H7 7.47 t 7.8 130.5 W09/CO - - - 174.3 
AMPP56/H8 7.40 d 7.4 131.0 G10/NH - - - - 
AMPP56/N9 - - - - G10/Hα,Hα' 3.92 d 16.5 41.9 
AMPP56/N10 - - - - G10/COOH - - - 171.7 
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Table 3: 1H- and 13C-NMR chemical shifts of cis-AzoChig1 peptide. All NMR spectra where recorded in CD3OD, thus no 
NH and OH signals were recorded. 
cis AzoChig1 H [ppm] m J [Hz] C [ppm] cis AzoChig1 H [ppm] m J [Hz] C [ppm] 
G01/NH2 - - - - AMPP56/C11 - - - 154.8 
G01/Hα,Hα' 3.61 dd 16.0, 5.0 41.4 AMPP56/H12 6.69 s - 121.6 
G01/CO - - - 167.0 AMPP56/C13 - - - 137.6 
Y02/NH - - - - AMPP56/H14 6.88 d 7.8 121.1 
Y02/Hα 4.62 m 7.5 56.3 AMPP56/H15 7.27 t 7.8 130.2 
Y02/Hβ,Hβ' 2.88, 2.74 dd 13.6, 8.1 38.3 AMPP56/H16 7.14 m - 130.0 
Y02/C1 - - - 128.2 AMPP56/H17,H17' 3.47 s - 43.1 
Y02/H2,H6 6.90 d 8.3 131.3 AMPP56/CO - - - 174.3 
Y02/H3,H5 6.62 d 8.3 116.1 G07/NH - - - - 
Y02/C4 - - - 157.4 G07/Hα,Hα' 3.90 dd 16.5, 10.4 44.0 
Y02/OH - - - - G07/CO - - - 172.1 
Y02/CO - - - 172.5 T08/NH - - - - 
D03/NH - - - - T08/Hα 4.39 d 4.4 60.0 
D03/Hα 4.97 m - 48.5 T08/Hβ 4.09 m - 68.5 
D03/Hβ,Hβ' 2.92, 2.60 dd 17.3, 4.7 37.1 T08/Hγ 1.10 d 6.5 19.9 
D03/COOH - - - 174.6 T08/OH - - - - 
D03/CO - - - 171.3 T08/CO - - - 172.1 
P04/N - - - - W09/NH - - - - 
P04/Hα 4.33 dd 8.9, 3.5 62.0 W09/Hα 4.80 dd 8.0, 5.5 55.5 
P04/Hβ,Hβ' 2.19, 2.07 m - 30.8 W09/Hβ,Hβ' 3.35, 3.15 m - 28.8 
P04/Hγ,Hγ' 1.93 m - 25.4 W09/NH - - - - 
P04/Hδ,Hδ' 3.71, 3.54 m - 48.6 W09/H2 7.13 m - 124.8 
P04/CO - - - 174.1 W09/C3 - - - 111.0 
AMPP56/NH - - - - W09/C3a - - - 128.8 
AMPP56/H2,H2' 4.24, 4.20 d 15.5 43.5 W09/H4 7.27 d 8.4 112.3 
AMPP56/C3 - - - 141.0 W09/H5 6.98 m - 119.8 
AMPP56/H4 6.80 s - 120.7 W09/H6 7.06 m - 122.3 
AMPP56/C5 - - - 155.1 W09/H7 7.57 m - 119.3 
AMPP56/H6 6.59 d 7.8 119.6 W09/C7a - - - 137.7 
AMPP56/H7 7.13 m - 124.7 W09/CO - - - 174.3 
AMPP56/H8 7.06 m - 127.6 G10/NH - - - - 
AMPP56/N9 - - - - G10/Hα,Hα' 3.94 d 16.5 42.0 
AMPP56/N10 - - - - G10/COOH - - - 172.9 
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Figure 3: Top: 1H-NMR spectrum of trans-AzoChig1 peptide in MeOD-d4. Bottom: 1H-NMR spectrum of cis-AzoChig1 
peptide in MeOD-d4. 
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Figure 4: 1H,1H-TOCSY NMR spectrum of cis-AzoChig1 peptide in MeOD-d4, c = 2 mM. 
 
Figure 5: 1H,1H-ROESY NMR spectrum of trans-AzoChig1 peptide in MeOD-d4, c = 2 mM. 
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Figure 6: 1H,1H-ROESY NMR spectrum of cis-AzoChig1 peptide in MeOD-d4, c = 2 mM. 
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3.2 AzoChig2 peptide 
The peptide AzoChig2 was synthesized according to the previously stated peptide synthesis strategy. After 
global deprotection and cleavage from the resin and subsequent diethyl ether precipitation, the peptide was 
purified by RP-HPLC with a water/acetonitrile (80:10 Æ 40:60) gradient. The product was obtained upon 
lyophilisation with a water/acetonitrile (60:40) mixture. HR ESI-MS (positive), m/z: found 1227.4891 
[C54H61FO14N12+iPrOH+2Na+H]1+, calc.: 1227.4858. HR ESI-MS (negative), m/z: found 1225.4738 
[C54H60FO14N12+iPrOH+2Na-H]1-, calc.: 1225.4712. 
 
 
Figure 7: Analytical RP-HPLC spectrum of AzoChig2 peptide. Retention time cis isomer = 14.3 min, trans isomer = 
15.6 min. 
 
 
 
Figure 8: Numbering of certain H and C atoms in AzoChig2 peptide.  
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Table 4: 1H- and 13C-NMR chemical shifts of trans-AzoChig2 peptide. All NMR spectra where recorded in CD3OD, thus no 
NH and OH signals were recorded. 
trans AzoChig2 H [ppm] m J [Hz] C [ppm] trans AzoChig2 H [ppm] m J [Hz] C [ppm] 
G01/NH2 - - - - AMPP56/C11 - - - 154.1 
G01/Hα,Hα' 3.65 dd 21.3, 16.5 41.4 AMPP56/H12 7.97 s - 125.1 
G01/CO - - - 167.1 AMPP56/C13 - - - 138.0 
Y02/NH - - - - AMPP56/H14 7.46 d 7.8 131.0 
Y02/Hα 4.63 t 7.5 56.2 AMPP56/H15 7.47 t 7.8 133.2 
Y02/Hβ,Hβ' 2.97, 2.83 dd 13.5, 7.7 38.3 AMPP56/H16 7.77 d 8.0 122.3 
Y02/C1 - - - 128.3 AMPP56/H17,H17' 3.74 s - 43.2 
Y02/H2,H6 7.01 d 8.3 131.4 AMPP56/CO - - - 174.4 
Y02/H3,H5 6.68 d 8.3 116.3 G07/NH - - - - 
Y02/C4 - - - 157.5 G07/Hα,Hα' 3.89 dd 18.3, 16.0 44.1 
Y02/OH - - - - G07/CO - - - 172.1 
Y02/CO - - - 172.8 T08/NH - - - - 
D03/NH - - - - T08/Hα 4.26 d 4.1 60.2 
D03/Hα 4.93 dd 8.7, 5.5 48.7 T08/Hβ 4.04 m - 68.2 
D03/Hβ,Hβ' 3.01, 2.61 dd 17.3, 4.7 37.0 T08/Hγ 1.04 d 6.3 19.9 
D03/COOH - - - 174.9 T08/OH - - - - 
D03/CO - - - 171.6 T08/CO - - - 172.3 
P04/N - - - - W09/NH - - - - 
P04/Hα 4.46 dd 8.9, 3.5 62.2 W09/Hα 4.65 t 7.3 56.2 
P04/Hβ,Hβ' 2.20, 2.07 d 8.3 30.8 W09/Hβ,Hβ' 3.27, 3.11 dd 14.6, 7.7 28.0 
P04/Hγ,Hγ' 1.97 bs - 25.4 W09/NH - - - - 
P04/Hδ,Hδ' 3.75, 3.60 m - 48.6 W09/H2 7.18 s - 125.0 
P04/CO - - - 174.2 W09/C3 - - - 107.7 
AMPP56/NH - - - - W09/C3a - - - 130.3 
AMPP56/H2,H2' 4.52, 4.41 d 15.5 43.5 W09/H4 7.24 dd 10.0, 2.1 103.7 
AMPP56/C3 - - - 141.3 W09/C5 - - - 157.7 
AMPP56/H4 7.75 s - 121.6 W09/H6 6.75 dt 8.7, 1.8 109.5 
AMPP56/C5 - - - 154.2 W09/H7 7.14 dd 8.5, 4.2 112.3 
AMPP56/H6 7.73 d 8.0 123.2 W09/C7a - - - 134.2 
AMPP56/H7 7.47 t 7.8 133.2 W09/CO - - - 174.2 
AMPP56/H8 7.39 d 7.4 130.6 G10/NH - - - - 
AMPP56/N9 - - - - G10/Hα,Hα' 3.92 dd 25.0, 18.0 41.9 
AMPP56/N10 - - - - G10/COOH - - - 172.1 
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Table 5: 1H- and 13C-NMR chemical shifts of cis-AzoChig2 peptide. All NMR spectra where recorded in CD3OD, thus no 
NH and OH signals were recorded. 
cis AzoChig2 H [ppm] m J [Hz] C [ppm] cis-AzoChig2 H [ppm] m J [Hz] C [ppm] 
G01/NH2 - - - - AMPP56/C11 - - - 154.8 
G01/Hα,Hα' 3.65 dd 21.3, 16.5 41.4 AMPP56/H12 6.69 s - 121.4 
G01/CO - - - 167.1 AMPP56/C13 - - - 137.6 
Y02/NH - - - - AMPP56/H14 7.14 d 7.8 129.8 
Y02/Hα 4.64 t 7.5 56.2 AMPP56/H15 7.28 t 8.1 130.3 
Y02/Hβ,Hβ' 2.98, 2.83 m - 38.3 AMPP56/H16 6.91 d 7.8 121.2 
Y02/C1 - - - 128.3 AMPP56/H17,H17' 3.47 dd 15.2, 8.3 43.1 
Y02/H2,H6 6.83 d 8.3 131.4 AMPP56/CO - - - 173.9 
Y02/H3,H5 6.59 d 8.3 116.1 G07/NH - - - - 
Y02/C4 - - - 157.4 G07/Hα,Hα' 3.86 dd 18.3, 16.0 44.2 
Y02/OH - - - - G07/CO - - - 172.1 
Y02/CO - - - 172.5 T08/NH - - - - 
D03/NH - - - - T08/Hα 4.41 d 4.1 59.9 
D03/Hα 4.98 m 8.7, 5.5 48.5 T08/Hβ 4.09 m - 68.5 
D03/Hβ,Hβ' 2.91, 2.58 dd 17.3, 4.7 37.1 T08/Hγ 1.11 d 6.3 19.8 
D03/COOH - - - 174.6 T08/OH - - - - 
D03/CO - - - 171.2 T08/CO - - - 172.0 
P04/N - - - - W09/NH - - - - 
P04/Hα 4.46 dd 8.9, 3.5 62.0 W09/Hα 4.59 t 7.5 56.2 
P04/Hβ,Hβ' 2.20, 2.07 d 8.3 30.8 W09/Hβ,Hβ' 3.27, 3.11 dd 14.6, 7.7 28.1 
P04/Hγ,Hγ' 1.97 bs - 25.5 W09/NH - - - - 
P04/Hδ,Hδ' 3.75, 3.60 m - 48.6 W09/H2 7.21 s - 125.0 
P04/CO - - - 174.2 W09/C3 - - - 111.3 
AMPP56/NH - - - - W09/C3a - - - 129.1 
AMPP56/H2,H2' 4.26, 4.19 d 15.5 43.5 W09/H4 7.27 m - 104.1 
AMPP56/C3 - - - 141.0 W09/C5 - - - 159.7 
AMPP56/H4 6.78 s 7.8 120.7 W09/H6 6.83 m - 110.5 
AMPP56/C5 - - - 155.1 W09/H7 7.24 m - 113.0 
AMPP56/H6 6.61 d 8.0 119.8 W09/C7a - - - 134.5 
AMPP56/H7 7.13 t 8.5 129.8 W09/CO - - - 172.5 
AMPP56/H8 7.05 d 7.8 127.6 G10/NH - - - - 
AMPP56/N9 - - - - G10/Hα,Hα' 3.92 dd 25.0, 18.0 41.9 
AMPP56/N10 - - - - G10/COOH - - - 172.1 
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Figure 9: Left: 1H-NMR spectrum of trans-AzoChig2 (2) peptide in MeOD-d4, c = 5 mM; Right: 1H-NMR spectrum of cis-
AzoChig2 (2) peptide in MeOD-d4, c = 5 mM. 
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Figure 10: Top: 19F-NMR spectrum of trans-AzoChig2 (2) peptide in MeOD-d4, c = 2 mM; Bottom: 19F-NMR spectrum of 
cis-AzoChig2 (1) peptide in MeOD-d4, c = 5 mM. Peak at -76 ppm originates from trifluoroacetic acid. 
 
Figure 11: 1H,1H-TOCSY NMR spectrum of cis-AzoChig2 peptide in MeOD-d4, c = 2 mM. 
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Figure 12: 1H,1H-ROESY NMR spectrum of trans-AzoChig2 peptide in MeOD-d4, c = 2 mM. 
Figure 13: 1H,1H-ROESY NMR spectrum of cis-AzoChig2 peptide in MeOD-d4, c = 2 mM.  
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3.3 AzoChig3 peptide 
The peptide AzoChig3 was synthesized according to the previously stated peptide synthesis strategy. After 
global deprotection and cleavage from the resin and diethyl ether precipitation, the peptide was purified by RP-
HPLC with a water/acetonitrile (80:10 Æ 40:60) gradient. The product was obtained upon lyophilisation with a 
water/acetonitrile (60:40) mixture. HR ESI-MS (positive), m/z: found 1306.5706 [C63H80O18N13+H]+, calc.: 
1306.5739. The signals of the recorded NMR spectra of the cis/trans-AzoChig3 could not be assigned due to 
excessive signal broadening. 
 
 
Figure 14: Analytical RP-HPLC spectrum of AzoChig3 peptide. Retention time cis isomer = 27.4 min, trans isomer = 
27.9 min. 
 
 
 
Figure 15: Numbering of certain H and C atoms in AzoChig3 peptide. 
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Figure 16: 1H-NMR spectrum of trans-AzoChig3 (2) peptide in MeOD-d4. Bottom: 1H-NMR spectrum of cis-AzoChig3 (2) 
peptide in MeOD-d4.  
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5.5.2 EXPERIMENTAL DATA OF ADDITONAL COMPOUNDS CHIGNOLIN 5.1, Y2W-AZOCHIG 5.5, Y2V-
AZOCHIG 5.6, P4T-AZOCHIG 5.7 AND Y2AZOPHE-CHIG 5.8 
5.5.2.1 SYNTHESIS OF PEPTIDES CHIGNOLIN $5.1, Y2W-AZOCHIG 5.5, Y2V-AZOCHIG 5.5, P4T-AZOCHIG 
5.7 AND Y2AZOPHE-CHIG 5.8 
The synthesis of peptides chignolin 5.1, Y2W-AzoChig 5.5, Y2V-AzoChig 5.5, P4T-AzoChig 5.7 and 
Y2AzoPhe-Chig 5.8 followed the general peptide synthesis protocol stated in the APPENDIX. Table 5.3 
depicts the coupling conditions of the different building blocks used for the automated peptide synthesis. 
As resin for all peptides a preloaded Wang LL N-(Fmoc)-Gly resin (NovaBiochem, Darmstadt/Germany) 
was used. 
 
Table 5.3: Coupling conditions for synthesis of peptides chignolin 5.1, Y2W-AzoChig 5.5, Y2V-AzoChig 5.5, P4T-
AzoChig 5.7 and Y2AzoPhe-Chig 5.8. 
Amino acid(s) Coupling method Steps Time (s) Temperature (°C) Power (W) 
Fmoc-AMPP-OH 1.26, 
Fmoc-AzoPhe-OH 1.27 
Photoswitch 
coupling 
1 1800 75  23 
Fmoc-Asp(t-Bu)-OH, Fmoc-Glu-
OH, Fmoc-Gly-OH, Fmoc-Pro-
OH, Fmoc-Thr(t-Bu)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-Tyr(t-Bu)-OH, 
Fmoc-Val-OH 
Standard single 
amino acid 
coupling 
1 480 75 23 
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5.5.2.2 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF CHIGNOLIN 5.1 
 
 
Figure 5.8:  HPLC spectrum of chignolin 5.1. Analytical HPLC spectrum of 5.1 with a water/acetonitrile gradient 
95:5 ⇾ 20:80 in 40 min. Rt = 11.9 min.  
 
 
Figure 5.9:  HRMS spectrum of chignolin 5.1. HRMS (+ESI) m/z: calc. for C48H64O18N11+ [M+H]+: 1082.4425; found: 
1082.4420. Calc. for C48H63O18N11Na 
+ [M+Na]+: 1104.4250; found: 1104.4244. ∆m = -0.54 ppm. 
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5.5.2.3 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF Y2W-AZOCHIG 5.5 
 
 
Figure 5.10:  HPLC spectrum of Y2W-AzoChig 5.5. Analytical HPLC spectrum of 5.5 with a water/acetonitrile gradient 
95:5 ⇾ 20:80 in 40 min. Rt = 14.9 min.  
 
 
Figure 5.11:  HRMS spectrum of Y2W-AzoChig 5.5. HRMS (+ESI) m/z: calc. for C56H64O13N13+ [M+H]+: 1126.4741; 
found: 1126.4739. ∆m = -0.18 ppm. 
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5.5.2.4 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF Y2V-AZOCHIG 5.6 
 
 
Figure 5.12:  HPLC spectrum of Y2V-AzoChig 5.6. Analytical HPLC spectrum of 5.6 with a water/acetonitrile gradient 
95:5 ⇾ 20:80 in 40 min. Rt,cis = 13.3 min, Rt,trans = 14.7 min.   
 
 
Figure 5.13:  HRMS spectrum of Y2V-AzoChig 5.6. HRMS (+ESI) m/z: calc. for C50H63O13N12+ [M+H]+: 1039.4632; 
found: 1039.4614. ∆m = -1.73 ppm. 
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5.5.2.5 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF P4T-AZOCHIG 5.7 
 
 
Figure 5.14:  HPLC spectrum of P4T-AzoChig 5.7. Analytical HPLC spectrum of 5.7 with a water/acetonitrile gradient 
95:5 ⇾ 20:80 in 40 min. Rt,cis = 14.4 min, Rt,trans = 16.0 min.   
 
 
Figure 5.15:  HRMS spectrum of P4T-AzoChig 5.7. HRMS (+ESI) m/z: calc. for C53H63O12N15+ [M+H]+: 1107.4521; 
found: 1107.4530. Calc. for C53H62O12N15Na 
+ [M+Na]+: 1129.4356; found: 1129.4351. ∆m = -0.44 ppm. 
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5.5.2.6 ANALYTICAL HPLC SPECTRUM AND MASS SPECTRUM OF Y2AZOPHE-CHIG 5.8 
 
 
Figure 5.16:  HPLC spectrum of Y2AzoPhe-Chig 5.8. Analytical HPLC spectrum of 5.8 with a water/acetonitrile 
gradient 95:5 ⇾ 20:80 in 40 min. Rt,cis = 13.4 min, Rt,trans = 15.4 min.   
 
 
Figure 5.17:  HRMS spectrum of Y2AzoPhe-Chig 5.8. HRMS (+ESI) m/z: calc. for C54H68O17N13+ [M+H]+: 1170.4851; 
found: 1170.4848. Calc. for C54H67O17N13Na 
+ [M+Na]+: 1192.4674; found: 1192.4676. ∆m = -0.26 ppm. 
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INDEX OF ABBREVIATIONS 
Abs. absolute 
AcOH Acetic acid 
AE Autonomous element 
AGT O6-alkyguanine DNA alkyltransferase 
An. RP-HPLC Analytical reversed-phase high pressure liquid chromatography 
au Arbitary units 
BC Benzylcytosine 
BG Benzylguanine 
BPO Dibenzoylperoxid 
CD Circular dichroism 
CIS Chemical induced shift 
CNS Central nerve system 
DAE Diarylethenes 
DMAP 4-Dimethylaminopyridine 
DMF N,N’-Dimethylformamide 
DMSO Dimethylsulfoxid 
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid 
ED Electron donating 
EDG Electron donating group 
EW Electron withdrawing 
EWG Electron withdrawing group 
Fig. Figure 
FSK Forskolin 
FT IR Fourier-transformation infrared  
GPCR G-protein coupled receptor 
GRK GPCR kinase 
HKR HEPES-Krebs-Ringer 
HTI Hemithioindigo 
IR Infrared 
KHMDS Potassium bis(trimethylsilyl)amide 
LiHMDS Lithium bis(trimethylsilyl)amide 
m-CPBA meta-Chloroperoxybenzoic acid 
MeCN Acetonitrile 
MeOH Methanol 
NBS N-Bromosuccinimid 
NMR Nuclear magnetic resonance 
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OD Optical density 
PAM Photoswitchable allosteric modulator 
PBS Phosphate buffered saline 
PCL Photochromic ligand 
PEG Polyethylene glycol 
PhMe Toluene 
Pr. RP-HPLC Preparative reversed-phase high pressure liquid chromatography 
PSS Photostationary state 
PTL Photoswitchable tethered ligand 
Py Pyridine 
ROS Reactive oxygen species 
ROS Reactive oxygen species 
rt Room temperature 
SEM Standard error of the mean 
SPPS Solid-phase peptide synthesis 
t-BuOH tert-Butanol 
t-BuOI tert-Butylhypoiodite 
T2D Type 2 diabetes mellitus 
TFA Trifluoroacetic acid 
TFE Trifluoro ethanol 
THF Tetrahydrofuran 
UV Ultraviolet 
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INDEX OF COMPOUNDS 
PART I  
1.1 Retinal 
1.2 Stilbene 
1.3 Diarylethene 
1.4 Hemithioindigo 
1.5 Azobenzene 
1.6 Bis(para-iodoacetamido)-azobenzene 
1.7 DENAQ; (E)-2-((4-((4-(Diethylamino)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-
2-oxoethan-1-aminium 
1.8 JB558; (E)-N-Cyclohexyl-5-((4-(diethylamino)phenyl)diazenyl)-1,3,4-thiadiazole-2-
sulfonamide 
1.9 Bis(para-chloroacetamido)-azobenzene 
1.10 (E)-N,N'-(Diazene-1,2-diylbis(3-(piperidin-1-yl)-4,1-phenylene))bis(2-
chloroacetamide) 
1.11 (E)-N,N'-(Diazene-1,2-diylbis(3-(diethylamino)-4,1-phenylene))bis(2-
chloroacetamide) 
1.12 (E)-N,N'-(Diazene-1,2-diylbis(3-(pyrrolidin-1-yl)-4,1-phenylene))bis(2-
chloroacetamide) 
1.13 (E)-N,N'-(Diazene-1,2-diylbis(3-(4-methylpiperazin-1-yl)-4,1-phenylene))bis(2-
chloroacetamide) 
1.14 (E)-1-Methyl-4-(phenyldiazenyl)-1H-pyrazole 
1.15 (E)-N,N'-(Diazene-1,2-diylbis(3,5-dimethoxy-4,1-phenylene))diacetamide 
1.16 (E)-N,N'-(Diazene-1,2-diylbis(3,5-difluoro-4,1-phenylene))diacetamide 
1.17 (E)-N,N'-(Diazene-1,2-diylbis(3,5-dichloro-4,1-phenylene))diacetamide 
1.18 Diethyl 4,4'-(diazene-1,2-diyl)(E)-bis(3,5-difluorobenzoate) 
1.19 (Z)-11,12-Dihydrodibenzo[c,g][1,2]diazocine 
1.20 (Z)-N,N'-(11,12-Dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)diacetamide 
1.21 (Z)-N,N'-(11,12-Dihydrodibenzo[c,g][1,2]diazocine-3,8-diyl)diacetamide 
1.22 AMPP, 3-[3-(Aminomethyl)phenylazo]phenylacetic acid 
1.23 APB, 4-[4-(Amino)phenylazo]benzoic acid 
1.24 AzoPhe, (S,E)-2-Amino-3-(4-(phenyldiazenyl)phenyl)propanoic acid 
1.25 para-BDCA, (Z)-N,N'-(11,12-Dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)bis(2-
chloroacetamide) 
1.26 Fmoc-AMPP, (E)-2-(3-((3-(((((9H-Fluoren-9-
yl)methoxy)carbonyl)amino)methyl)phenyl)diazenyl)phenyl)acetic acid 
1.27 Fmoc-AzoPhe, (S,E)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-
(phenyldiazenyl)phenyl)propanoic acid 
1.28 AMBD, (Z)-2-(8-(((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)methyl)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-3-yl)acetic acid 
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1.29 m-BDCA, (Z)-N,N'-(11,12-Dihydrodibenzo[c,g][1,2]diazocine-3,8-diyl)bis(2-
chloroacetamide) 
1.30 DABT, (E)-N,N'-(Diazene-1,2-diylbis(benzo[d]thiazole-2,6-diyl))bis(2-
chloroacetamide) 
1.31 3-(Aminomethyl)anilin 
1.32 (9H-Fluoren-9-yl)methyl (3-aminobenzyl)carbamate 
1.33 2-(3-Nitrophenyl)acetic acid 
1.34 2-(3-Nitrosophenyl)acetic acid 
1.35 L-N-tert-Butoxycarbonyl-para-phenylalanine 
1.36 N-(tert-Butoxycarbonyl)-L-phenylalanine-4’-azobenzene 
1.37 para-Tolylacetic acid 
1.38 tert-Butyl 2-(4-((bromotriphenylphosphaneyl)methyl)phenyl)acetate 
1.39 tert-Butyl (E)-2-(4-(4-cyanostyryl)phenyl)acetate 
1.40 2-(4-(4-((2,5-Dioxopyrrolidin-1-yl)methyl)phenethyl)phenyl)acetic acid 
1.41 2-(4-(4-((2,5-Dioxopyrrolidin-1-yl)methyl)-2-nitrophenethyl)-3-nitrophenyl)acetic 
acid 
1.42 (Z)-2-(8-((2,5-Dioxopyrrolidin-1-yl)methyl)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-3-yl)acetic acid 
1.43 2-(3-Amino-4-(2-amino-4-((2,5-dioxopyrrolidin-1-yl)methyl)phenethyl)phenyl)acetic 
acid 
1.44 (Z)-2-(8-((2,5-Dioxopyrrolidin-1-yl)methyl)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-3-yl)acetic acid 
1.45 Methyl 2-(3-amino-4-(2-amino-4-((2,5-dioxopyrrolidin-1-
yl)methyl)phenethyl)phenyl)acetate 
1.46 Methyl (Z)-2-(8-((2,5-dioxopyrrolidin-1-yl)methyl)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-3-yl)acetate 
1.47 (Z)-2,9-Dibromo-11,12-dihydrodibenzo[c,g][1,2]diazocine 
1.48 (Z)-11,12-Dihydrodibenzo[c,g][1,2]diazocine-2,9-diamine 
1.49 4,4'-(Ethane-1,2-diyl)dianiline 
1.50 (Z)-11,12-Dihydrodibenzo[c,g][1,2]diazocine-3,8-diamine 
1.51 2-Amino-6-nitrobenzothiazole 
1.52 1,2-Bis(6-nitrobenzothiazol-2-yl)diazene 
1.53 2-(4-(Bromomethyl)phenyl)acetic acid 
1.54 tert-Butyl 2-(4-(bromomethyl)phenyl)acetate 
1.55 tert-Butyl 2-(4-(4-(aminomethyl)phenethyl)phenyl)acetate 
1.56 Di-tert-butyl (11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)(Z)-dicarbamate 
1.57 4,4'-(Ethane-1,2-diyl)bis(3-nitroaniline) 
1.58 
 
(E)-2,2'-(Diazene-1,2-diyl)bis(benzo[d]thiazol-6-amine) 
PART II  
II.1 MAQ, (E)-2-((4-((4-(2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-
yl)acetamido)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-aminium 
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II.2 4-GluAzo, (2S,4R)-2-Amino-4-((E)-3-(4-((E)-
phenyldiazenyl)phenyl)allyl)pentanedioic acid 
II.3 ATA-3, (S,E)-2-Amino-3-(5-(2-(3-((4-(dimethylamino)phenyl)diazenyl)benzyl)-2H-
tetrazol-5-yl)-3-hydroxy-1H-pyrazol-4-yl)propanoic acid 
II.4 Metformin; N,N-Dimethylimidodicarbonimidic diamide 
2.1 TOP271, SLRRS SCFGG RMDRI GAQ (AMPP, 1.22) CNSFR Y 
2.2 N24AzoPhe-ANP; SLRRS SCFGG RMDRI GAQSG LGC (AzoPhe, 1.24) SFRY 
2.3 S25AzoPhe-ANP; SLRRS SCFGG RMDRI GAQSG LGCN (AzoPhe, 1.24) FRY 
3.1 Metformin, N,N’-Dimethylimidodicarbonimidic diamide 
3.2 Glimeperide, 3-Ethyl-4-methyl-N-(4-(N-(((1r,4r)-4-
methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-
carboxamide 
3.3 Sitagliptin, (R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-
a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 
3.4 Exenatide, HGEGT FTSDL SKQME EEAVR LFIEW LKWGG PSSGA PPPS-NH2 
3.5 Liraglutide, HAEGT FTSDV SSYLE GQAAK(gEP) EFIAW LVKGR G 
3.6 LirAzo, HAEGT FTSDV SSYLE (AMPP, 1.22) AAK EFIAW LVKGR G 
3.7 LirAzo2, HAEGT FTSDV SSYLE (AMPP, 1.22) AK EFIAW LVKGR G 
3.8 LirAzo3, HAEGT FTSDV SSYLE (AMPP, 1.22) K EFIAW LVKGR G 
3.9 gEp-LirAzo, HAEGT FTSDV SSYLE (AMPP, 1.22) AAK(gEP) EFIAW LVKGR G 
4.1 BG-LirAzo, HAEGT FTSDV SSYLE (AMPP, 1.22) AAK EFIAW LVKGR C(PEG4)-BG 
4.2 ExONatide, HGEGT FTSDL SKQME EEAVR LFIEW LKWGG PSSGA PPPC(PEG4)-BG 
4.3 ExOFFatide, DL SKQME EEAVR LFIEW LKWGG PSSGA PPPC(PEG4)-BG 
4.4 BG-Lira, HAEGT FTSDV SSYLE GQAAK EFIAW LVKGR C(PEG4)-BG 
4.5 BG-PEG4-SPDP, N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-1-(3-(pyridin-2-
yldisulfaneyl)propanamido)-3,6,9,12-tetraoxapentadecan-15-amide 
4.6 S39C-Ex4(1-39), HGEGT FTSDL SKQME EEAVR LFIEW LKWGG PSSGA PPPC-NH2 
4.7 S39C-Ex4(9-39), DL SKQME EEAVR LFIEW LKWGG PSSGA PPPC-NH2 
4.8 G36C-Lira, HAEGT FTSDV SSYLE GQAAK EFIAW LVKGR C 
4.9 
 
G36C-LirAzo, HAEGT FTSDV SSYLE (AMPP, 1.22) AAK EFIAW LVKGR C 
PART III  
III.1 AzoTrpZip2, ATZ, SWTWE (AMPP, 1.22) KWTWK-NH2 
5.1 Chignolin, GYDPE TGTWG 
5.2 AzoChig1, GYDP (AMPP, 1.22) GTWG 
5.3 AzoChig2, GYDP (AMPP, 1.22) GT (5-FW) G 
5.4 AzoChig3, PEG3-GYDP (AMPP, 1.22) GTWG 
5.5 Y2W-AzoChig, GWDP (AMPP, 1.22) GTWG 
5.6 Y2V-AzoChig, GVDP (AMPP, 1.22) GTWG 
5.7 P4T-AzoChig, GYDT (AMPP, 1.22) GTWG 
5.8 Y2AzoPhe-Chig, G (AzoPhe, 1.24) DPE TGTWG 
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GENERAL REMARKS  
Chemicals, solutions and compounds 
The chemicals and solutions used throughout this work were either purchased from Sigma-Aldrich 
(Munich/Germany), ABCR (Karlsruhe/Germany) or VWR (Ismaning/Germany). Compounds and resins for 
peptide synthesis were purchased from NovaBiohem (Merck Millipore, Darmstadt/Germany), Orpegen 
Peptide Chemicals (Heidelberg/Germany) or Rapp Polymere (Tübingen/Germany).  
Thin-layer chromatography and flash chromatography on silica gel 
Thin-layer chromatography reaction control was undertaken on aluminium foils (silicagel 60 F254, Merck 
KGaA, Grafen/Germany). Compounds were detected utilizing either fluorescence quenching at λ = 254 
nm or by dyeing with ninhydrin solution (1.5 g ninhydrin, 15 mL glacial acetic acid and 500 mL methanol. 
Flash chromatography was done on silica gel (grain size 35-70 µm, Acros Organics, Geel/Belgium) with 
nitrogen pressure (0.2-1.0 bar). 
Peptide Synthesizer  
Peptides were synthesised on a CEM Liberty 1 Peptide Synthesizer with a CEM Discovery Microwave (CEM 
GmbH, Kamp-Lintfort/Germany) under standard Fmoc conditions (with or without microwave). Detailed 
information on peptide synthesis protocols, resins, coupling reagents and conditions can be found under 
GENERAL PEPTIDE SYNTHESIS. 
Reversed-phase HPLC 
Analytical RP-HPLCs were performed on Jasco (Jasco Germany GmbH, Groß-Umstadt/Germany) devices 
(PU-2080 Plus, LG-2080-02-S, DG-2080-53 and MD-2010 Plus) with a Phenomenex 
(Aschaffenburg/Germany) Aeris column (C18, 5 µm, 250 x 4.6 mm). A water/acetonitrile gradient with 
0.1% TFA with a flow of 1 mL·min-1 was used as eluent. Purification through semi-preparative RP-HPLCs 
was performed on Jasco (Groß-Umstadt/Germany) devices (PU-2087 Plus, LG-2080-02-S and UV-2075 
Plus) with a Phenomenex (Torrance/USA) Aeris column (XBC18, 5 µm, 250 x 21.2 mm). As eluent, a 
water/acetonitrile gradient with 0.1% TFA and 20 mL/min flow was used.  
NMR spectroscopy 
NMR spectra were recorded on Varian (Darmstadt/Germany) AC 300 (300 MHz), WH 400 (400 MHz) and 
AMX 600 (600 MHz), as well as on Bruker (Billerica/USA) AV-III (800 MHz) devices. All spectra were 
recorded at room temperature and chemical shifts δ are denoted in ppm based on TMS as external, or DSS 
as internal standard, respectively. Deuterated solvents CDCl3, CD3OD, CD3OH and DMSO-d6 were used 
for the experiments. The detected resonances of the remaining protons in these solvents was used as 
internal standard [δ (CDCl3) = 7.26, δ (CD3OD) = 3.31 and δ (DMSO-d6) = 2.50 ppm]. J-coupling constants 
are given in Hz and the multiplicity is abbreviated as s = singlet, d = doublet, t = triplet, q = quartet and m 
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= multiplet. NMR spectra were analyzed with CCPN Analysis V2.4.2 and MestReC V8.1.4-12489 
(Mestrelab Research, Santiago de Compostela/Spain) software.  
Mass spectrometry 
Electron ionization (EI) measurements were recorded on a Thermo Finnigan MAT 95 (Thermo Fisher 
Scientific Inc., Waltham/USA) mass spectrometer. Denoted are the ionization method, the mass-to-charge 
ratio value (m/z) and the related fragmentation. The resolution of EI-MS is 1000 u and of HR-EI-MS is 5000 
u. Electron spray ionization (ESI) measurements were performed on a Thermo Finnigan LTQFT (Thermo 
Fisher Scientific Inc., Waltham/USA) mass spectrometer, with the same denotion. 
CD spectroscopy  
CD measurements were done on a Jasco 810 CD spectrometer with a Jasco CDF-4265 Peltier-Element 
(Jasco Germany GmbH, Groß-Umstadt/Germany) and with Milli-Q water, phosphate buffer (20mM, pH 
5.5) or methanol as solvent. Used cuvettes were of 1 mm thickness. Baseline correction was achieved by 
pure Milli-Q water, phosphate buffer or methanol spectra. Calculation of sample concentrations was done 
via the specific absorption at 323 nm, with eazobenzene = 25000 L · mol-1 · cm-1. Recorded spectra were 
evaluated with the software Origin 8.0 (OriginLab Corporation, Northampton/USA) and were not 
smoothed.  
IR spectroscopy  
IR spectroscopy was performed with a Bruker IFS 66 (Bruker Optik GmbH, Ettlingen/Germany). All spectra 
were recorded with c = 5.0 mM solutions in CD3OD at different temperatures.  
UV/Vis spectroscopy  
UV spectra were recorded on a Cary50 UV/Vis spectrometer (Agilent, Santa Clara/CA/USA) or a Jacso V-
650 UV/Vis spectrometer, with a Jasco PAC-743 Peltier-Element (Jasco Germany GmbH, Groß-
Umstadt/Germany) and Milli-Q water, phosphate buffer (20 mM pH 5.5) or methanol as solvent. Spectra 
were recorderd at 5 °C and cuvettes used were of 1 or 10 mm thickness.  
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GENERAL PEPTIDE SYNTHESIS 
As resin for the solid-phase peptide synthesis amino acid preloaded resins, which deliver free carboxylic 
acids or amides with different amino acid loadings were used. The synthesis of the peptides was performed 
on a 0.1 mmol scale and with standard coupling reagents HBTU/HOBt·H2O (0.5 M) in DMF, activated 
with DIEA (2 M) in DMF. The amino acid building blocks with standard residual protecting groups were 
coupled with a fivefold excess (2 M solutions). Special amino acid building blocks were coupled with a 
two-fold excess of HATU/HOAt·H2O (2.0 eq., 0.5 M) in DMF and NMM (4.0 eq.) in DMF. Consequent 
Fmoc deprotection was performed by treatment with piperidine in DMF (1:4). Final Fmoc-deprotection 
was followed by global deprotection of residual protecting groups and cleavage from the resin with a 
TFA/phenol/triisopropylsilane/H2O (88:5:5:2) cocktail within 2 hrs at room temperature under inert 
atmosphere. The resultant solution was filtered, concentrated under reduced pressure and precipitated in 
40 mL chilled diethyl ether and stored overnight at -32 °C. After centrifugation and removal of the diethyl 
ether the resulting precipitated crude peptide was purified with RP-HPLC to yield the desired peptide 
products. 
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